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oguanine DNA glycosylase (OGG1) and corrected to G/Cs, with the assistance of the downstream BER
machinery. During replication, GO can mispair with adenine. GO/A mispairs are addressed by MYH-
initiated BER that removes the As and replaces them with Cs to generate GO/Cs, which are substrates
for OGG1- dependent BER. Dysfunction of MYH leads to G:C to T:A transversions and is linked to
MYH-associated polyposis (MAP). During the past decade, repair of oxidative DNA lesions such as GO
was shown to involve also the postreplicative mismatch repair system (MMR), but its role within this
process remained obscure. GO/A mispairs were known to be poor substrates for MMR, but we show here
that, in an in vitro MMR assay based on circular lesion- containing plasmids and human cell extracts, the
intermediates of GO/A - but not GO/C - processing by BER can serve as strand discrimination signals for
MMR. These observations were not restricted to human cell extracts, but were observed also in extracts of
Xenopus laevis eggs. During S-phase, GO would be present predominantly in the parental DNA strand.
Thus, “hijacking” of strand breaks arising during MYH-dependent GO/A processing by BER would help
direct the mismatch repair process correctly to the daughter strand. In contrast, OGG1- generated nicks
at GO/C sites would direct MMR erroneously to the parental strand. Our data thus show that BER-
mediated processing of oxidative DNA damage is coordinated to help MMR improve replication fidelity.
In a complementary study, we set out to study the interactome of the mismatch recognition factor MutS￿
during oxidative DNA damage response. We had hoped that identification of interaction partners of
these MMR proteins might help us understand the details of the interplay of the different pathways of
DNA metabolism and DNA damage signaling in cells subjected to oxidative stress. I generated a novel
set of expression vectors and cell lines that could be used for future mass spectrometric analysis of the
interacting partners of MutS￿. I also confirmed that MMR deficiency leads to a decreased cell survival
and a prolonged G2/M arrest during oxidative stress. Poly(ADP-ribose) polymerase 1(PARP-1) is an
enzyme that is extremely rapidly activated by single-strand breaks (SSBs), to which it binds with high
affinity. This ’nick protector’ enzyme has been assigned a role in BER that is currently ill- defined,
however, it has recently acquired substantial clinical importance, because its inhibition effectively kills
BRCA1/-2 deficient breast and ovarian cancer cells. PARP inhibition is generally believed to give rise to
toxic SSB/PARP-1 complexes that can only be repaired in the presence of BRCA1/-2, but the underlying
causes of those SSBs are undefined yet. We wanted to learn whether these breaks might stem from the
processing of spontaneous oxidative damage. Using cell survival assays with human BRCA1-deficient
cell lines, we show that MYH knockdown attenuates the toxic effect of PARP inhibitors. These findings
show that DNA oxidation is a source of lesions that contribute to the toxicity of PARP inhibition in
BRCA-deficient cells and suggest that augmentation of oxidative damage processing might increase the
efficacy of PARP inhibitors in the clinic.
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Summary 
Our DNA is constantly exposed to spontaneous oxidative stress, which results from 
metabolic byproducts and which represents a key threat to genomic stability. 
Oxidation of DNA results in accumulation of the mutagenic 8-hydroxy-2’-
deoxyguanosine (GO), which is mainly removed by the base excision repair (BER) 
pathway. G/C base pairs are oxidized to GO/Cs, which are recognized by 
oxoguanine DNA glycosylase (OGG1) and corrected to G/Cs, with the assistance 
of the downstream BER machinery. During replication, GO can mispair with 
adenine. GO/A mispairs are addressed by MYH-initiated BER that removes the As 
and replaces them with Cs to generate GO/Cs, which are substrates for OGG1-
dependent BER. Dysfunction of MYH leads to G:C to T:A transversions and is 
linked to MYH-associated polyposis (MAP). 
During the past decade, repair of oxidative DNA lesions such as GO was shown to 
involve also the postreplicative mismatch repair system (MMR), but its role within 
this process remained obscure. GO/A mispairs were known to be poor substrates for 
MMR, but we show here that, in an in vitro MMR assay based on circular lesion-
containing plasmids and human cell extracts, the intermediates of GO/A - but not 
GO/C - processing by BER can serve as strand discrimination signals for MMR. 
These observations were not restricted to human cell extracts, but were observed 
also in extracts of Xenopus laevis eggs. During S-phase, GO would be present 
predominantly in the parental DNA strand. Thus, “hijacking” of strand breaks 
arising during MYH-dependent GO/A processing by BER would help direct the 
mismatch repair process correctly to the daughter strand. In contrast, OGG1-
generated nicks at GO/C sites would direct MMR erroneously to the parental strand. 
Our data thus show that BER-mediated processing of oxidative DNA damage is 
coordinated to help MMR improve replication fidelity.  
In a complementary study, we set out to study the interactome of the mismatch 
recognition factor MutSα during oxidative DNA damage response. We had hoped 
that identification of interaction partners of these MMR proteins might help us 
understand the details of the interplay of the different pathways of DNA 
metabolism and DNA damage signaling in cells subjected to oxidative stress. I 
generated a novel set of expression vectors and cell lines that could be used for 
future mass spectrometric analysis of the interacting partners of MutSα. I also 
confirmed that MMR deficiency leads to a decreased cell survival and a prolonged 
G2/M arrest during oxidative stress.  
Poly(ADP-ribose) polymerase 1(PARP-1) is an enzyme that is extremely rapidly 
activated by single-strand breaks (SSBs), to which it binds with high affinity. This 
'nick protector' enzyme has been assigned a role in BER that is currently ill-
defined, however, it has recently acquired substantial clinical importance, because 
its inhibition effectively kills BRCA1/-2 deficient breast and ovarian cancer cells. 
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PARP inhibition is generally believed to give rise to toxic SSB/PARP-1 complexes 
that can only be repaired in the presence of BRCA1/-2, but the underlying causes 
of those SSBs are undefined yet. We wanted to learn whether these breaks might 
stem from the processing of spontaneous oxidative damage. Using cell survival 
assays with human BRCA1-deficient cell lines, we show that MYH knockdown 
attenuates the toxic effect of PARP inhibitors. These findings show that DNA 
oxidation is a source of lesions that contribute to the toxicity of PARP inhibition in 
BRCA-deficient cells and suggest that augmentation of oxidative damage 
processing might increase the efficacy of PARP inhibitors in the clinic. 
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Zusammenfassung 
Die menschliche DNS ist fortwährend spontanem oxidativen Schaden ausgesetzt, 
der als Nebenprodukt des Stoffwechsels entsteht und somit eine große Gefahr für 
die genomische Stabilität darstellt. DNS Oxidation führt zur Anreicherung von 
mutagenem 8-hydroxy-2'-deoxyguanosin (GO), das hauptsächlich durch Basen-
Exzisionsreparatur (BER) repariert wird. G/C Basenpaare können zu GO/C oxidiert 
werden. Diese werden von der DNS Glykosylase OGG1 erkannt und mit Hilfe der 
nachgeschalteten BER Enzyme zu G/C korrigiert. Während der Replikation kann 
GO jedoch auch Fehlpaarungen mit Adenin (A) eingehen. Hierbei entstehende 
GO/As werden von der DNS Glykosylase MYH adressiert und nachfolgend durch 
BER repariert. Dabei wird das A entfernt, durch C ersetzt und somit ein GO/C 
Basenpaar generiert, welches erneut ein Substrat für OGG1-abhängige BER 
darstellt. Fehlfunktionen von MYH resultieren in G:C zu T:A Transversionen und 
stehen im Zusammenhang mit der Entstehung von MYH-assoziierter Polyposis 
(MAP). 
In den letzten Jahren wurde gezeigt, dass auch postreplikative 
Fehlpaarungsreparatur (mismatch repair = MMR) in die Reparatur von oxidativen 
DNA Läsionen, wie z.B. GO, involviert ist. Seine Rolle in diesem Prozess ist 
jedoch weitestgehend ungeklärt. Es ist bekannt, dass GO/A Fehlpaarungen 
schlechte Substrate für MMR darstellen. Allerdings zeigen wir hier, dass 
Zwischenprodukte der GO/A Prozessierung durch BER, nicht aber 
Zwischenprodukte der GO/C Prozessierung, als Strangdiskriminierungssignal für 
MMR dienen können. Dies zeigten wir in humanen Zellextrakten anhand von 
zirkulären Plasmiden, die entsprechende Läsionen trugen. Wir machten diese 
Beobachtungen nicht nur in humanen Zellextrakten, sondern auch in Extrakten aus 
Xenopus laevis Eiern. Während der S-Phase liegt GO vorwiegend im parentalen 
DNS-Strang vor. Daher würde MMR, das seinen Reparaturvorgang an 
Strangbrüchen (= 'nicks') initiiert, die während MYH-abhängiger GO/A-
Prozessierung durch BER auftreten, korrekterweise zum Tochterstrang dirigiert 
werden. Im Gegensatz dazu würden OGG1-generierte 'nicks' an GO/C Stellen 
MMR fälschlicherweise zum parentalen Strang dirigieren. Unsere Daten zeigen 
somit, dass die Prozessierung von oxidativem DNS Schaden durch BER so 
koordiniert ist, dass sie gleichzeitig zu einer Erhöhung der Replikationsgenauigkeit 
durch MMR führt. 
In einer ergänzenden Studie sollte das Interaktom des 
Fehlpaarungserkennungsfaktors MutSα während oxidativer DNS Schadensantwort 
bestimmt werden. Die Identifizierung von neuen Interaktionspartnern der MMR 
Proteine könnte genaueren Aufschluss darüber geben, wie das Zusammenspiel der 
verschiedenen Signalwege des DNS Metabolismus und der DNS 
Schadenssignalisierung in Zellen, die oxidativem Stress ausgesetzt sind, abläuft. 
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Hierzu generierten wir ein neuartiges Set an Expressionsvektoren und Zelllinien, 
die für zukünftige massenspektrometrische Analysen von MutSα 
Interaktionspartnern verwendet werden könnten. Weiterhin konnten wir bestätigen, 
dass MMR-Defizienz zu verringertem Zellüberleben sowie verlängertem G2/M-
Arrest führt.  
Poly(ADP-ribose) Polymerase 1 (PARP-1) ist ein Enzym, das extrem schnell durch 
DNS Einzelstrangbrüche aktiviert wird und mit hoher Affinität an diese bindet. 
Dieses 'nick-Protektor' Enzym scheint eine bisher noch nicht abschließend geklärte 
Rolle während BER zu spielen. Dennoch erlangte PARP-1 kürzlich erhebliche 
klinische Bedeutung, denn seine Inhibierung führt zur erfolgreichen Abtötung von 
BRCA1/-2 defizienten Brust- und Ovarialkrebszellen. Generell nimmt man an, 
dass die Inhibierung von PARP-1 zu toxischen Einzelstrangbruch/PARP-1 
Komplexen führt, die nur in der Anwesenheit von BRCA1/-2 repariert werden 
können. Allerdings sind die zugrundeliegenden Verursacher der 
Einzelstrangbrüche bisher undefiniert. Wir wollten daher herausfinden, ob die 
Brüche durch die Prozessierung spontaner oxidativer DNS Schäden entstehen 
könnten. Dazu führten wir Sensitivitätsstudien mit humanen BRCA1-defizienten 
Zelllinien durch und zeigten, dass MYH knockdown die toxische Wirkung von 
PARP-1 Inhibitoren verringerte. Die DNS Oxidation stellt somit eine Quelle für 
Schäden dar, die zur Toxizität von PARP Inhibitoren in BRCA-defizienten Zellen 
beitragen. In Bezug auf die klinische Anwendung zeigt dieses Ergebnis, dass eine 
Steigerung von oxidativer DNS Schadensprozessierung den Effekt von PARP 
Inhibitoren erhöhen könnte. 
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Acronyms 
AO:   2-hydroxyadenine 
AP-site:  apurinic site 
BER:   base excision repair 
CRC:  colorectal cancer 
Dox:   doxycycline 
ds:  double-stranded 
DSB:   double-strand break 
FAP:   familial adenomatous polyposis 
GO:   8-oxoG = 8-oxoguanine 
HNPCC:  hereditary non-polyposis colorectal cancer 
HR:   homologous recombination 
ICL:   interstrand crosslink repair 
LP-BER:  long-patch base excision repair 
MAP:  MYH-associated polyposis 
MEF:  mouse embryonic fibroblasts 
MMR:  mismatch repair 
MSI:   microsatellite instability 
MTX:  methotrexate 
NER:  nucleotide excision repair 
NHEJ:  non-homologous end joining 
PAR:   poly(ADP-ribose) 
PARP:  poly(ADP-ribose) polymerase 
PARPi:  PARP inhibitor/inhibition 
ROS:   reactive oxygen species 
SL:   synthetic lethality 
SP-BER:  short-patch base excision repair 
SSB:   single-strand break 
ss:  single-stranded 
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1 Introduction 
1.1 DNA damage & repair 
DNA is the carrier of our genetic information and encodes all proteins that are 
necessary for the metabolism and function of the cells. When Watson and Crick 
uncovered the molecular structure of DNA in 1953, its potential for replication and 
encoding information became evident for the first time. Nevertheless, their 
statement: "It has not escaped our notice that the specific pairing we have 
postulated immediately suggests a possible copying mechanism for the genetic 
material" [1], was a big understatement. Since DNA is continuously exposed to 
numerous DNA damaging agents, its faithful replication depends on multiple other 
factors too, like accurate polymerase activities and various DNA repair 
mechanisms. The absence of those factors can lead to gene mutations. Although 
mutations are indispensable for evolution, they become dangerous when affecting 
genes that are critical for the control of cell growth. In prokaryotes, the loss of 
essential genes leads to cell death, but this is not necessarily the case in higher 
eukaryotes. Here, cells can transform into a malignant cell population and lead to 
cancer.  
Although DNA is highly stable, it is a complex organic molecule that is susceptible 
to modifications by both exogenous and endogenous sources. The former derive 
from the environment, such as ultraviolet (UV) light, ionizing radiation (IR), 
chemicals or tobacco smoke [2, 3], whereas the three major forms of endogenous 
DNA damage are i) spontaneous depurination, ii) deamination and iii) reactive 
metabolites. Depurination occurs about 5000 times per cell per day and results in 
the loss of adenine or guanine by spontaneous hydrolysis of their N-glycosyl 
linkage to deoxyribose, resulting in abasic sites [4]. The most common 
spontaneous deamination, which occurs about 100 times per cell per day, converts 
cytosines to uracils, leading to U/G mispairs [4, 5]. Reactive metabolites occur in 
the form of reactive nitrogen (RNS) or oxygen species (ROS). The latter represent 
the greatest threat to genomic integrity; as many as 10'000 oxidations were 
estimated to take place per cell per day [6, 7]. 
To overcome the deleterious effects of DNA lesions, nature evolved a large set of 
DNA repair mechanisms with broad and partially-overlapping substrate 
specificities [2]. They present three major groups i) direct DNA damage reversal, 
ii) DNA single-strand repair, including base excision repair (BER), mismatch 
repair (MMR) and nucleotide excision repair (NER), and iii) DNA double-strand 
repair, namely homologous recombination (HR), non-homologous end-joining 
(NHEJ) and interstrand crosslink (ICL) repair. 
The different repair pathways will be the subject of the next chapters, followed by 
an introduction about the cellular sources of ROS and their effects on DNA. 
The meaning of faithful 
replication 
Exogenous and endogenous 
sources of DNA damage 
DNA repair pathways 
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Subsequently, I will provide a detailed overview of how BER and MMR are 
involved in the metabolism of oxidative DNA damage repair. This will be followed 
by a summary of the current knowledge about the protein PARP-1, with special 
regard to its involvement during BER. 
1.2 Direct DNA damage reversal 
The simplest and fastest way to deal with highly mutagenic and cytotoxic lesions is 
by direct chemical reversal of the DNA damage. This single-enzyme mechanism is 
essentially error-free, but targets only a limited substrate range. In contrast to most 
other repair mechanisms, it does not involve any incisions of the DNA sugar-
phosphate backbone. There are essentially three main types of direct DNA damage 
reversal systems: the removal of alkylation damage by i) alkyltransferases or ii) 
dioxygenases as well as the ii) elimination of UV-light-generated lesions by 
photolyases [8]. 
Alkylation damage derives from drugs like N-methyl-N'-nitro-N-nitroso-guanidine 
(MNNG), but may also arise from endogenous sources like the metabolite S-
adenosylmethionine (SAM). Alkyltransferases have evolved to repair methylated 
guanines, such as the mutagenic product O6-methylguanine (O6-meG). In bacteria 
this is performed by the C-terminal part of the O6-Agt protein, while in humans it is 
the O6-meG-DNA methyltransferase (MGMT). MGMT flips the O6-meG base out 
of the DNA duplex into its active site and removes the methyl group by irreversibly 
transferring it onto its cysteine residue [9]. MGMT is thus inactivated and is 
cleaved by ubiquitin-mediated proteasomal degradation [10].  
The specific repair of two other methylation products 1-methyladenine and 3-
methylcytosine is achieved by dioxygenases, namely AlkB in E. coli and 
ABH2/ABH3 in humans. This happens by iron-catalyzed oxidation and results in 
the release of the methyl-group as formaldehyde.  
Covalently-linked pyrimidine dimers induced by UV-radiation can be repaired by 
photolyases. They have been identified in various organisms, but not in mammals. 
They contain chromophoric groups and use the photon energy of blue light (300-
500 nm) in order to break the covalent bonds between the pyrimidines, thus 
regenerating the original bases [8, 11]. 
  
Direct DNA damage reversal 
Alkyltransferases 
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1.3 Single-strand repair 
Single-strand repair occurs if only one strand of the DNA helix contains a lesion. 
Depending on the nature of the lesion and the cell cycle stage, one of three single-
strand repair pathways will be deployed: base excision repair, mismatch repair or 
nucleotide excision repair. All use the second, intact DNA strand as template to 
correct the damaged strand. 
1.3.1 Base excision repair 
Base excision repair (BER) is indispensable for the maintenance of genome 
integrity and protects against premature aging, cancer and neurodegenerative 
diseases. It is a key guardian against multiple DNA alterations that frequently 
occur in DNA through oxidation, alkylation and deamination. Those base lesions 
cause generally only small distortions of the structure of the DNA helix, but 
because they may be mutagenic, or because they may destabilize DNA through 
spontaneous base loss, they must be efficiently removed from the genome. To 
ensure their faithful recognition and repair, a number of different DNA 
glycosylases have evolved. The first DNA glycosylase was discovered by Thomas 
Lindahl in 1974. He described an enzyme, today known as uracil-DNA glycosylase 
(UNG), that released uracil from DNA by cleavage of the N-glycosidic bond. He 
furthermore observed concomitant cleavage of the phosphodiester bond, followed 
by repair steps involving an exonuclease, a DNA polymerase and a DNA ligase 
[12] and thus outlined the basic steps of BER: i) base recognition and excision by a 
DNA glycosylase ii) incision of the abasic (AP) site iii) end processing by an 
endonuclease or lyase activity and iiii) polymerase-mediated repair synthesis and 
ligation (Figure 1-1). Currently, eleven human DNA glycosylases that recognize a 
wide range of DNA base modifications are known (Table 1-1) and can be 
subdivided into four structurally distinct superfamilies; helix-hairpin-helix (HhH) 
glycosylases including OGG1 and MYH, uracil DNA glycosylases (UDGs), 3-
methyl-purine glycosylases (MPG) and endonuclease VIII-like (NEIL) 
glycosylases. In terms of viability, fertility and mutation frequencies, single DNA 
glycosylase knockout mice display relatively mild phenotypes [14], with the 
exception of TDG, the inactivation of which is embryonic lethal in mice [15, 16]. 
Double or triple knockout mice display severe phenotypes, suggesting that some 
have overlapping functions in terms of substrate recognition. For instance, 
MYH/OGG1 double knockout mice have shortened life spans and are cancer prone 
[17]. Redundancy amongst the different DNA glycosylases allows backup repair 
mechanisms within the BER pathway and therefore leads to high repair accuracy. 
  
Single-strand repair 
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Table 1-1:  Mammalian DNA glycosylases. 
 Overview about the main substrates, modes of action and mutant phenotypes of the DNA 
glycosylases. 
Type of 
base lesion 
Name Physiological substrates Mono (M) / 
bi (B) 
functionality 
Mouse knockout (ko)/ 
knockdown (kd) phenotype 
Uracil in 
ssDNA & 
dsDNA 
UNG U, 5-FU, ss- and ds-DNA M ko: viable, B-cell lymphomas, 
disturbed antibody 
diversification 
 SMUG U, 5-hmU, 5-FU, ss- and 
ds-DNA 
M kd: moderate increase in 
mutation frequency (C  T) 
Pyrimidine 
derivates in 
mismatches 
MBD4 T, U, 5-FU, εC, opposite 
G, ds-DNA 
M ko: viable, elevated mutation 
frequency (C  T) 
 TDG T, U, 5-FU, εC, 5-hmU, 
5-fC, 5-caC; opposite G, 
ds-DNA 
M ko: embryonic lethal, aberrant 
DNA methylation and 
imbalanced chromatin marks 
in CpG-rich promoters 
Oxidative base 
damage 
OGG1 8-oxoG, fapy, opposite 
C, ds-DNA 
B ko: viable, accumulation of 8-
oxoG, elevated mutation 
frequency (G  T) 
 MYH A opposite 8-oxoG, C or 
G, 2-hA opposite G, ds-
DNA 
M ko: viable, see OGG1 
Alkylated 
purines 
MPG 3-meA, 7-meG, 3-meG, 
hypoxanthine, εA, ss- 
and ds-DNA 
M ko: viable, elevated levels of 
ethenoA and hypoxanthine 
Oxidized, ring-
fragmented or - 
saturated 
pyrimidines 
NTHL1 Tg, fapy-G, 5-hC, 5-hU, 
ds-DNA 
B ko: viable 
 NEIL1 Tg, fapy-G, fapy-A, 8-
oxoG, 5-hU, 5-hC, ss- 
and ds-DNA 
B ko: metabolic syndrome, 
increased damage levels in 
mitochondrial DNA; kd: 
hypersensitive to γ-radiation 
 NEIL2 As NTHL1 and NEIL1 B unknown 
 NEIL3 fapy-G, fapy-A, prefers 
ss-DNA 
B ko: normal 
U, uracil; A, adenine; T, thymine; C, cytosine; G, guanine; ss, single-stranded; ds, double-stranded; 
5-hm, 5-hydroxymethyl; 5-FU, 5-fluorouracil; ε, etheno; 5-fC, 5-formylcytosine; 5-caC, 5-
carboxylcytosine; 8-oxoG, 8-oxo-7,8-dihydroguanine; Tg, thymine glycol; FaPy, 2-6-diamino-4-
hydroxy-5-N-methylformamidopyrimidine; me, methyl; h, hydroxyl 
Taken from [13]. 
Although DNA glycosylases are highly specialized enzymes with different 
structures and substrate specificities, they all share a common mode of action. They 
flip aberrant bases out of the DNA helix in order to trap and subsequently excise 
them. The enzyme moves along the DNA helix and inserts an amino acid side 
Structure & function of DNA 
glycosylases 
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chain (in cases of OGG1: Phe 114, or MYH: Tyr 165) into the minor groove of the 
double helix to search for vulnerable sites. While normal Watson-Crick base pairs 
are not disturbed by this intercalation, abnormal base pairs are disrupted, which 
leads to extrusion of the aberrant base into the exo-site of the enzyme. If it is not 
the 'right' base, it will be released back into the DNA helix, otherwise it will be 
passed to the active-site pocket. Thus, the base will be fixed in a position that 
allows cleavage of its N-glycosidic bond [18]. There are three hypotheses how the 
DNA glycosylase efficiently finds its target while the latter two gained more and 
more importance. The first is that the enzyme flips out each base but only removes 
those that fit into its binding pocket. The second is that it additionally recognizes 
weakened Watson-Crick base pairs and only flips out specific bases. A third 
scenario suggests that 'breathing' of non Watson-Crick base pairs leads to transient 
extrusions of such bases, which only have to be trapped by the enzyme when they 
are extrahelical [19]. 
In terms of their catalytic mechanism, DNA glycosylases are subdivided into 
monofunctional and bifunctional enzymes (Table 1-1). Both will initiate nucleotide 
removal that results in 3'-hydroxy (OH) and 5'-phosphate (P) termini that can 
subsequently be used by a polymerase and a ligase respectively to refill the gap and 
seal the nick. However, the mechanism of creating these termini differs. 
Monofunctional glycosylases, such as MYH, UNG, SMUG1, MBD4, TDG and 
MPG, excise the substrate base by using a deprotonated water molecule as a 
nucleophile to attack the sugar C1', resulting in cleavage of the N-glycosidic bond 
and thus a free base and an apurinic (AP) site [13]. Further processing by apurinic 
endonuclease 1 (APE1) creates a nick 5' of the AP-site thus generating a 3'-OH and 
5'-deoxyribophosphate (dRP) termini. This is removed by the amino-terminal dRP 
lyase activity of polymerase-β [20], thus generating a single nucleotide gap 
containing 3'-OH and 5'-P termini (Figure 1-1).  
OGG1, NTH1, NEIL1, NEIL2 and NEIL3, which process oxidized bases, belong 
to the family of bifunctional glycosylases. They possess an additional AP-lyase 
activity that can further process the AP-site via β (e.g. OGG1, NTH1) or βδ (e.g. 
NEILs) elimination reaction. In the first case, the resultant 3'-phospho α,β-
unsaturated aldehyde (3' PUA) will be cleaved by APE1, while, in the latter case, 
the resultant 3'-P group will be eliminated by polynucleotide kinase 3'-phosphatase 
(PNKP). Both cases result in 3'-OH and 5'-P DNA ends, which can be used by 
polymerases and ligases, respectively [13, 21]. This last step of repair synthesis can 
occur via either short- or long-patch base excision repair (Figure 1-1). 
Monofunctional DNA 
glycosylases 
Bifunctional DNA 
glycosylases 
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Figure 1-1:  Subpathways in base excision repair. 
BER is initiated by mono- or bifunctional DNA glycosylases and can occur as either short- (right 
panel) or long-patch (left panel) repair. A DNA glycosylase recognizes the base lesion and excises the 
base by cleavage of the N-glycosidic bond (excision step). The resultant AP-site gets excised by either 
APE1 (upon action of monofunctional glycosylases) or the AP lyase activity of bifunctional 
glycosylases (incision step). End processing occurs via the lyase activity of polymerase-β, APE1 or 
PNKP, respectively. The resultant 3'-OH group will be elongated by a polymerase and the remaining 
nick will be sealed by a ligase (repair synthesis step). Taken from [22]. 
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Short-patch (SP) BER can appear in replicating as well as in non-replicating cells 
and leads to the replacement of only a single nucleotide. The single-strand break is 
recognized by X-ray repair cross-complementing 1 (XRCC1), which was described 
as a scaffold protein that coordinates the activities of its interacting partners such as 
polymerase-β and DNA ligase III (LIG III). [23-25]. The latter are responsible for 
gap filling and nick sealing (Figure 1-1).	   
In contrast, long-patch (LP) BER appears in replicating cells and displaces 2 to 10 
nucleotides [26] by a process that uses proteins that are also involved in replication. 
While polymerase-β	   is	   likely	   to	   incorporate	   the	   first	   nucleotide	   in	   LP	   repair	  
[27], the elongation step in this pathway is performed by a replicative polymerase 
such as -δ or -ε. Additional players required during this process are the 
polymerase's processivity factor proliferating cell nuclear antigen (PCNA) and its 
loading factor replication factor C (RFC). While flap endonuclease-1 (FEN-1) 
excises the displayed oligonucleotide, DNA ligase I (LIG I) is required for nick 
sealing [26, 28]. 
The choice between short- and long-patch BER depends on various factors, such as 
cell cycle stage, the type of lesion and the DNA glycosylase, ATP concentration or 
the structure of the 5' termini [29]. While ATP shortage was shown to result in 
XRCC1-promoted strand displacement by polymerase-β and LP-BER [30], 
efficient removal of 5'-dRP sites seemed to be important for the process of SP-BER 
[31], since otherwise the 5'-dRP site would make the nick refractory to ligation. 
However, the major role in pathway choice is played by the type of lesion and cell 
cycle stage. For example, the DNA glycosylases MYH and UNG were suggested to 
be involved mainly in LP-BER, since both enzymes preferentially locate within 
replication foci [32, 33]. Furthermore, MYH interacts with the replicating enzymes 
PCNA, RPA, APE1 and MSH6 [34, 35]. This hypothesis was further substantiated 
by a study showing that MYH-mediated repair of GO/A mismatches in HeLa 
extracts was completely abolished by the polymerase-α/-δ/-ε inhibitor aphidicolin 
[36]. The involvement of MYH-initiated BER during S-phase makes sense, since 
GO/A mismatches can only arise during replication and should be repaired 
immediately in order to prevent mutagenesis in the next round of replication. It was 
also hypothesized that NEIL1 and NEIL2, which preferentially excise lesions from 
DNA bubbles [37], which also occur at replication forks, might act during 
replication via LP-BER, while NTH1 that shares many substrates with NEILs, 
would act outside of S-phase via SP-BER [29]. OGG1 was also demonstrated to act 
via short-patch BER [38, 39]. However, there is no experimental evidence 
indicating in which cell cycle stage OGG1 might act. 
  
Short-patch BER 
Long-patch BER 
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1.3.2 Mismatch repair 
Postreplicative Mismatch repair (MMR) is a key guardian of genomic integrity. It 
has evolved to improve the fidelity of replicative polymerases by several orders of 
magnitude [40, 41]. Those incorporate non-complementary nucleotides with a 
frequency of 1:10'000 to 1:100'000 [42]. These replication errors can be recognized 
and repaired by the polymerase's intrinsic proofreading exonuclease activity, thus 
increasing replication fidelity by approximately 2 orders of magnitude. This is 
when MMR comes into play and detects mismatches that escaped the polymerase's 
proofreading process, thus increasing replication fidelity by approximately another 
3 to 4 orders of magnitude (Figure 1-2). 
 
Figure 1-2:  Determinants of replication fidelity. 
Above the line: relative contribution of polymerases, their proofreading activity and mismatch repair 
to replication fidelity. Below the line: representative values for the rates of single-base substitutions 
by different DNA polymerases. Taken from [43]. 
Mismatches are defined as non-Watson-Crick base pairs or small loops of 
extrahelical nucleotides, also referred to as insertion/deletion loops (IDLs), that 
arise from slippage of the two strands during replication [44]. Mismatches hence 
consist of undamaged DNA and become 'invisible' for repair after the next round of 
replication. To ensure efficient mismatch correction, MMR has to satisfy three 
criteria [44]. First, it has to correct the error before the next round of replication. 
The recruitment of MMR proteins to replicating DNA is probably enabled by an 
interaction of the mismatch recognition factors with the replication fork [44-47]. 
Second, in order to repair a broad range of different mismatches with different 
structures, MMR must be able to recognize different distortions in the DNA helix. 
Third, since the parental strand carries - by definition - the correct genetic 
information, MMR has to distinguish the parental from the daughter strand in order 
to direct the repair to the error-containing, newly synthesized strand. How this is 
achieved in pro- and eukaryotes, will be discussed in detail in the following 
sections. Beforehand, an overview of proteins involved in MMR pathways of E. 
coli and eukaryotes is shown in Table 1-2. 
Postreplicative MMR 
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Table 1-2: MMR factors in E. coli and eukaryotes and their functions. 
E. coli Eukaryotes Function 
MutS MutSα (MSH2-6) Mismatch recognition 
 MutSβ (MSH2-3)  
MutL MutLα (MLH1-PMS2) Molecular matchmaker; 
strand-specific endonuclease, 
 MutLβ (MLH1-PMS1) termination of excision 
 MutLγ (MLH1-3)  
MutH  strand-specific endonuclease 
UvrD (MutU)  DNA helicase 
ExoI, ExoX  3'-5' Exonuclease; mismatch excision 
ExoVII, RecJ EXOI 5'-3' Exonuclease; mismatch excision 
Pol III Holoenzyme Pol Repair synthesis 
β clamp PCNA Molecular matchmaker; repair synthesis 
γ Complex RFC β, respectively, PCNA loading; 3' nick-directed 
repair; activation of MutLα endonuclease 
Ssb RPA Single-stranded DNA-binding protein; repair 
synthesis 
 HMGB1 Accessory protein; stimulated excision 
 PARP Accessory protein; improved mismatch 
selectivity 
Modified from [44]. 
1.3.2.1 MMR in prokaryotes 
The MMR system has been extensively studied in E. coli. In 1989 it has first been 
reconstituted in vitro, using the recombinant proteins MutH, MutL, MutS, DNA 
helicase II (UvrD), single stranded DNA binding protein (Ssb), DNA polymerase 
III holoenzyme, exonuclease I and DNA ligase [48]. In E. coli, the MutS 
homodimer recognizes and binds the biosynthetic error and subsequently recruits 
the MutL homodimer in an ATP-dependent manner. The resulting ternary complex 
activates MutH endonuclease that incises the erroneous strand. Strand 
discrimination occurs via methylation. Newly synthesized strands in E. coli are 
methylated at the N6 position of adenine in GATC sites by deoxyadenine 
methylase (Dam). Since Dam lags behind the replication fork, transiently hemi-
methylated GATC sites are recognized by MutH and incised in the unmethylated 
strand [49, 50]. One of four exonucleases, together with UvrD helicase [51, 52], 
then degrades this strand towards and past the mismatch. Depending on the 
position of the nick relative to the mismatch, strand degradation will require either 
the 5'-3' exonucleases ExoVII or RecJ or the 3'-5' exonucleases ExoI or ExoX [53, 
54]. The gap is then filled-in by DNA polymerase III and the remaining nick is 
sealed by DNA ligase.  
Mismatch repair in 
prokaryotes 
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1.3.2.2 MMR in eukaryotes 
In eukaryotes, the situation is more complex than in E. coli. The main players act in 
the form of heterodimers and have diversified into more substrate-specific proteins 
(Table 1-2). MutS homologue 2 (MSH2) dimerizes with MSH6 or MSH3 to form 
MutSα or MutSβ heterodimers, respectively [55]. MutSα is more abundant and 
recognizes base-base mismatches and IDLs of one or two extrahelical nucleotides 
[56], while MutSβ binds to larger IDLs. However, studies with MutS knockout 
mice suggest their functions to be partially redundant [57-59]. MutL homologue 1 
(MLH1) dimerizes with post-meiotic segregation protein 2 (PMS2), PMS1 or 
MLH3 to form MutLα, MutLβ or MutLγ heterodimers, respectively [60]. Of the 
three, MutLα plays the most important role during MMR. The function of MutLβ 
is not defined yet, but might play a backup role for MutLα [40]. MutLγ is mainly 
involved in meiotic recombination, but may also play a role as MutLα backup [40, 
61]. Several years ago, the minimal human MMR system has been reconstituted 
from purified recombinant proteins. It is composed of MutSα or MutSβ, replicating 
protein A (RPA), exonuclease I (EXOI), proliferating cell nuclear antigen (PCNA), 
replication factor C (RFC), polymerase-δ and DNA ligase I [62, 63]. 
MMR is initiated by the binding of MutSα or MutSβ to the mismatch/IDL, 
followed by recruitment of MutLα. ATP hydrolysis causes a conformational 
change of MutSα, which converts it into a sliding clamp, enabling it to diffuse 
along the DNA backbone in either 5' or 3' direction, while searching for a strand 
discrimination signal [40]. This is where pro- and eukaryotes differ. Since 
eukaryotes lack d(GATC) methylation, MMR is targeted to the newly synthesized 
strand by strand discontinuities, such as preexisting termini [64]. Those might be 
gaps between Okazaki fragments on the lagging strand or 3' termini of the primer 
on the leading strand [40, 65] (Figure 1-3). 
  
MutS and MutL 
heterodimers 
Eukaryotic MMR 
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Figure 1-3:  Strand discrimination signals in E. coli and eukaryotes. 
Left: In E. coli, the newly synthesized strand (dark blue) is transiently unmethylated at GATC sites 
(empty circles) and can be incised by MutH either 5' or 3' to the mispair; filled circles, Dam 
methylated GATC sites. Right: In eukaryotes, the repairosome consisting of MutSα, MutLα, PCNA, 
RFC and RPA will identify the 3' terminus of the primer strand and MutLα will introduce random 
nicks at distal sites on the same strand (orange arrows). Taken from [65]. 
If the nick is 5' from the misincorporated nucleotide, MutSα/MutLα-stimulated 
EXOI will degrade the mismatch-containing strand in 5' to 3' direction. Once it has 
removed the mismatch, EXOI is no longer activated by MutSα, and is inhibited by 
MutLα and single-stranded DNA-bound RPA [66]. Since EXOI acts only in 5'-3' 
direction, an intrinsic endonucleolytic activity of the MutLα subunit PMS2, 
capable of inserting single-strand breaks in the vicinity of the mismatch, is required 
if the nick is 3' from the misincorporated nucleotide. In this case, MutLα 
endonuclease is activated in a MutSα-, RFC-, PCNA- and ATP-dependent manner 
[67, 68] and makes DNA incisions with a bias for the distal side of the mispair 
relative to the original strand break. Thereby it generates 5' nicks that serve as entry 
sites for MutSα/ MutLα -activated EXOI. Resynthesis is catalyzed by polymerase-δ 
and ligase I [40, 41] (Figure 1-4). 
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Figure 1-4:  5'- and 3'-directed mismatch repair in eukaryotes. 
A G/T mismatch made by polymerase-δ is detected by MutSα, which slides along the DNA contour 
searching for strand discontinuities. Right panel: If it encounters a nick 5' of the mismatch, the 5'-3' 
exonuclease EXOI can immediately be loaded to perform strand degradation. Left panel: If the strand 
discontinuity is 3' of the mismatch, such as the terminus of the leading strand, MutSα could displace 
the polymerase from its complex with PCNA. Loading of MutLα and reversal of the direction of the 
travel of the protein complex would allow MutLα to introduce nicks in the leading strand, which can 
then be used for EXOI-catalyzed strand degradation. For details see text. Modified from [69]. 
While MMR has been extensively studied in vitro, less is known about its 
mechanism in vivo. This has been addressed in some recent studies. Discrimination 
between the parental and daughter strand in eukaryotes remains puzzling, due to 
the unequal incidence of preexisting nicks in the two strands. Elevated levels of 
ribonucleotide (rNMP) incorporation into the leading strand were reported [70, 71] 
and intermediate products of their processing were shown to serve as entry sites for 
MMR [72]. rNMP processing might thus contribute to MMR activity on the 
leading strand to a certain extent, however, the origin of other essential strand 
discrimination signals remains to be elucidated. Two other studies addressed the 
interplay between chromatin and MMR. One of those revealed the epigenetic 
histone mark H3K36me3 to be required for MutSα recruitment to the chromatin in 
vivo. This was shown to occur via direct interaction with the PWWP domain of 
MMR in vivo 
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MSH6 [73]. Another study showed that the accessibility of mismatches in the 
chromatin for MMR proteins is facilitated by MSH6-mediated inhibition of 
nucleosome assembly by chromatin assembly factor 1 (CAF-1) [74]. This 
inhibition occurs via direct interaction of a PWWP-containing domain of MSH6 
with CAF-1. Since MSH6 plays an important role during the initial steps of MMR, 
the next section will provide a closer look at the structure of MutSα, especially of 
MSH6. 
The MSH6 protein was first described in 1995 as a partner of MSH2 [56]. Both 
proteins consist of five conserved domains, while MSH6 contains an additional N-
terminal disordered domain (Figure 1-5 A). All five domains of MSH6 and MSH2 
dimerize as an asymmetric mirror image with each domain juxtaposed (Figure 1-5 
B). Domain 1 allows DNA mismatch binding, which is conferred by the Phe-X-Glu 
motif of MSH6 and which is highly specific for the mismatched nucleotide [75]. 
This domain is connected via domain 2 to the lever, comprising domain 3. Domain 
4, the clamp region, allows unspecific DNA binding, while domain 5 contains an 
ATPase activity [76-78]. The latter has been subject of extensive studies and 
though the precise mechanistic outcomes of ATP binding and hydrolysis are not 
yet completely understood, it is likely involved in altering MutSα DNA binding 
activity and structural conformation [44, 79]. However, also the N-terminal domain 
of MSH6 has sparked interest, as there is emerging evidence that it is involved in 
MMR-dependent DNA damage response and communication with other DNA 
repair pathways [79, 80]. Both could be mediated by posttranslational 
modifications. In fact, a poly(ADP-ribose) binding site [81] as well as 22 distinct 
phosphorylation sites of MSH6 were identified within its N-terminus [79, 80]. It is 
likely that alterations in phosphorylation patterns might regulate its role in repair 
and signaling processes. Indeed, within the described phosphorylation sites, four 
CDK2 and one ATM/ATR recognition motif have been identified, suggesting its 
association with cell cycle and/or DNA damage responses [79, 82]. A role of the 
N-terminal MSH6 PWWP domain in chromatin packaging and its recruitment to 
chromatin has been discussed in the previous section. Furthermore, the nuclear 
localization signal (NLS), which is not present in MSH2, is required for 
MSH6/MSH2 heterodimer transport into the nucleus [79]. The conserved and 
extreme N-terminal PIP motif (QXX(L/I)XXFF) (aa 4-11) allows interaction with 
PCNA. This is required, though not indispensable, for 5'-directed MMR [45] and 
furthermore assumed to be responsible for recruitment of MMR proteins to 
replicating DNA [46, 47, 83, 84]. Besides this, PCNA was shown to activate 
MutLα endonuclease [67].  
  
Structure of MutSα 
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Figure 1-5:  Structure of MutSα. 
A) MSH2 (upper image) and MSH6 (lower image) domains in a comparative linear array. The 
domains (D) are abbreviated as follows. PIP: PCNA-interacting peptide, NLS: nuclear localization 
signal, FXE = Phe-X-Glu motif. Numbers of amino acids are indicated above the illustrated domains. 
B) MutSα in DNA binding configuration. Adapted from [79]. 
Beyond their function in the canonical mismatch repair pathway, MMR proteins 
are involved in a variety of other processes, such as meiotic and mitotic 
recombination, interstrand crosslink repair, DNA damage signaling and stability of 
trinucleotide repeats [85-93]. The role of MMR proteins in immunoglobulin class 
switching and somatic hypermutation, as well as in non-canonical MMR is 
interesting, since it is somehow counteracting their usual role in preventing 
mutagenesis [85, 94-97]. MMR has also been linked to oxidative DNA damage 
processing, however, its involvement in this process is still poorly understood and 
will be discussed in chapter 1.8. 
1.3.3 Nucleotide excision repair 
Nucleotide excision repair (NER) is the most versatile repair pathway in terms of 
lesion recognition. It addresses an extraordinarily wide class of helix-distorting 
lesions that interfere with base-pairing or obstruct normal replication and 
transcription. These lesions mostly derive from exogenous sources such as 
chemicals or UV-light that induces the formation of cyclopyrimidine dimers 
(CPDs) or 6-4 photoproducts (6-4PPs) [98]. But also protein-DNA complexes can 
be recognized by NER [99]. Inborn defects in NER genes are associated with three 
Role of MMR in other 
metabolic pathways 
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syndromes: Xeroderma pigmentosum, Cockayne syndrome and 
Trichothiodystrophy, all characterized by extreme sun sensitivity [100, 101]. The 
basic steps of NER are a) damage recognition, b) dual strand incision on either side 
of the lesion, c) release of the damage-containing oligomer, d) repair synthesis and 
e) ligation. The proteins involved in this reaction are not conserved amongst pro- 
and eukaryotes. While the former require only three proteins (UvrA, UvrB, UvrC), 
human NER comprises six core enzymes, namely RPA, XPA, XPC, TFIIH, XPG 
and XPF⋅ERCC1 [102-104]. In general, NER consists of two subpathways, global 
genome NER (GG-NER) and transcription-coupled NER (TC-NER). While GG-
NER surveys the entire genome, TC-NER repairs lesions on transcribed strands 
that block the elongating RNA polymerase [98, 105]. The two subpathways are 
therefore initiated differently. In GG-NER, bulky DNA lesions are detected by the 
enzyme complex XPC-RAD23B (Figure 1-6, A-B). TFIIH that comprises the 
helicases XPB and XPD interacts with XPC-RAD23B and forms a complex (C). 
The helicases unwind the DNA in both directions, whereas stalling of XPD at the 
modification verifies the lesion (C). This leads to the recruitment of RPA, XPA and 
XPG (D). Subsequent recruitment of ERCC1-XPF leads to the incision of the 
modified DNA strand 5' to the lesion (E). Subsequent XPG-mediated 3' strand 
incision leads to the release of a ∼30 nucleotides long oligomer in humans (F) 
[106]. The gap is then filled by polymerase δ/ε and its associated factors, and the 
remaining nick is sealed by DNA ligase IIIα/XRCC1 or DNA ligase I (G) [107]. 
TC-NER functions similarly, except that it does not require XPC-RAD23B for 
initiation, but rather stalling of the RNA polymerase and the factors CSA and CSB. 
 
Figure 1-6:  Global genome nucleotide excision repair. 
Unwinding of the DNA is followed by excision of the lesion-containing oligomer. DNA synthesis and 
ligation complete the repair process. For details see text. Taken from [107]. 
page 16 Role of Mismatch Repair, Base Excision Repair and PARP-1 in the Processing of Oxidative DNA Damage 
 
 Simone Repmann / IMCR - Institute of Molecular Cancer Research / D-BIOL 
Ei d gen öss isch e Tech n isch e H och sch ul e  Z ür i ch 
Swi ss  Fede ra l In s ti tu te  o f Tech n olo g y Zu r ich  
1.4 Double-strand repair 
As discussed in the beginning, if only one strand contains a lesion, it can be 
repaired with the help of the second strand that serves as template. In contrast, 
double-strand breaks (DSBs) are critical for the cell, since there is no template 
readily available for repair. DSBs can be induced by exogenous factors such as 
ionizing radiation (IR) or endogenous factors such as reactive oxygen species 
(ROS). In eukaryotes, two major pathways have evolved in order to repair DSBs, 
namely, homologous recombination (HR) and non-homologous end-joining 
(NHEJ). A third, minor pathway is single-strand annealing (SSA) repair. The 
choice of the repair pathway depends on the cell cycle phase. While NHEJ and 
SSA can act throughout the cell cycle, HR activity is restricted to S-phase [2, 108, 
109]. HR is the preferred pathway during S-phase, since it is essentially error-free. 
In contrast, NHEJ and SSA represent faster repair mechanisms, but are error-prone, 
which can lead to the loss of genetic information. 
1.4.1 Homologous recombination 
Homologous recombination (HR) uses the sister chromatid as template for re-
synthesis of the damaged strand. It takes place in three core steps: end resection, 
strand invasion and resolution (Figure 1-7, right panel). The initial step, end 
resection, involves the MRE11/RAD50/NBS1 (MRN) complex, BRCA1 and CtIP 
[110]. The endonuclease activity of MRE11 initiates the process by inserting a nick 
at a distance from the DSB [111]. This can be further processed in order to 
generate a single-stranded 3' overhang. The roles of BRCA1 and CtIP during end 
processing are less clear, but both were shown to promote HR [110, 112] and 
notably, BRCA1 interacts with both CtIP and MRN [113, 114]. The resultant 3' 
single-stranded DNA overhang is rapidly bound by RPA. RAD51 competes with 
RPA for binding to the DNA strand and will replace it with the help of its mediator 
BRCA2. In the absence of BRCA2, no RAD51 foci can be formed on the DSBs 
[115-117]. The RAD51 filament directs strand invasion to the homologous strand 
of the undamaged sister chromatid, thereby mediating the search for homologous 
sequences [118, 119]. A DNA polymerase will extend the 3' end using the 
homologous sequence as template. The resultant Holliday junctions can be 
resolved by e.g. MUS81/EME1 [120-122].  
A subpathway of HR is the single-strand annealing (SSA) mechanism. This does 
not require a sister chromatid, but uses sequence homologies of the complementary 
strand for strand annealing. The DSB is recognized by the MRN complex and 
processed until regions of homology on the two sides of the breaks are exposed. 
These regions are then paired and the overhangs are cropped off, so that the duplex 
ends can be ligated [99] (Figure 1-7, left panel). 
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As both HR and SSA rely on DNA end resection, both depend on BRCA1. In 
contrast to HR, SSA does not rely on strand invasion and can therefore dispense 
with BRCA2. This becomes apparent from the observation that defects in BRCA1 
lead to decreases in both HR and SSA, while loss of BRCA2 only decreases HR 
and, as a consequence, leads to stimulation of the alternative pathway SSA [123, 
124]. Even though BRCA1 and BRCA2 act at different steps during HR, both are 
essential for this process and defects in either gene, lead to increased breast cancer 
susceptibility. 
1.4.2 Non-homologous end-joining 
Since error-free HR is available during S-phase, non-homologous end-joining 
(NHEJ) occurs predominantly in G0- and G1-phases of the cell cycle when no 
sister chromatid is available. The fact that it is error-prone does not mean that it is 
just a poor alternative to HR. It is actually required during the processes of the 
immune response, such as V(D)J and class switch recombination (CSR). The core 
enzymes of classical NHEJ (c-NHEJ) are DNA-PK, XRCC4 and DNA ligase IV. 
DNA-PK consists of the DSB-binding heterodimer Ku70/80, as well as the DNA-
PK catalytic subunit (DNA-PKcs) [125] that contains a kinase activity. Once 
activated, DNA-PK phosphorylates itself and other c-NHEJ proteins [126-128]. 
The actual repair process is initiated by Ku-binding to the DSB, which then recruits 
DNA-PKcs. The proteins bring the double-strand DNA ends into close proximity, 
which can then be rejoined by XRCC4/DNA ligase IV (Figure 1-7, middle panel). 
Before ligation, DNA ends might have to be processed to generate blunt ends. 
Several factors have been suggested to be involved in this processing, including 
MRN, Artemis, PNK and WRN [129].  
In the absence of Ku70/80, a 20-fold less efficient alternative NHEJ (alt-NHEJ) 
pathway, also referred to as microhomology-mediated end-joining (MMEJ), has 
been observed [130]. Similar to SSA, it uses 3-16 base pair homologous sequences 
to align the broken strands and rejoin them by DNA ligase III [131]. 
When it comes to pathway choice, end resection is a major determinant of whether 
HR or NHEJ is used for DSB repair. Both pathways seem to keep each other in 
check. Thus, while Ku promotes NHEJ, its absence results in increased HR [132, 
133], suggesting that the presence of Ku at DNA ends blocks access to the end 
resection machinery. Also the proteins 53BP1 and RIF1 promote NHEJ, and four 
recent publications showed that this is because they prevent 5'-3' DNA end 
resection, as well as accumulation of BRCA1 at sites of DNA damage, specifically 
in G1 phase of the cell cycle [134-137]. In the absence of 53BP1, HR is increased 
[138] and, interestingly, the absence of 53BP1 or RIF1 even restored end-resection 
and HR in BRCA1-deficient cells [137, 139]. Conversely, HR might antagonize 
BRCA1 & BRCA2 in HR 
and SSA 
Classical NHEJ 
Alternative NHEJ 
Pathway choice 
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NHEJ by clipping Ku from the DNA ends by MRN and CtIP, thus allowing end 
resection [109] . 
 
Figure 1-7:  Double-strand break repair. 
Error-free repair during S- and G2-phases of the cell cycle is mediated by homologous recombination 
(right panel). Error-prone repair during G0- and G1-phase is mediated by non-homologous end-
joining (middle panel) or single-strand annealing (left panel). For details see text. Modified from 
[140]. 
1.4.3 Crosslink repair 
DNA interstrand crosslinks (ICLs) are highly toxic to the cell since they prevent 
the unwinding of the DNA helix, which leads to the block of replication and 
transcription. Natural sources of ICLs are byproducts of lipid peroxidation [141]. 
Also many chemotherapeutic drugs induce ICLs such as platinum-containing drugs 
(e.g. cisplatin), nitrogen mustards (e.g. melphalan) or mitomycin C. Fanconi 
anemia (FA) proteins represent the hub of ICL repair. FANCM recognizes the 
damage, which leads to the recruitment of the FA core complex (FANCA, 
FANCB, FANC, FANCE, FANCF, FANCG, FANCL) to the stalled replication 
fork and FANCD2/FANCI monoubiquitylation [142-144]. The latter allows the 
recruitment of nucleases to the sites of DNA damage [145]. Unhooking of the 
crosslink by dual incision of the DNA strand is followed by translesion synthesis 
(TLS) (see chapter 1.5), NER and HR that mediate damage bypass, removal of the 
crosslink and recombination of the broken ends, respectively [146]. Also BRCA1 
and -2 play a role during ICL repair since they are involved during the HR-step 
[147, 148], with BRCA1 participating also in the ubiquitylation of FANCD2 [149, 
150]. Defects in one of the 13 FA genes lead to a rare autosomal-recessive or X-
Crosslink repair 
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chromosome-linked disease that involves chromosomal instability and high 
sensitivity to ICL-inducing agents. 
1.5 DNA damage bypass 
Under certain circumstances, repair at replication forks could cause their collapse. 
In these cases, it is favorable for the cell to continue DNA replication and to repair 
it at a later time point. This can be achieved by translesion synthesis (TLS). TLS is 
conserved throughout evolution and relies on specialized polymerases that have 
more flexible base pairing properties than replicative polymerases. TLS 
polymerases are therefore characterized by low fidelity, a lack of proofreading 
activity, as well as relatively poor processivity. However, this allows them to 
temporarily take over DNA synthesis from polymerases-δ, -ε or -α in order to 
bypass certain lesions (see Table 1-3).  
Table 1-3: TLS human DNA polymerases. 
Polymerase name Polymerase family Proposed function 
η (eta) Y Bypass UV lesions 
ι (iota) Y Bypass UV lesions 
κ (kappa) Y Bypass UV lesions 
Rev1 Y Incorporation of C opposite abasic sites 
λ (lambda) X BER, NHEJ 
µ (mu) X NHEJ 
θ (theta) A DNA repair 
ν (nu) A Unknown 
ζ (zeta) B Bypass synthesis 
Modified from [43]. 
For example, the TLS polymerase-η has a large active site, which enables it to 
accommodate both bases of UV-induced cyclobutane pyrimidine dimer (CBP) in 
such a manner that the linked thymidines can correctly pair with incoming adenines 
[151, 152]. Mutations in polymerase-η lead to the clinical syndrome Xeroderma 
pigmentosum variant (XPV) [153], which is, similarly to XPA-XPG mutation-
associated disease, characterized by an increased risk of sunlight-induced skin 
cancer [154]. X-family polymerase members, such as polymerase-β and -λ, are 
involved in accurate bypass of the oxidative DNA lesion 8-oxoguanine, as 
discussed in chapters 1.6.4 and 1.7.1. On undamaged DNA, TLS polymerase 
activity would lead to mutations. Its access to DNA is therefore highly regulated by 
a polymerase switch. Both replication arrest and RPA-coated single-stranded DNA 
lead to monoubiquitylation of the proliferating cell nuclear antigen (PCNA) at 
lysine 164 by the E3 ubiquitin ligase RAD18 and the E2 ubiquitin conjugator 
RAD6 [155]. This allows a direct interaction of ubiquitin-PCNA with the 
ubiquitin-binding motif (UBM) or ubiquitin-binding zinc (UBZ) domain of Y-
Translesion synthesis 
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family polymerases [156, 157]. Phosphorylation and ubiquitylation of TLS 
polymerases have also been observed, but how they might regulate TLS is still 
unclear [158-162]. The best understood example is polymerase-η. This was shown 
to be monoubiquitylated on its carboxyl-terminus, which in turn inhibits its 
interaction with PCNA [160]. This suggests that ubiquitylation could be another 
regulator of TLS and that polymerase-η has to be deubiquitylated before it can be 
recruited to stalled replication forks. 
1.6 Cellular response to oxidative stress 
Life on earth has evolved in the presence of oxygen that allowed the evolution of 
aerobic creatures. However, their cellular respiration leads to the production of 
reactive oxygen species (ROS), which are a continuous threat to genome integrity 
and which led to the evolution of a battery of defense mechanisms. In the first 
instance, enzymatic as well as non-enzymatic antioxidants counter the 
accumulation of ROS in cellular compartments (see chapter 1.6.2). Remaining 
radicals can, however, oxidize the deoxynucleotide pool, which is in turn 
'detoxified' by the enzyme MTH1 (see chapter 1.7.4). However, oxidized 
nucleotides can still be introduced into DNA. In order to counteract their 
mutagenic potential, sophisticated systems have evolved in order to correctly 
bypass (see chapter 1.6.4) or repair these lesions (see chapter 1.7.1). The defense 
mechanisms and ways to deal with threat of oxidative DNA damage are discussed 
in detail in this and the following chapters. 
1.6.1 Sources of oxidative stress 
All aerobic organisms rely on mitochondrial respiration in order to generate energy 
in the form of ATP. This process strongly depends on the presence of oxygen that 
is converted into water molecules during this process. Nevertheless, normal cellular 
metabolism is also well established as a major source for endogenous ROS. During 
the electron transport of mitochondrial respiration, oxygen captures electrons and is 
thus transiently converted into ROS. Normally, its reaction with other molecules is 
prevented by the cytochrome oxidase complex that only releases the oxygen radical 
when paired with two hydrogen molecules, thus forming a non-reactive water 
molecule. However, this system is leaky and 1-5% of electrons escape from 
complexes of the electron transport chain and form superoxide anion radicals    
(O2-) in the presence of oxygen [163, 164]. Other endogenous sources of ROS are 
peroxisomes and inflammation [165]. The latter process involves phagocytes that, 
within a respiratory burst, release superoxide radicals and hydrogen peroxide 
(H2O2) that interact via the Haber-Weiss reaction to form highly reactive hydroxyl 
radicals (OH) [166] that destroy cells infected with bacteria or viruses. However, 
surrounding cells can also be affected. In addition, ROS can be generated by 
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exogenous sources such as ionizing or ultraviolet radiation, chemotherapeutic 
drugs or heavy metals [167-169]. 
ROS are oxygen-containing molecules that have an unpaired electron (Figure 1-8, 
shown in red) in its outermost shell of electrons and hence exhibit extremely high 
chemical reactivity. ROS include superoxide anions (O2-), peroxide (O22-) and 
hydroxyl radicals (OH) while oxygen (O2) and hydrogen peroxide (H2O2) 
represent reactive precursors. Although H2O2 is less reactive than some other ROS, 
it plays an important role during oxidative damage and carcinogenesis, since it is 
able to easily diffuse through biological membranes, which enables it to reach 
other cellular compartments, including the DNA-containing nucleus [170] ). 
 
Figure 1-8:  Electron structures of common reactive oxygen species (ROS). 
Unpaired electrons are indicated in red. Hydroxyl ion is presented as comparison to the hydroxyl 
radical, but is not a ROS. Oxygen and hydrogen peroxide represent unstable, reactive molecules but 
are, per definition, not ROS, since they do not have any unpaired electrons. Adapted from 
www.biotek.com. 
1.6.2 Antioxidants 
Reactive oxygen species can give rise to irreversible oxidation of cellular 
macromolecules such as lipids, proteins and DNA. However, the production of 
ROS during cellular metabolism is natural and living organisms have thus adapted 
by evolving a large number of antioxidant systems, which can be subdivided into 
two groups: enzymatic and non-enzymatic. 
Amongst the enzymatic antioxidants, three groups of enzymes have evolved: 
superoxide dismutases (SOD), catalases and peroxidases (Table 1-4). Superoxide 
dismutases play an important role in converting superoxide anions (O2-) that are 
generated e.g. during the electron transport chain of cellular respiration, into less 
toxic hydrogen peroxide and oxygen [172]. The antioxidant activity of SODs 
derives from their metal cofactors: manganese (Mn), copper (Cu) or zinc (Zn) that 
are bound to the enzyme. While Mn SOD is primarily present in mitochondria, the 
other two SODs are found in the cytosol. Since H2O2 is unstable and reactive, it has 
to be further detoxified. This is where catalases and peroxidases, which are further 
subdivided into peroxiredoxins (PRXs) and glutathione peroxidases (GPXs), come 
Definition & types of ROS 
Antioxidants 
Enzymatic antioxidants 
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into play. Catalases are located in peroxisomes or in the cytosol and degrade H2O2 
to water and oxygen, thereby finishing the detoxification reaction that was initiated 
by SOD [172]. Glutathione peroxidases can also reduce free hydrogen peroxide 
to water [172]. The reaction involves oxidation of the selenocysteine residue of two 
reduced monomeric glutathiones (GSH) by H2O2, which then results in a 
glutathione disulfide (GSSG) and two water molecules. Peroxiredoxin can also 
reduce H2O2 to a harmless water molecule. 
Table 1-4: Enzymatic antioxidants, their cellular location, substrates and corresponding reactions.  
Enzymatic antioxidant Cellular location Substrate Reaction 
Superoxide dismutase 
(Mn/Cu/Zn SOD) 
Mitochondrial matrix 
(Mn SOD) 
Cytosol (Cu/Zn SOD) 
Superoxide (O2-) 2 O2- + 2 H+  
H2O2 + O2 
Catalase Peroxisomes 
 
Hydrogen peroxide 
(H2O2) 
2 H2O2  O2 + 2 H2O 
Glutathione peroxidase 
(Gpx) 
Cytosol Hydrogen peroxide 
(H2O2) 
H2O2 + 2 GSH  
GSSG + 2 H2O 
Peroxiredoxin (Prx) Cytosol Hydrogen peroxide 
(H2O2) 
H2O2 + PrxS2  
Prx(SH)2 + 2 H2O 
Modified from [171]. 
In addition to those three main players in anti-ROS metabolism, there are also a 
number of non-enzymatic antioxidants. They include vitamins (e.g. A, C, E), 
organosulfur compounds (e.g. glutathione), coenzyme Q10, enzyme-bound 
minerals (e.g. zinc, selenium), carotenoids, nitrogen compounds (e.g. uric acid), 
phenolic acids and flavonoids [173]. They differ in their mode of action and 
cellular localization and thus represent another effective defense system against 
ROS. 
1.6.3 Oxidative damage on DNA 
If cellular ROS production exceeds the capacity of the natural defense mechanisms, 
cells undergo oxidative stress, which has been linked to aging, neurodegenerative 
diseases and also cancer. The latter is a consequence of DNA mutations that can be 
caused by ROS reaching the nucleus in the form of H2O2, since this small and 
uncharged chemical compound is able to easily diffuse through biological 
membranes and hence reach diverse cellular compartments [174]. Hydrogen 
peroxide spontaneously reduces to the highly-reactive hydroxyl radical (OH), 
which can then attack the DNA [168]. The electron-rich double bonds in the DNA 
bases, as for instance between N7-C8 of purines or C5-C6 of pyrimidines, as well 
as their labile hydrogens are especially vulnerable to radical attack [168]. However, 
more than 20 base lesions caused by reactive oxygen and free radical species have 
been identified (Figure 1-9). 
Non-enzymatic antioxidants 
Oxidative DNA damage 
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Figure 1-9:  DNA base products of interaction with reactive oxygen and free radical species. 
Taken from [168]. 
Of the four DNA bases, guanine has the lowest redox potential and is thus 
particularly susceptible to oxidation [18, 175]. The main products of guanine 
oxidation are 7,8-dihydro-8-oxo-guanine (8-oxoguanine, GO) and 2,6-diamino-4-
hydroxy-5-formamidopyrimidine (fapy-G). Their generation and structures are 
represented in Figure 1-10. 
 
Figure 1-10: Formation and structures of 8-oxoguanine (GO) and fapy-G. 
A hydroxyl radical attacks C8 of guanine thus forming either GO or fapy-G. Modified from [176]. 
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1.6.4 8-Oxoguanine 
8-Oxoguanine (GO), is one of the most abundant and also best-investigated lesions 
created by ROS. Its steady state levels are estimated to be 103 lesions per cell per 
day in normal tissues and up to 105 lesions per cell per day in cancer tissues [170, 
177, 178]. It is also used as a cellular biomarker to indicate the amount of oxidative 
stress [172].  
8-Oxoguanine endangers genomic integrity, since it does not only form Watson-
Crick-like base pairs with cytosine, but also functionally mimics thymidine and can 
hence form a Hoogsteen mispair with adenine (Figure 1-11) [18]. Those are 
mutagenic if unrepaired, and lead to G to T transversions, as described in detail in 
chapter 1.7.1.  
In order to pair with adenine, GO has to adopt a syn conformation as a prerequisite 
to form a GO(syn):A(anti) mispair. Such anti - syn base pairs can only occur via 
Hoogsteen base pairing, which is mediated by the hydrogen atom on the N7 
position as well as the oxo-group at the C6 position of the purine [18]. Such base 
pairs are rather rare; the majority of the DNA helix consists of Watson-Crick base 
pairs, in which the bases are in anti conformation (e.g. G/C and A/T) and purines 
form hydrogen bonds with their oxo-group at the carbon position 6 (C6), their NH 
group at N1 and their nitrogen group at carbon position 2 (C2). 
 
Figure 1-11: Structures of 8-oxoguanine-containing base pairs. 
The structures of the Watson-Crick base pairs G(anti)/C(anti) and T(anti)/A(anti) are compared with 
GO(anti)/C(anti) and the Hoogsteen mispair GO(syn)/A(anti). Adapted from [18]. 
  
Incidence of GO 
Ambiguous base pairing 
properties of GO 
Watson-Crick versus 
Hoogsteen base pairing 
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In an ideal case, DNA polymerases should not generate GO/A mispairs and even if 
they did, they should excise the mispaired nucleotide with the help of their 
proofreading activity. This is not the case; instead, GOs are efficiently bypassed by 
replicative polymerases. This happens at the cost of mutations, since these enzymes 
preferentially incorporate A opposite GO in the template strand [179-183]. This was 
clearly illustrated in a study by Hsu et al. [184]. Snapshots of X-ray crystal 
structures of Bacillus stearothermophilus (BF) DNA polymerase I fragment, which 
behaves analogously to replicative polymerases-α and -δ with respect to GO 
replication, were taken during GO/C and GO/A replication. Anti GO conformation in 
the template strand, a pre-requisite for pairing with C, lead to distortions in the 
template strand and also in the polymerase, as observed when polymerases 
encounter mismatches with their active site. This prevented the next template base 
from interaction with the pre-insertion site of the polymerase, explaining the 
polymerase's problem to elongate from GO/C base pairs. In contrast, 
GO(syn)/A(anti) mispairs did not lead to template or polymerase active site 
distortions. This is because the geometry of its minor groove, an area that the 
polymerase interacts with, is virtually identical to that of an A/T base pair and is 
therefore not recognized as a mismatch by the proofreading activity [184]. These 
data explain the more facile insertion of an A rather than a C opposite GO, its lack 
of detection as well as its ease of elongation by replicative polymerases. However, 
bypass of GO was shown to be correct in 80% of the cases in vivo [183], indicating 
that there must be other ways to bypass GO correctly. This can happen via a 
polymerase switch, where stalling of a replicative DNA polymerase leads to PCNA 
monoubiquitination and subsequent recruitment of a translesion synthesis (TLS) 
polymerase to the site of DNA damage [185] (see chapter 1.5). Although both 
polymerase-η and -λ can correctly bypass GO [186-188], it was shown that, in the 
presence of PCNA and RPA, polymerase-λ bypassed it more correctly. Its 
preference of C incorporation was 1200-fold higher than of A, while for 
polymerases-η it was only 68-fold [189]. Since polymerase-δ pauses at sites of GO, 
it was suggested that the error-free bypass of GO by polymerase-λ occurred via a 
polymerase switch [190]. This was not observed for polymerases-β and -η [190], 
supporting the observation that polymerase-λ is the most important and faithful 
polymerase during correct GO bypass. However, it does not only play a crucial role 
during GO replication, but also repair. Since every polymerase has a certain error-
rate, also GO replication will result in a certain percentage of A misincorporations. 
Those mutagenic mismatches are countered by MYH-initiated base excision repair. 
Also during this repair process, polymerase-λ seems to faithfully incorporate C 
opposite GO, as described in the following chapter.	  
Bypass of 8-oxoguanine 
page 26 Role of Mismatch Repair, Base Excision Repair and PARP-1 in the Processing of Oxidative DNA Damage 
 
 Simone Repmann / IMCR - Institute of Molecular Cancer Research / D-BIOL 
Ei d gen öss isch e Tech n isch e H och sch ul e  Z ür i ch 
Swi ss  Fede ra l In s ti tu te  o f Tech n olo g y Zu r ich  
1.7 Base excision repair in oxidative stress & disease	  
1.7.1 The 'GO system' - Base Excision repair of 8-oxoguanine 
As previously described, base excision repair (BER) repairs a very diverse range of 
base modifications, amongst those, the major byproduct of oxidative DNA damage: 
8-oxoguanine (GO). Thereby it makes use of a highly coordinated process referred 
to as the 'GO system'. As described in the last chapter, GO has ambiguous base 
pairing properties and can pair either with C or A [18]. While GO/C base pairs do 
not endanger genomic integrity, GO/A mispairs are mutagenic and result in G to T 
transversions if left unrepaired [191-194]. To counteract this, an ancient repair 
system has evolved, including the key players MutT, MutM and MutY [195]. In 
vertebrates, these proteins have orthologs: MTH1, OGG1 and MYH (= Mutyh, 
hMYH), respectively (Figure 1-12) [196]. The functions of the vertebrate orthologs 
are as follows. In the first instance, MTH1 counteracts incorporation of GO by 
eliminating it from the nucleotide pool by hydrolyzing dGOTP to dGOMP [197]. 
However, if GO arises in the template strand, thus leading to GO/C base pairs, 
OGG1 will excise the GO and subsequent processing by short-patch BER and 
polymerase-β will restore a G/C base pair [39, 198]. However, if GO/C remains 
unrepaired, polymerases might incorporate an A opposite the GO in the next round 
of replication [199]. In this case, MYH would remove the A from the GO/A 
mispair, and further processing by BER would re-generate a GO/C [200], which 
represents a substrate for OGG1. In order to prevent futile MYH-induced repair at 
GO/A sites, the BER polymerase has to insert a C opposite the GO rather than an A. 
Although polymerase-β and polymerases-δ/-ε are the main polymerases acting 
during short- and long-patch BER [27, 201-204], polymerase-λ	   was	   shown	   to 
accurately perform repair upon MYH-initiated BER. This occurs via long-patch 
BER (see chapter 1.3.1). In the presence of RPA and PCNA, polymerase-λ 
incorporates cytosine opposite GO 145-fold more efficiently than polymerase-β	  and 
additionally elongates the primer by one nucleotide [200, 205]). 
BER of 8-oxoguanine 
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Figure 1-12: Base excision repair pathways of 8-oxoguanine (GO). 
GO/C	   base	   pairs	   are	   addressed	   by	   OGG1-­initiated	   short-­patch	   BER	   that	   will	   remove	   GO	   and	  
polymerase-­β will incorporate a G. However if GO was not repaired successfully, in the next round of 
replication, adenine can be incorporated opposite GO, thus creating a target for MYH. It removes A 
from GO/A mismatches via long-patch BER. The resultant gap will be filled with a C by polymerase-λ,	  
thus	   resulting	   in	   a	   GO/C	   base	   pair,	  which	   represents	   a	   target	   for	   OGG1	   again.	  Unrepaired GO/A 
lesions will result in G to T transversions. 5'dRP: 5' deoxyribophosphate, 3'ddR5P: 3' phospho α,β-
unsaturated aldehyde. Taken from [206]. 
1.7.2 MYH 
Due to the frequent occurrence of GO in the DNA, as well to the mutagenic 
potential of GO/A mispairs, the absence of MYH would be expected to lead to 
increased spontaneous mutagenesis. Indeed, this is the case in MYH-deficient 
mouse embryonic stem cells and fibroblasts (MEFs) [207, 208]. In line with this, 
GO levels were also increased in the livers of MYH knockout mice [209]. Based on 
these findings, an increased tumor incidence would be expected in these mice, but 
the available data are somewhat controversial [17, 210]. 
This is not the case in humans. Twelve years ago, a new cancer type was 
discovered, today known as MYH-associated polyposis (MAP). This discovery 
was made by Al-Tassan and colleagues who studied a British family with three 
siblings suffering from multiple colorectal adenomas and carcinomas [191]. 
Sequencing of the APC gene in germline DNA samples excluded an inherited APC 
gene defect that is associated with familial adenomatous polyposis (FAP) and that 
leads to the described phenotype. Instead, colorectal tumors of the patients 
The effect of MYH 
deficiency in mice 
The history of MUTYH-
associated polyposis (MAP) 
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exhibited unusually high proportions of somatic G:C to T:A transversions in their 
APC genes. Since MutY-deficient E. coli exhibit the same mutation footprint [194], 
the patients' MYH genes were analyzed and found to be mutated; the patients were 
compound heterozygotes for the missense variants Tyr179Cys and Gly396Asp 
(this nomenclature refers to the longest MYH transcript NM_001128425.1). 
Corresponding mutations in E. coli MutY caused a decreased activity of those 
mutants on GO/A and G/A substrates [191]. Taken together, these findings 
indicated that MYH mutations were the cause of G to T transversions in the APC 
gene, which in turn led to a cancer phenotype similar to FAP.  
Although 303 unique MYH variants have been reported to date, in the LOVD 
database (www.lovd.nl/mutyh) in western European populations, the majority (up 
to 82%) was reported to be Y179C or G396D missense variants [211, 212]. Their 
location within the MYH gene is shown in Figure 1-13. Both regions are involved 
in GO recognition [213], thus explaining the decreased MYH activity in these 
variants [191]. Many more MYH variants of MAP patients have been tested by the 
time and all were impaired in GO/A repair [214-218] (see also chapter 1.8.1). 
Germline mutations in MYH are inherited in an autosomal recessive manner and 
are associated with colorectal polyposis. Although also extracolonic tumors have 
been reported in MAP, they only account for a small minority. A possible 
explanation for the colorectal phenotype in MAP might be the exposure of the 
large bowel to high levels of oxidative stress [211]. Resultant APC and KRAS gene 
mutations in the colon can be explained by the fact that G:C to T:A mutations in 
MAP patients predominantly affect GAA sites [191, 192], of which the APC gene 
contains 211. Since G to T transversions in GAA sites generate a stop codon, it is 
not surprising that the APC tumor suppressor gene is specifically susceptible to 
inactivation in the absence of MYH. Since a germline defect in both the APC gene, 
the underlying cause for FAP, and the MYH gene results in APC mutations, it is 
obvious that the phenotype of MAP, exhibiting ten to a few hundred colonic 
adenomatous polyps [211], resembles the phenotype of attenuated FAP (10-100 
adenomas) or FAP (100-1000 adenomas). In order to make the right diagnosis, 
analysis of the APC and MYH genes is therefore required. 
Apart from this, MAP caused carcinomas are near diploid and mostly microsatellite 
stable (MSS). The fact that microsatellite instability (MSI), a hallmark of MMR-
deficient tumors, was absent in those cancers led to the assumption that defects in 
both BER and MMR were not compatible with cellular survival. This assumption 
was refuted by the description of six MAP patients that contained tumors with high 
MSI (MSI-H) [219, 220]. In three cases, the MSI could be attributed to loss of the 
MMR protein MLH1 [221-223]. In one of these cases, the lack of MLH1 
expression could be traced back to biallelic methylation of the MLH1 promoter 
[221] while in another case a G to T transversion in the MLH1 gene led to complete 
Genotype of MAP 
Phenotype of MAP 
MMR mutations in MAP 
Doctoral Thesis Introduction  page 29 
 
 Simone Repmann / IMCR - Institute of Molecular Cancer Research / D-BIOL 
Ei d gen öss isch e Tech n isch e H och sch ul e  Z ür i ch 
Swi ss  Fede ra l In s ti tu te  o f Tech n olo g y Zu r ich  
depletion of the MLH1 RNA levels [222]. While MLH1 promoter methylation is 
rather unlikely to be a consequence of MYH malfunction, G to T transversions 
likely resulted from MYH dysfunction. Very recently, a seventh MAP patient with 
MSI-H tumors has been identified [224], Here, biallelic MYH mutations led to two 
somatic G to T mutations in the MSH2 gene, resulting in its loss of expression, 
MSI and tumorigenesis [224]. Although such cases of coexistent MMR and MYH 
defects are rare and their biological relevance remains to be elucidated, the 
described studies show that both defects are not mutually exclusive as suggested 
[225]. Furthermore, they demonstrated that MLH1 or MSH2 genes can be affected 
by MYH deficiency [222, 224] and hence the latter can mimic Lynch syndrome 
and lead to a wrong diagnosis.  
Although MYH dysfunction is mostly caused by the common Y179C and G396D 
missense mutations [211, 212], also its phosphorylation status seems to regulate its 
activity in vitro [226-228]. First hints were gained by Gu and Lu [226] who 
discovered that recombinant MYH purified from bacteria showed lower 
glycosylase and A/G binding activity than native MYH present in human cell 
extracts. Since bacterially-expressed recombinant MYH lacks posttranslational 
modifications (PTMs), its low activity was attributed to its phosphorylation status. 
Indeed, shrimp alkaline phosphatase (SAP) treatment of native MYH significantly 
decreased its activity [226], indicating that phosphorylation is needed for proper 
MYH function. This finding was confirmed by Parker et al. [228], who showed 
that protein kinase C or A (PKC or PKA) or casein kinase II treatment of human 
colorectal cancer cell extracts that lack MYH gene mutations but display defective 
GO/A repair, increased their GO/A repair capacity. At the same time, GO/A repair 
did not change in extracts with functional MYH. This indicates that in proficient 
cells MYH is already phosphorylated to a certain extent [228]. While the 
corresponding phosphorylation sites on MYH were unknown at that time, Kundu et 
al. [227] discovered a Ser524 phosphorylation site, which is located in the GO 
recognition domain within the PCNA binding region. This locus could explain the 
effect of phosphorylation on GO/A repair. An overview about the different MYH 
domains is provided in Figure 1-13. 
 
Figure 1-13: Schematic representation of the functional MYH domains. 
The loci of the most common MYH variants Y179C and G396D are indicated. Modified from [216]. 
Posttranslational 
modifications of MYH 
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Although very little is known about PTMs of MYH, it was recently shown to also 
undergo ubiquitylation by the E3 ubiquitin ligase Mule [229]. While this 
modification occurs in the 475 to 535 amino acid region and is responsible for 
MYH degradation, non-ubiquitylated forms of MYH accumulated on the 
chromatin. 
1.7.3 OGG1 
In contrast to MYH, OGG1 possesses not only a DNA glycosylase activity but also 
an AP lyase activity that allows the insertion of a nick into the DNA backbone via β-elimination. OGG1 is less well represented across phylogeny but present in most 
eukaryotic genomes. The enzyme was originally discovered in yeast in 1996, and 
one year later described in mammals [230-233]. It is the functional analog to the 
Fpg enzyme in bacteria [233, 234]. Both provide the major activity for removal of 
GO opposite cytosine, but also excise other oxidized pyrimidines or ring-
fragmented purines such as fapy-G [235, 236]. Many DNA glycosylases were 
shown to bind more strongly to the AP-sites they generated than to their substrates. 
This ensures protection of the noncoding and chemically unstable AP-site until 
cleavage of the phosphodiester bond allows processing by other BER enzymes and 
the release of the DNA glycosylase. Its release from the AP-site is therefore rate 
limiting and determines the turnover rate of the enzyme [237-241]. Surprisingly, 
the turnover rate of OGG1 was shown to be very slow, which was attributed to its 
weak lyase activity that cleaved AP-sites at half the rate of the glycosylase activity 
[240, 242]. However, addition of APE1 substantially increased the activity of 
OGG1 [240]. 
It remains to be elucidated whether its weak lyase activity is only an in vitro effect 
of OGG1 that was purified from bacteria [240, 242], or whether this is the same in 
vivo. The former assumption would be supported by the finding of Hu et al. [243] 
who showed that OGG1 is phosphorylated by the protein kinase Cdk4 and that this 
modification increases its incision activity on GO/C sites. Since proteins purified 
from bacteria lack proper posttranslational modifications, they would also miss 
such activating phosphorylation. Apart from Cdk4, two other kinases acting on 
OGG1 were described: c-ABL and PKC. But they failed to change OGG1 activity 
[243, 244]. Instead, protein fractionation of HeLa cells revealed that serine-
phosphorylated OGG1 was exclusively found on the chromatin [244]. This 
suggests that this modification affects the localization of OGG1.  
The fact that inactivation of OGG1 in S. cerevisiae leads to G to T transversions 
suggests a role for OGG1 in cancer prevention. Although OGG1 null mice exhibit 
abnormal levels of GO in their genome, the spontaneous mutation rate is only 
moderately increased and the mice do not develop malignancies [245, 246]. This 
can probably be explained by the function of MYH that acts as 'backup' pathway 
OGG1 glycosylase/AP lyase 
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and avoids G to T transversion mutations, but cannot remove the GOs from the 
genome. Although OGG1 gene defects have been observed in human lung and 
kidney cancer [247-251], it is currently not known to what extent they contributed 
to the cancer development. Overall, OGG1 mutations may have a limited impact in 
the development of tumors, due to the guardian function of MYH that counteracts 
the mutagenic potential of GO. 
1.7.4 MTH1 
Although research mainly focuses on the damage in double stranded DNA, the free 
dNTP precursor pool is also susceptible to DNA damage, hence also to reactive 
oxygen species (ROS). To counter the incorporation of damaged dNTPs and NTPs 
into DNA or RNA, an enzyme, MTH1, the human analog of bacterial MutT, has 
evolved in order to sanitize the (d)NTP pool. To do so, it efficiently hydrolyzes 
oxidized purine nucleoside triphosphates, such as 8-oxo-dGTP, 8-oxo-GTP, 2-
hydroxy(OH)-dATP and 8-oxo-dATP [197, 252] to monophosphates. Although 
seven different splice variants of MTH1 were identified, most of them encode an 
18 kDa variant [253], which is mostly localized in the cytoplasm and only to a low 
extent in mitochondria [254]. Defects in the bacterial mutT gene lead to a 100 to 
10'000 fold increase of A:T to C:G transversions [255], confirming its essential 
role in the removal of oxidized dATPs. Although MTH1 also removes oxidized 
dGTPs, the lack of G:C to T:A transversions can be explained by the activity of 
MutM/OGG1 and MutY/MYH (see chapter 1.7.1). The accumulation of 
transversion mutations in the absence of MTH1 suggests a role of this enzyme in 
cancer prevention. However, no report has described a link to human cancers to 
date. 
In contrast, inhibition of MTH1 was very recently described to selectively eradicate 
cancer cells but not normal cells, implicating that the latter can dispense with 
MTH1 [256, 257]. Due to this cancer-specific effect, MTH1 inhibition was 
suggested as a future therapeutic approach for cancer treatment [256, 257]. Gad et 
al. describe MTH1 as a 'non-oncogene addiction' target, since it is not a typical 
oncogene, but is indispensable for the survival of cancer cells. Hence its inhibition 
is suggested to cause lesser side effects in normal tissues than chemotherapeutic 
agents. MTH1 inhibitors could thus be more broadly applicable, irrespectively of 
the cancer genotype. This would also allow treatment of heterogeneous cancer 
tissues, as well as cancers without targetable mutations. The principle of this novel 
form of therapy was also described as 'cancer phenotypic lethality' [256]. However, 
both this and 'synthetic lethality' approaches (see chapter 1.9.4.1) have pros and 
cons, and the clinical applicability of 'non-oncogene addiction' target inhibition 
remains to be tested in future. 
MTH1 
Inhibition of MTH1 as novel 
cancer therapy 
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1.8 Mismatch repair in oxidative stress & disease 
1.8.1 Mismatch repair in oxidative DNA damage response 
Although it is well established that 8-oxoguanine (GO) is predominantly repaired 
by base excision repair (BER) (see chapter 1.7.1), several lines of evidence indicate 
that mismatch repair (MMR) is also involved in the processing of such lesions.  
In Saccharomyces cerevisiae, which lacks the BER enzyme MYH, MMR was 
linked to oxidized DNA metabolism. Earley and Crouse described a substantial 
increase in G to T transversion mutations in MSH2- or MSH6-deficient strains, 
which was decreased under anaerobic conditions [258]. They explained the high 
mutation rate with adenine misincorporations opposite GO, which would normally 
be prevented by MMR. This assumption was confirmed by genetic studies of Ni et 
al., showing that mutation rates and G:C to T:A transversions were synergistically 
increased in MutSα and OGG1 mutant strains [259]. Hence, this study proved that 
MutSα-dependent MMR is the major mechanism in S. cerevisiae by which GO/A is 
repaired.  
This is different in most pro- and eukaryotes. They possess MYH glycosylase, 
which initiates GO/A repair. Still, MMR-deficient cells exhibit sensitivity and 
prolonged G2/M arrest upon H2O2 treatment [260], suggesting a role of MMR 
during oxidative DNA lesion processing. Though its precise role is still poorly 
understood, it has been substantiated in various studies. Thus, GO levels were 
increased in the DNA of MSH2-deficient mouse embryonic fibroblasts (MEFs) 
[246], as well as in several organs of MSH2 knockout mice [208]. Studies in 
MMR-deficient MEFs showed that overexpression of MTH1, which eliminates 
dGOTP from the nucleotide pool, reduced steady-state and H2O2-induced GO levels 
[246], as well as mutation rates and microsatellite instability (MSI) at the hprt-
locus [261]. Those data point towards a replication-coupled role of MMR in the 
removal of GO from the newly-synthesized DNA strand [246, 261].  
However, in vitro data revealed that GO/A and GO/C base pairs were inefficiently 
recognized by MutSα [262], unless they were located in certain sequence contexts 
that resembled frameshift intermediates in C or A repeats [263]. In line with this, 
Mazurek et al. [264] determined the binding efficiency of MutSα as well as its 
ADP to ATP exchange rate on GO/C-containing oligos to be similar to homoduplex 
oligos. While both factors were increased on GO/A oligos, they were still low 
compared to G/T, GO/T or GO/G oligos [264]. 
The discrepancy between the data gained in vitro and in mice can be explained by 
recent data from Gu et al. [35]. They demonstrated MutSα, in particular MSH6, to 
directly interact with MYH and to stimulate its binding and glycosylase activity on 
GO/A sites, thereby raising the possibility that MYH and MutSα may act in the 
MMR in oxidative DNA 
damage response 
GO/A repair in yeast 
GO repair in mice 
GO repair in vitro 
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MutSα and MYH in 
oxidative DNA lesion repair? 
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same pathway. In this regard, Russo et al. [208] made some interesting 
observations. In MEFs, GO levels increased similarly in the absence of MSH2, 
MYH or both proteins when compared to wild type, hence confirming a role of 
both proteins in the same pathway. The observations made in MEFs differed from 
those made in mouse organs. Several organs only showed increased GO levels in 
MSH2-/-, but not in MYH-/- knockout mice. A synergistic increase in GO levels was 
observed in double-knockout mice, indicating independent functions of both 
proteins during oxidative DNA metabolism in vivo. This was confirmed by studies 
about life spans of mice, which were longer in MSH2-/-/MYH-/- double knockout 
mice than in MSH2-/- knockout animals. This observation implies that the shorter 
life span of MSH2-deficient mice could be caused by MYH activity [208]. 
However, a completely novel role of MutSα during oxidative DNA damage repair 
was recently described by Zlatanou et al. [265]. They unraveled an alternative 
pathway in response to oxidative stress that is independent of BER, but that 
depends on MutSα-provoked PCNA monoubiquitylation and subsequent 
recruitment of polymerase-η. They suggest that MMR and BER might recognize 
different forms of oxidative DNA modifications and that their mutual interference 
could help in their successful repair, especially in clustered lesions. During this 
process, polymerase-η may enable DNA damage bypass [265]. 
The observation about an interaction between MSH6 and MYH also attracted 
clinical interest. Several MYH mutations identified in MYH-associated polyposis 
(MAP) patients lie within or close to the MSH6 binding site, raising the question 
about a role of the disturbed MYH - MSH6 interaction during MAP progression. 
The phenotypes of different MYH variants were characterized in three studies 
[214-216]. All MYH mutants were strongly impaired or defective in GO/A repair, 
irrespective of the location of the mutation. Studies of Bai et al. [214, 215] 
demonstrated that three MYH missense mutations R227W, V232F and R231L that 
lie within or adjacent to the putative MSH6 binding domain and are associated with 
MYH polyposis, do not affect the interaction of the mutant with MSH6. Thus, the 
question whether a disturbed MSH6 - MYH interaction would play a role during 
MAP progression, currently remains open. 
1.8.2 The role of mismatch repair in cancer and drug resistance 
Defects in MMR were linked to Lynch syndrome, also known as hereditary 
nonpolyposis colon cancer (HNPCC) and predispose to tumors of the colon, 
endometrium, ovary or other tissues [267]. Those tumors display a mutator 
phenotype known as microsatellite instability (MSI), which results from defective 
repair of insertion/deletion loops during replication. HNPCC accounts for 
approximately 3% of all colorectal cancer cases [267, 268]. It is mainly linked to 
defects in the MMR genes, which can be caused by hypermethylation of the MLH1 
promoter or germline mutations in the MMR genes MLH1, MSH2, MSH6, PMS2 
Do MYH-MSH6 interactions 
play a role during MAP? 
HNPCC 
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and PMS1 [268-270]. The majority of mutations affect MLH1 (50%) and MSH2 
(40%), only to a minor extent MSH6 (10%) and PMS2/PMS1 genes [268]. Also 
knockouts of the MMR genes MSH2, MSH3, MSH6, MLH1, PMS1, PMS2 and 
EXOI in mice brought about MSI and therewith linked tumor development, 
reflecting the known functions of MMR proteins in tumor suppression. The tumor 
phenotypes in mice are summarized in Table 1-5.  
Table 1-5: Phenotypes of MMR-deficient knockout mice. 
Gene MSI Tumor Fertility 
MSH2 Yes Lymphoma, GI, skin, 
and other tumors 
Yes 
MSH3 Yes Tumor free or GI 
tumors at a very late 
age 
Yes 
MSH6 Low MSI in 
dinucleotide repeats 
Lymphoma, GI and 
other tumors 
Yes 
MLH1 Yes Lymphoma, GI, skin, 
and other tumors 
No 
PMS1 Mononucleotide repeats 
only 
None Yes 
PMS2 Yes Lymphoma and 
sarcoma 
Male infertile 
MLH3 Yes Not available No 
EXOI Yes Lymphoma No 
GI = gastrointestinal. Adapted from [271]. 
Interestingly, it has been shown that some HNPCC patients with MSH6 germline 
mutations also exhibited MYH mutations [225, 266], as described in the following 
two studies. Puijenbroek et al. identified a HNPCC patient with a MSH6 germline 
mutation that was at the same time compound heterozygous for MYH [225]. The 
question whether MYH was mutated due to dysfunction of MSH6, could be 
excluded since nuclear MSH6 was still expressed and the tumor did not show 
microsatellite instability (MSI), a hallmark of MMR deficiency. It only exhibited G 
to T transversions [225], resulting from MYH-defects. A study of Niessen et al. 
[266] showed that colorectal and endometrial tumors with MSH6 missense 
mutations showed significantly higher frequencies of coexisting monoallelic MYH 
mutations than MMR-proficient colorectal cancer patients. But again, MYH 
mutations were not caused by MSI and the link between MMR and MYH gene 
mutations in those cases remains unclear. It also remains to be elucidated whether 
such coexistence of BER and MMR mutations leads to faster progression of cancer 
[221]. 
Since MMR is not only involved in repair but also in the detection of various kinds 
of DNA damage, MMR-deficient tumors show resistance to many drugs. 
Treatment of those cancers therefore represents a major challenge. Resistance has 
MYH mutations in HNPCC 
MMR defects confer DNA 
damage tolerance 
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been reported to methylating agents (MNNG, MNU, temozolomide, procarbazine), 
alkylating agents (busulfan), platinum-containing drugs (cisplatin, carboplatin), 
antimetabolites (6-thioguanine) and topoisomerase II inhibitors (etoposide, 
doxorubicin) [272]. For instance, SN1 methylating agents such as MNNG, MNU or 
temozolomide, generate a variety of adducts, including the cytotoxic lesion O6-
methylguanine [273]. In MMR-proficient cells, MeG/C and MeG/T would be 
recognized by MutSα [274]. As MeG is in the template strand, MMR would 
repeatedly attempt to repair the lesion until the replication fork would arrest. This 
is known as the futile cycling model. In the absence of MMR, cells would not 
process the lesions and survive, at the cost of mutations [40, 275]. Interestingly, a 
PARP inhibitor AG14361 has been shown to restore temozolomide sensitivity in 
MMR-deficient cells, potentially due to impaired BER activity at other 
temozolomide-induced DNA lesions, such as N7-methylguanine or N3-
methyladenine [276]. However, the futile cycling model could also explain 
resistance to other alkylating agents, platinum drugs and 6-thioguanine that form 
base pairs resembling non-Watson-Crick pairs, thus representing potential targets 
for MutSα. The mechanism for resistance to topoisomerase II inhibitors is less 
defined yet [272]. Other drugs were reported to be equally effective in MMR-
deficient and -proficient tumors. An overview is provided in Table 1-6.  
Table 1-6: The effect of loss of MMR on sensitivity to cytotoxic agents. 
Resistance No effect 
Busulfan BCNU a 
Carboplatin Melphalan 
Cisplatin Oxaliplatin 
Doxorubicin Paclitaxel 
Etoposide Perfosfamide 
Mercaptopurine Transplatin 
MNNG  
MNU  
Procarbazine  
Temozolomide  
6-Thioguanine  
a BCNU, 1,3-bis(2-chloroethyl)-1-nitrosourea.  
Adapted from [272]. 
For instance, the nitrogen mustard melphalan, a bifunctional SN2 alkylator, is 
equally effective in MMR-proficient and -deficient cells [272, 277], possibly 
because it does not form DNA adducts, such as MeG [278]. Paclitaxel, a mitotic 
inhibitor, does not interfere with DNA and is therefore effective also in cells 
lacking MMR. While MMR-deficient cells are 2-fold resistant to Cisplatin [279, 
280], sensitivity of cells to the platinum-containing drugs Oxaliplatin and 
Transplatin seems not to be affected by MMR status [272]. Interestingly, 
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interstrand crosslinking agents, such as 1-(2-chloroethyl)-3-cyclohexyl-nitrosourea 
(CCNU) or 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) are the only agents 
described to date, that are more toxic to MMR-deficient than -proficient cells [281-
283] and hence deserve to be examined in more detail. However, this difference is 
not large and has not been seen in all experimental systems [277]. In conclusion, 
since effective treatments of MMR-deficient tumors are still rare, drugs making use 
of MMR deficiency according to the concept of synthetic lethality (chapter 
1.9.4.1), could be a promising alternative. 
1.8.3 Synthetic lethality in MMR-deficient tumors 
A body of data described sensitivity to oxidative stress and accumulation of 8-
oxoguanine (GO) in genomic DNA of MMR-deficient cells [208, 246, 260] (see 
chapter 1.8.1). Oxidative DNA damage thus represents an exception to the other 
drugs and might be a good target for exploiting the concept of synthetic lethality 
(SL) in MMR-deficient tumors. Indeed, some work in this field has been done by 
the research group of Alan Ashworth. A small molecule library screen identified 
the chemotherapy drug Methotrexate (MTX) to be specifically lethal to MSH2-
deficient cells [284]. Further experiments revealed that treatment with this drug 
resulted in increased GO levels in both MMR-proficient and -deficient cells. In 
MSH2-proficient cells, GOs were rapidly cleared, while they remained in the DNA 
of MSH2-deficient cells, potentially explaining the biological effect of MTX in 
MutSα-deficient cells. The accumulation of GO upon methotrexate treatment was 
attributed to the antimetabolite's property to inhibit dihydrofolate reductase 
(DHFR), which is involved in folic acid synthesis [284]. This in turn has 
antioxidant properties. This discovery resulted in a currently ongoing phase II 
clinical trial, testing the response of metastatic MSH2-deficient colorectal cancers 
to methotrexate [clinicalTrials.gov Identifier: NCT00952016]. Another study 
reported MSH2 to be synthetic lethal with polymerase-β (POLB), while MLH1 
was synthetic lethal with polymerase-γ (POLG) [285]. Upon POLB/G knockdown, 
MMR-deficient cells exhibited lower survival than their MMR-proficient 
counterparts. In the absence of MSH2/POLB, nuclear GO levels were increased, 
while MLH1/POLG synthetic lethality led to accumulation of GO in mitochondria 
[285]. Those data suggested a BER-independent or BER-backup role for MMR in 
oxidative DNA damage response and proposed polymerase targeting as a 
therapeutic approach. A recent publication of the same research group uncovered 
PTEN-induced putative kinase 1 (PINK1) to be synthetic lethal with MSH2, MSH6 
or MLH1 dysfunction [286]. PINK1 protects against oxidative stress-induced 
apoptosis by suppressing cytochrome c release from mitochondria [287]. 
Knockdown of PINK1 resulted in nuclear and mitochondrial accumulation of GO in  
Synthetic lethality in MMR-
deficient tumors 
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both MutSα- and MutLα-deficient backgrounds. Thus, based on the principle of 
synthetic lethality, PINK1 was also proposed as therapeutic target in such tumors 
[286]. 
1.9 PARP-1 and PARP inhibition 
1.9.1 PARP family 
In 1963, a NAD-dependent protein modification, today known as poly(ADP-
ribosyl)ation (PAR), was described for the first time [288]. Since then, 17 enzymes 
containing an ADP-ribosyltransferase catalytic core have been identified and this 
family was named PARP, which stands for poly(ADP-ribose) polymerase. In fact, 
some of the PARP family members were shown to be mono- and not poly-ADP-
ribosyltransferases. Hence, the name PARP does not fit to the catalyzed reactions 
and structural features of all of the PARP family members and a new nomenclature 
had therefore been proposed lately [289]: ARTD, an abbreviation for ADP-
ribosyltransferase Diphteria toxin-like. However, the term PARP is still more 
conventional. Among all family members, the best characterized is poly(ADP-
ribose) polymerase-1 (PARP-1). Its enzymatic activity and function, especially 
during DNA repair, will be discussed in detail in the following sections. 
1.9.2 Structure & function of PARP-1 
The PARP-1 protein consists of several structural and functional domains (Figure 
1-14). The amino-terminal DNA binding domain contains three zinc finger motifs, 
of which are two involved in DNA binding. The BRCT domain can be auto-
modified by PAR or mediate interactions with other proteins. While the function of 
the WGR (Trp-Gly-Arg) motif is as-yet unknown, the carboxyl-terminal catalytic 
domain is responsible for NAD+ binding to the highly conserved signature (Sig) 
motif, which defines the PARP family of proteins. The PARP regulatory domain 
(PRD) within the catalytic domain interacts with the substrate-binding site and is 
thought to control branching of the PAR chain [290]. 
 
Figure 1-14: Structural and functional domains of PARP-1. 
PARP-1 is a 116 kDa protein and contains the following domains. Zn1, Zn2 (amino acids 1-372): zinc 
finger motifs, ZBD: zinc binding domain, NLS: nuclear localization signal, BRCT: BRCA1 C-
terminus motif within an auto-modification domain (amino acids 372-524) also serving as site for 
protein-protein interactions, WGR (amino acids 525-643): unknown function. The carboxy-terminal 
catalytic domain (amino acids 653-1014) contains a PARP regulatory domain (PRD) and a highly 
conserved signature motif (Sig). Taken from [290]. 
PARP family 
Structure of PARP-1 
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PARP-1 can be activated by DNA breaks. Following its activation and binding to 
DNA breaks, the intrinsic enzymatic activity of PARP-1 catalyzes the transfer of 
ADP-ribose units from nicotinamide adenine dinucleotide (NAD+) onto target 
proteins or onto itself. As the polymer is negatively charged, auto-modification of 
PARP-1 leads to its repulsion and dissociation from the DNA. The enzymatic 
actions of poly(ADP-ribose) glycohydrolase (PARG) and ADP-ribose hydrolase 
(ARH) allow recycling of the PAR polymers and the PARP-1 molecule itself 
(Figure 1-15). 
 
Figure 1-15:  Enzymatic activities of PARP-1 and PARG. 
(A) PARP-1 on DNA strand breaks. DNA binding and activation of PARP-1 results in auto-modification of the protein by PARylation. 
After dissociation of the enzyme from the DNA, poly(ADP-ribose)glycohydrolase (PARG) mediated PAR degradation allows recycling 
of the PAR polymers and PARP-1. Taken from [291]. (B) Biosynthesis of NAD+ and PAR as well as degradation of PAR polymers. The 
latter is mediated by PARG, which hydrolyses glycosidic ribose-ribose bonds, and subsequently by ADP-ribose hydrolase (ARH), which 
removes the remaining mono-ADP-ribose from the protein. Taken from [292]. 
PARP-1 is an abundant nuclear protein, playing a key role in the regulation of a 
variety of nuclear processes, including DNA repair and gene regulation such as 
chromatin remodeling and transcription [290]. PARP-1 operates via three main 
mechanisms: i) its intrinsic catalytic domain allows posttranslational modification 
of other target genes, which modulates their function. ii) Also auto-modification 
can change its interacting properties with other proteins. iii) Furthermore, its BRCT 
Enzymatic activity of  
PARP-1 
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domain allows PAR-independent interactions with a variety of other proteins. Here, 
PARP-1 might serve as a scaffold protein, recruiting and directing proteins to their 
place of action. Other posttranslational modifications on PARP-1, e.g. 
ubiquitylation, acetylation, phosphorylation and SUMOylation have also been 
reported [292], thus broadening the mode of action of PARP-1.  
Remodeling of chromatin represents one of its major tasks. Thus, it was shown that 
PARP-1 activity on histone H1 [293], or other chromatin remodeling enzymes like 
ALC1 [294], leads to relaxation of the chromatin. Other data revealed PARP-1 to 
be involved in chromatin condensation by a mechanism in which the histone 
macroH2A1.1 senses PARP-1 activation and transiently compacts chromatin [295]. 
Furthermore, PARP-1 was shown to regulate gene expression by modulating the 
methylation status of DNA. This could be achieved through inhibition of Dnmt1 
methyltransferase by polymers of ADP-ribose [296]. Other studies showed PARP-
1 to stimulate or inhibit activators of transcription such as NF-κB [290]. 
1.9.3 PARP-1 in DNA repair 
PARP-1 has also been linked to various DNA repair processes. The following 
sections will provide a detailed overview about current knowledge of its diverse 
roles during homologous recombination, non-homologous end-joining, mismatch 
repair and base excision repair, whereas its role during the latter is by far most 
intensively studied. 
1.9.3.1 PARP-1 in homologous recombination 
Several studies showed that loss of PARP-1 did not affect homologous 
recombination (HR) of endonuclease-induced DNA double strand breaks (DSBs) 
or gene targeting efficiency [297, 298]. In contrast, hydroxyurea (HU) treatment, 
which causes dNTP depletion and replication fork arrest, led to an increased 
number of Rad51 foci [297], elevated levels of sister chromatid exchanges (SCEs) 
[298] and hence a hypermutagenic phenotype in cells that lacked PARP-1. In line 
with this, overexpression of PARP-1 in hamster cells caused over-accumulation of 
poly(ADP-ribose) and suppression of alkylation-induced SCE [299]. Overall, those 
data suggest that PARP-1 prevents inappropriate DNA recombination during repair 
and reactivation of stalled replication forks, while being dispensable in HR of 
DSBs. Insights into how PARP-1 could control HR processes at stalled replication 
forks, were gained by Bryant and colleagues. They observed PARP-1 binding to 
and activation by stalled replication forks, followed by PARP-1- and Mre11-
mediated replication fork restart. This was proposed to happen by PARP-1-
mediated Mre11 recruitment to the fork and Mre11-promoted end resection [300].  
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1.9.3.2 PARP-1 in non-homologous end-joining 
To date, only a few studies have addressed a possible role of PARP-1 in classical 
non-homologous end-joining (c-NHEJ). Most of them point towards its 
involvement via interaction with DNA-PK. In vitro studies revealed a stimulatory 
effect of PARP-1 on the kinase activity of DNA-PK by PARylation. Indeed, DNA-
PKcs has been identified as a PAR-associated protein [301], indicating that 
PARylated DNA-PK exists in vivo. Vice versa, DNA-PK can phosphorylate PARP. 
Although not well understood yet, this mutual interference of the two enzymes 
suggests a coordinated function of them during double-strand break repair [302]. 
Their interaction was recently confirmed in vivo by the purification of a PARP-
1/DNA-PK complex. Electron microscopy of this complex revealed that PARP-1 
caused major conformational changes in the DNA-PK synaptic dimer assembly 
[303]. However, further studies will be required for the better understanding of the 
role of PARP-1 during c-NHEJ. 
If c-NHEJ is genetically impaired, a slowly acting backup pathway, identified as 
alternative NHEJ (alt-NHEJ), can still perform repair of a large number of double 
strand breaks (DSBs) [304] (see chapter 1.4.2). It is widely accepted that PARP-1 
together with the XRCC1 - DNA ligase III complex is involved in alt-NHEJ. In 
vitro studies showed that those three enzymes promote end-joining, independent of 
the c-NHEJ complex DNA-PK/XRCC4-ligase IV [305]. The function of PARP-1 
in this backup pathway was confirmed by the finding that its inhibition 
compromises rejoining of DNA DSBs in the absence of the c-NHEJ factor 
Ku70/80 [306]. The role of PARP-1/XRCC1/DNA ligase III as back-up pathway, 
can be explained by competition of PARP-1 and Ku70/80 for binding to DNA 
DSBs. Due to the higher binding affinity of Ku70/80 to irradiation-induced lesions, 
PARP-1 activity on such lesions is suppressed and becomes only apparent in the 
absence of Ku70/80 [306]. The involvement of PARP-1 in alt-NHEJ, could also 
explain the embryonic lethal phenotype of PARP-1/Ku80 double null mice [307]. 
1.9.3.3 PARP-1 in mismatch repair 
A potential role of PARP-1 in mismatch repair (MMR) is also rather unexplored 
yet. The studies that have been done propose PARP-1 to be involved in this 
process. In silico studies suggested the MutSα component MSH6 to contain a 
poly(ADP-ribose)- (PAR-) binding sequence motif (see chapter 1.3.2.2), consisting 
of 20 amino acids that contain a cluster rich in basic amino acids and a pattern of 
hydrophobic amino acids interspersed with basic residues [81]. Polymer blot 
analysis confirmed PAR to interact with the 295-317 amino acid region of MSH6 
[81], suggesting that PAR binding of MSH6 could interfere with the mismatch 
recognition step of MutSα.  
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It was recently reported that MSH6 recruitment to the chromatin in vivo might be 
mediated by an interaction between the PWWP domain of MSH6 and the histone 
mark H3K36me3 [73]. Interestingly, unpublished data from our laboratory [370] 
revealed the PWWP domain of MSH6 to physically interact with PARP-1, which 
in turn is known to modulate chromatin. It would be interesting to elucidate 
whether PARP-1 is involved during the recruitment process of MSH6 to chromatin 
in vivo. The fact that MSH6 also contains a PAR binding site [81], would appear to 
support such an idea.  
Interestingly, the research group of Paul Modrich discovered that PARP-1 
enhanced the mismatch-dependence of 5'-directed excision in human mismatch 
repair in vitro [308]. In other words, the effect that 5' nicked mismatch-containing 
plasmids are preferentially repaired over 5' nicked homoduplex substrates, was 
increased in the presence of PARP-1. Such an effect of PARP-1 was not observed 
in 3'-directed excision [308]. They further narrowed this effect of PARP-1 to its 
Zinc finger-containing DNA binding domain, as well as to its BRCT domain. The 
latter was shown to physically interact with MutSα, RPA, EXOI and RFC. The 
catalytic domain of PARP-1, responsible for NAD+ binding, was not involved in 
this effect. Overall, they attributed the observed effect to a preferential suppression 
of EXOI by PARP-1 on 5' nicked homoduplex substrates than on 5' nicked 
heteroduplex substrates. Experiments suggested that a function of PARP-1 on the 
nick itself was rather unlikely. They hereby postulated PARP-1 to inhibit 
unspecific EXOI activities on 5' nicked homoduplex substrates. Since EXOI acts 
only in 5' to 3' direction, 3' nicked substrates are not affected by unspecific EXOI 
degradation, and therefore do not have to be protected by PARP-1-mediated EXOI 
suppression.  
1.9.3.4 PARP-1 in base excision repair 
Originally, base excision repair (BER) was described to follow a 'passing the baton' 
model [309], a well-coordinated process, in which single-strand break 
intermediates deriving from glycosylase and endonuclease/lyase activities, are 
passed from one enzyme to another and are inaccessible for other enzymes. This 
model was challenged by the discovery of PARP-1, which was shown to bind those 
'inaccessible' nicks and thus being involved in BER. First hints about a role of 
PARP-1 in BER were gained with PARP-1 knockout mice. Those are viable and 
fertile and have no overt phenotype. Nevertheless, they are sensitive to 
monofunctional alkylating agents and γ-irradiation that cause a variety of lesions, 
including damage that is recognized by base excision repair (BER) [310, 311]. 
Other studies linked the roles of PARP-1 and poly(ADP-ribosyl)ation (PAR) to 
oxidative stress [312, 313], which also generates lesions that are addressed by 
BER. The involvement of PARP-1 in BER was further substantiated by various 
studies. Thus it was shown to physically and/or functionally interact with key 
MSH6 interacts with   
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actors of the BER process like OGG1 [314], XRCC1 [315, 316], DNA ligase III 
and polymerase-β [317]. Also the processing of UNG- or OGG1-generated abasic 
(AP) -sites by BER was impaired in PARP-1-depleted extracts [316]. Moreover, 
PARP-1 was shown to bind to AP-sites in vitro and to be extensively modified by 
poly(ADP-ribosyl)ation upon APE1 activity at those sites [318]. 
These findings lead to a 'two-step' BER model [319] in which, upon generation of a 
nick by a glycosylase and endonuclease, PARP-1 detects and binds the strand 
break via its zinc finger domain (Figure 1-16). Thus, PARP-1 transiently protects 
the nick [320, 321] and simultaneously auto-modifies itself and other enzymes by 
PAR. It serves as a 'recruiting platform' for XRCC1, polymerase-β and DNA ligase 
III on the nick. Since the PAR modification on PARP-1 is negatively charged, this 
leads to a reduced affinity of the enzyme for DNA, it dissociates and allows access 
to the other repair proteins. However, although such model and other studies 
suggest that the presence of PARP-1 stimulates the BER process [316-318] and 
therefore accelerates single-strand break (SSB) repair [313], other studies show 
that PARP-1 is not absolutely required in these processes. 
 
Figure 1-16: Illustration of DNA SSB repair, and two models of BER. 
The 'two-step' BER model consists of strand incision by a glycosylase and endonuclease and 
subsequent single-strand break repair. The latter includes PARP-1 binding to the nick and auto-
PARylation of PARP-1, which is required for the recruitment of the downstream BER enzymes. The 
'one-step' BER model does not depend on PARP-1 activity. PARP-1 can bind transiently to the nick, 
but is not required for an efficient BER process. Modified from [319]. 
While mice lacking the key BER enzymes APE1 [322], polymerase-β [323] or 
XRCC1 [324] are not viable, PARP-1 knockout mice are [310, 311], indicating that 
PARP-1 is not an essential factor of the BER machinery. Furthermore, studies of 
Satoh and Lindahl demonstrated that, in the presence of NAD+, single-strand 
break-containing plasmids were repaired to the same extent when PARP-1 was 
present or absent in cell extracts [325]. Data from that time were supported by 
recent studies of Ström et al. [326], in which the absence of PARP-1 did not affect 
Two-step BER model 
One-step BER model 
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alkylation-induced SSB repair. Those studies support the currently accepted 'one-
step' BER model (Figure 1-16), in which the nick protector PARP-1 can transiently 
bind to DNA glycosylase-initiated nicks, but is not essential for the following BER 
process. 
1.9.4 PARP inhibition 
1.9.4.1 The principle of synthetic lethality 
PARP requires NAD+ for its enzymatic activity. To inhibit PARP, the development 
of NAD+-competitive nicotinamide mimics is therefore evident. Thus, the first 
PARP inhibitor (PARPi) which was described in 1971 was nicotinamide itself 
[327]. Since then, a multitude of PARP-inhibiting NAD+ analogs have been 
developed (Figure 1-17). Optimization of potency of inhibition and substrate 
specificity of these compounds have been the biggest challenges and are, due to the 
high sequence similarities amongst the different PARP family members, still 
challenging today. Although the reason for PARP inhibitor-mediated cell death 
was not understood yet, first clinical studies with this drug for cancer therapy were 
already performed in 2003. However, first important observations about the 
specific effect of PARP inhibitors in certain tumor tissues were only made in 2005. 
BRCA1- or BRCA2-deficient tumors were shown to be specifically killed by 
PARP inhibitors [328, 329]. The use of a DNA repair enzyme inhibitor, which 
specifically kills a tumor holding a certain mutation, in the absence of any 
exogenous DNA damage, presented a novel kind of cancer treatment at this time 
[328]. This observation represents an example for the 'concept of synthetic 
lethality' and was probably the first example that attained clinical application. 
 
Figure 1-17: Chemical structure of the PARP inhibitor and NAD+ analog Olaparib. 
Taken from [330]. 
The 'concept of synthetic lethality' is defined as a situation in which a defect in one 
of two genes individually has no implication on cell's fate, while a defect in both 
genes leads to cell death. 
Synthetic lethality of BRCA1- or BRCA2 mutations with inhibition of PARP-1 
was originally explained based on the 'two-step' BER model. Since in this model 
History of PARP inhibitors 
Concept of synthetic lethality 
Original model 
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PARP-1 is required for recruiting XRCC1, polymerase-β and DNA ligase III repair 
complex to glycosylase/endonuclease-induced nicks, it was assumed that inhibition 
of PARP-1 would interrupt the pathway and lead to an accumulation of single-
strand breaks (SSBs). Unrepaired SSBs would collapse replication forks into 
double-strand breaks, which would normally be repaired by BRCA-dependent 
homologous recombination (HR) (see chapter 1.4.1). But in the absence of BRCA, 
cells would undergo apoptosis [328, 329]. Furthermore it was assumed that PARP 
inhibition would show the same effect as the absence of the PARP-1 enzyme itself. 
Lately, this assumption was challenged by the following findings. The idea that 
PARP inhibition would lead to the same phenotype as the absence of PARP-1 was 
refuted by the observation that BRCA-defective cells were shown to be more 
sensitive to PARP inhibitors than to siRNA-mediated PARP-1 knockdown [328]. 
In line with this, depletion of PARP-1 did not affect alkylation-induced SSB repair, 
while the inhibition of PARP-1 lead to SSB accumulation [326]. Furthermore, 
already early in vitro studies done by Satoh and Lindahl demonstrated that, in the 
presence of NAD+, single-strand break-containing plasmids were equally well 
repaired irrespectively of whether PARP-1 was present or absent, but less 
efficiently repaired upon PARP inhibition [325]. Also siRNA-mediated depletion 
of XRCC1, which should also interrupt BER repair and leave behind SSBs, did not 
sensitize human BRCA2-deficient ovarian cancer cell lines [331]. Since these data 
showed that the absence of neither BER enzymes nor PARP-1 was toxic to HR-
deficient cells but only the inhibition of PARP-1, a new so-called 'trapping model' 
was proposed, which represents the currently accepted model. It suggests that 
PARP-1 transiently binds to SSBs. But since upon PARP-1 inhibition, PAR auto-
modification would be inhibited by the PARP inhibitor, PARP-1 would be trapped 
on the lesion (Figure 1-18). This enzyme-DNA complex could then be converted to 
a more toxic lesion during replication [319], representing a substrate that can only 
be repaired in the presence of HR. 
 
Figure 1-18:  Trapping model of PARP-1 inhibition. Modified from [319]. 
Trapping model 
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One explanation of how PARP inhibition could lead to cell death of HR-deficient 
cells was delivered by Patel et al. [331], who showed that non-homologous end-
joining (NHEJ) was stimulated specifically in HR-deficient cells upon PARP 
inhibition. Disabling of NHEJ by DNA-PK inhibition rescued sensitivity of these 
cells towards PARP inhibitors, suggesting that error-prone NHEJ might cause 
genomic instability in these cells. 
The progresses that were made in understanding the effects of PARP inhibition are 
important for efficient clinical applications. While the 'original model' implicates 
that PARP inhibition is most effective in cells with low PARP-1 levels, the 
currently accepted 'trapping model' suggests the opposite. Such understanding is 
especially valuable in terms of personalized medicine. 
1.9.4.2 Clinical applications of PARP inhibitors 
While PARP inhibitors represent promising drugs for the treatment of 
cardiovascular diseases and diabetes [332], their widest and most advanced 
application concerns the treatment of cancer. First clinical trials with potent PARP 
inhibitors started in year 2003 [333]. Several different PARP inhibitors are 
currently tested in clinical trials [330]. One of the most advanced and promising 
inhibitors is Olaparib (AZD2281) (Figure 1-17), which is currently in phase III 
clinical trials. Within the clinical studies, two different treatment approaches are 
pursued. The small molecules can be either applied as single agents or as 
combination treatment.  
The potency of PARP inhibitors as monotherapy for cancer cells with defects in 
DNA repair genes was discovered in 2005 [328, 329]. This finding was evaluated 
by following phase I clinical studies. Amongst them, the PARP inhibitor Olaparib 
was successfully tested in BRCA1 or BRCA2 mutation carriers [334]. Since 2013, 
the drug is being further evaluated as monotherapy in patients with BRCA mutated 
ovarian cancers in a phase III clinical study [clinicalTrials.gov Identifier: 
NCT01844986]. In the last couple of years, an increasing amount of other gene 
mutations has been reported to be synthetic lethal with PARP inhibition, such as 
PTEN [335]. PTEN gene mutations have been encountered in several cancers like 
prostate, endometrial, melanoma or brain tumors [330] and have been reported to 
cause homologous recombination defects [335]. 
Also colorectal cancer types that display microsatellite instability (MSI), 
accounting for 15% of all colorectal cancers, were tested for response to PARP 
inhibition in a phase II trial [clinicalTrials.gov Identifier: NCT00912743]. These 
studies could be promising, since 80% of MSI tumors were shown to be mutated in 
MRE11 [336], a protein also being involved in homologous recombination. Since 
the MRE11 gene contains a poly(T)11 tract, it might be predisposed for secondary 
mutations caused by MSI. Indeed, experiments showed that MRE11 deficiency in 
NHEJ confers PARPi 
sensitivity in HR-deficient 
cells 
Future perspective 
Clinical application 
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Monotherapy for MMR-
deficient tumors 
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microsatellite unstable colorectal cancer cells resulted in increased sensitivity to 
PARP inhibition [337]. A similar observation was done in ATM-deficient mantle 
cell lymphoma cells [338]. 
Other tumor types, which do not fulfill the prerequisite of synthetic lethality with 
PARP inhibitors, can be treated using combination therapy. Thus, additional 
exogenous DNA damage, which would normally be repaired in a PARP-dependent 
manner, will remain when PARP is inhibited. Another possibility is, that the HR-
machinery would be saturated by the tremendous amounts of generated DNA 
lesion - PARP-1 complexes. Examples are combinations with alkylating agents, 
topoisomerase I inhibitors, platinum drugs, radiation, nucleoside analogs or 
antimetabolites. This multiplicity of combinations resulted in a large number of 
clinical trials. 
Because of an increased tolerance to DNA damage, MMR-deficient tumors are 
resistant to some standard cancer chemotherapies such as platinum-based drugs, 
alkylating agents or inhibitors of topoisomerases, raising the need for more 
effective treatments. Interestingly, a study by Curtin et al. revealed that MMR-
deficient colorectal carcinoma cells that were resistant to the alkylating agent 
Temozolomide could be sensitized by additional treatment with the PARP inhibitor 
AG14361 [276]. A similar observation was made with MMR-deficient leukemia 
cells using the PARP inhibitor Veliparib (ABT-888) [339]. In both studies this 
effect was more pronounced in MMR-deficient than in -proficient cells, and should 
therefore be further explored.  
As is the case for many drugs, resistance towards PARP inhibitors has been 
reported in preclinical and clinical settings. Two main molecular mechanisms for 
this phenomenon have been observed. On the one hand it was shown that 
secondary mutations of BRCA1 or -2 genes could restore the proteins function. In 
particular in CAPAN1 cells, an intragenic deletion reconstituted the open reading 
frame of BRCA2, allowing expression of new functional isoforms [340]. On the 
other hand, upregulation of P-glycoproteins, key transporters involved in pumping 
xenobiotics out of cells, was described [341]. One explanation for that could be the 
role of PARP-1 as a 'master epigenetic regulator of gene expression', thereby also 
regulating P-glycoprotein promoter activity [342, 343]. Although drug resistance is 
a crucial issue, PARP inhibitors have tremendous therapeutic potential. New PARP 
inhibitors that should overcome resistance are currently being developed. One 
example is the inhibitor AZD2461, which is not targeted by P-glycoprotein. 
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2 Aims 
This introduction described the various repair mechanisms that contribute to the 
maintenance of genomic integrity, with a particular focus on repair pathways and 
proteins that are involved in oxidative DNA damage repair. Since oxidative stress 
is the major endogenous source of DNA damage and therefore linked to cancer and 
aging, it attracted our particular interest and we set out to learn more about its 
effect on cellular repair metabolism. It is well established that base excision repair 
(BER) is the main repair pathway of oxidative DNA lesions, such as 8-oxoguanine 
(GO). Here, the DNA glycosylases MYH and OGG1 are of unique importance, 
since they synergistically contribute to GO removal from the DNA (see chapter 
1.7.1). During the past years, experimental evidence implicated also postreplicative 
mismatch repair (MMR) in the processing of oxidative DNA damage, but the mode 
of its involvement is largely unknown (see chapter 1.8.1). 
I set out to elucidate the above phenomenon. Given that MMR was reported to 
exert a stimulatory effect on BER of GO, I decided to study how MMR and BER 
interact at sites of oxidative DNA damage. Within this project, I wanted to test 
whether BER processing of GO affects MMR activity and fidelity. 
An unbiased approach that might deliver additional insights into the largely 
unknown role of MMR in the metabolism of oxidative DNA damage is the 
characterization of the interactome of the main mismatch binding factor MutSα. A 
second aim of my PhD thesis was thus to generate expression vectors and cell lines 
that could be used for future mass spectrometric analysis of proteins interacting 
with MSH6 and/or MSH2. 
The third aim of my work focused on the role of PARP-1 and PARP inhibition 
during BER of oxidative DNA lesions. PARP inhibitors efficiently kill BRCA-
deficient breast and ovarian cancer cells. PARP inhibition leads to lethality, 
because single-strand break (SSB) - PARP-1 complexes that persist in the DNA 
upon PARP inhibition give rise to toxic lesions during replication that can only be 
repaired by homologous recombination (HR), which is defective in BRCA-
deficient cells. However, the source of the SSBs is currently unknown. Since the 
toxic effect of PARP inhibition does not require any additional sources of 
exogenous DNA damage, we hypothesized that it might depend on the main source 
of spontaneous DNA damage: oxidative stress. This would be in line with earlier 
studies, in which PARP-1 was linked to oxidative DNA damage response. 
Additionally, PARP-1 is known to have a role during BER. We therefore set out to 
test whether BER-mediated processing of oxidative damage contributes to PARP 
inhibitor sensitivity of HR-deficient cells. 
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3 Results 
3.1 Interdependence of base excision repair and mismatch repair 
during the processing of 8-oxoguanine in human cells 
3.1.1 Manuscript 
The following manuscript is in preparation and deals with the interdependence of 
base excision repair (BER) and mismatch repair (MMR) during the processing of 
oxidative DNA damage. We studied this phenomenon using substrates containing a 
single GO/A mispair or GO/C base pair in the close proximity of a G/T mismatch. 
Upon incubation with extracts of human cells or Xenopus laevis eggs, the G/T 
mispair is corrected to A/T or G/C, but only if a nick, which serves as a MMR 
initiation site, is introduced into the G or T strand, respectively. We showed that 
strand discontinuities arising during MYH-initiated BER of GO/A can also serve as 
MMR initiation sites. Since GO/A mispairs can only arise during replication 
through insertion of an A opposite GO in the template strand, we suggest that 
higher eukaryotes may use GO/A sites as additional strand discrimination signals 
for postreplicative MMR. This would lead to greater MMR efficiency and thus to 
an improved replication fidelity. 
Not all DNA glycosylases would favorably influence MMR efficiency. OGG1-
mediated processing of GO/C sites would misdirect MMR to the GO-containing 
template strand and lead to MMR-induced mutagenesis. Interestingly, we showed 
that GO/C was not processed in our extracts and thus did not activate MMR. These 
findings suggest that the processing of oxidative damage by the different pathways 
of DNA metabolism is tightly regulated, thus resulting in a beneficial effect on 
MMR fidelity. 
 
I contributed to this study by designing, performing and analyzing the experiments, 
as well as by drafting and editing the manuscript. 
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Abstract  
The major product of DNA oxidation, 8-oxoguanine (GO), has ambiguous 
base-pairing properties and is thus highly mutagenic. Although DNA 
oxidation gives rise to GO/C base pairs, GO in the template strand can pair 
with either C or A during replication. Similarly, oxidation of nucleotide pools 
can lead to dGOMP incorporation opposite template C or A. GO/C pairs are 
repaired to G/Cs by base excision repair (BER), which is in eukaryotes 
initiated by OGG1 glycosylase/lyase. OGG1-initiated BER should not address 
GO/A mispairs, because this would generate T/As instead of G/Cs. Instead, 
GO/A repair is initiated by MYH glycosylase, which removes the A. BER then 
regenerates a GO/C that can be re-addressed by OGG1. In Saccharomyces 
cerevisiae, which lacks MYH, GO/A mispairs are processed by post-replicative 
mismatch repair (MMR), and this pathway has been linked to oxidized DNA 
metabolism also in mammals. We show here that the human MMR system 
does not address GO/As in vitro, but that the intermediates of this MYH-
dependent BER process act as MMR initiation sites in extracts of human cells 
or Xenopus laevis eggs. Unexpectedly, this was not the case for GO/Cs. We 
postulate that MMR in higher eukaryotes adopted GO/A processing 
intermediates as strand discrimination signals.  
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Introduction 
Reactive oxygen species arising during cellular metabolism or through the action 
of external agents represent a constant threat to genomic integrity of all organisms. 
Although estimates vary, resting human cells harbor in their DNA between 1000 
and 10’000 residues of 8-oxo-2’-deoxyguanosine, the predominant product of 
DNA oxidation [1-3]. This nucleoside has mutagenic potential, because the 
modified base, 8-oxoguanine (GO), can adopt either anti or syn conformation about 
the glycosidic bond [4, 5]. In resting cells, most GO residues are in GO/C pairs, in 
which GO is in the anti conformation. In eukaryotes, these lesions are addressed 
primarily by 8-oxoguanine DNA glycosylase (OGG1), a glycosylase/lyase that 
removes the oxidized base and cleaves the sugar-phosphate backbone to initiate a 
process of base excision repair (BER), which ultimately replaces the oxidized 
nucleotide with a dGMP [4]. 
Should GO persist in the DNA until replication, however, the polymerases α, δ or ε 
will insert a C opposite anti-GO to form a Watson-Crick-like GO/C base pair, but an 
A opposite syn-GO to form a Hoogsteen GO/A mispair [6-8]. The former lesions 
can be repaired by OGG1-dependent BER to G/C, but OGG1 does not address 
GO/A mispairs. Instead, they are recognized by the MutY homolog (MYH) 
glycosylase, which removes the mispaired A and thus initiates a BER process that 
generates a GO/C, which can then be repaired to G/C by OGG1-dependent BER [9, 
10]. 
The above scenario is further complicated by the fact that incorporation of a 
dGOMP into the nascent DNA strand opposite C or A can give rise to C/GO and 
A/GO base pairs. These events should be rare, as dGOTP in nucleotide pools is 
readily hydrolyzed to dGOMP by the MutT homolog 1 (MTH1) protein [11-13]. 
However, when C/GO or A/GO do arise, they could present a problem to the repair 
machinery. Thus, although OGG1-dependent BER would eliminate the C/GO pairs, 
MYH-mediated removal of an A in the template strand from an A/GO mispair 
would give rise to an AC (TG in the opposite strand) transversion mutation. 
That the latter mutagenic events are rare can be inferred from the finding that DNA 
oxidation gives rise predominantly to GT rather than AC transversions [14-17]. 
This implies that the activity of MYH during replication is restricted to GO/A rather 
than A/GO mispairs. How might this be achieved? One possible scenario involves 
the participation of mismatch repair (MMR) [18-20].  
By removing errors of DNA polymerases (primarily base-base mismatches and 
insertion-deletion loops) from the nascent strand, MMR improves replication 
fidelity by up to three orders of magnitude [21, 22]. Given the mispairing potential 
of GO, it seemed logical to anticipate that MMR would be involved in the 
processing of oxidative DNA damage. Unexpectedly, GO/A and GO/C were shown 
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to be poor substrates for the human mismatch recognition protein MutSα (a 
heterodimer of MSH2 and MSH6) [23] and neither lesion was efficiently repaired 
in an in vitro MMR assay [23, 24]. However, in vivo, MMR deficiency was shown 
to lead to an extended G2/M arrest and hypersensitivity to H2O2 treatment [25], 
which was accompanied by accumulation of GO in genomic DNA [26, 27]. 
Overexpression of MTH1 decreased GO levels as well as mutation rates at the 
HPRT locus of MMR-deficient cells, which implicated MMR in the removal of GO 
from the nascent DNA strand [26, 28]. One explanation for this discrepancy might 
be that MMR is not directly involved in GO processing, but rather that it might 
modulate BER efficiency, as suggested by the identification of a physical 
interaction between MYH and MutSα, which increased the binding affinity of 
MYH for GO/A [19].  
The likely interplay between BER and MMR in GO processing requires further 
study. Recent description of a process activated by oxidative DNA damage that 
requires MMR but not BER proteins, and that involves MutSα-dependent PCNA 
monoubiquitylation and recruitment to chromatin of the translesion polymerase η 
[29] suggests that MMR might play additional roles in GO metabolism. In this 
study, we studied the cross-talk between BER and MMR and show that the MMR 
excision machinery is activated by strand breaks arising after MYH-catalyzed 
removal of adenines from GO/A mispairs in extracts of human cells or Xenopus 
laevis eggs. A similar stimulation was observed neither with GO/C-containing 
substrates, nor with substrates containing 2-hydroxyadenine (AO), another product 
of DNA oxidation [3], even though AO/C and AO/G mispairs were previously 
shown to be addressed by MYH [30, 31].  
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Results 
GO/A mispairs are not addressed by canonical MMR, but their processing by 
MYH is stimulated by MutSα 
BER and MMR are mechanistically distinct biochemical pathways. They differ 
principally in their substrate specificity and in repair patch size. The specificity of 
BER is dictated by the enzymes that initiate the process, DNA glycoslases, which 
recognize and excise a limited number of substrates (mostly modifed bases) [32]. 
The repair process is thus initiated at the site of the modification and involves the 
replacement of a single (short-patch BER) [33] or only 2-6 (long-patch BER) 
nucleotides [34, 35]. MMR addresses non-Watson-Crick base pairs that arise 
during replication, but, in contrast to BER, the excision process initiates at a site 
distal to the mispair, at a strand discontinuity that denotes the nascent (and thus the 
error-containing) DNA strand. The repair tracts can thus be several hundred 
nucleotides long [36, 37]. Because we wished to study the potential interplay of 
BER and MMR in the processing of substrates that could conceivably be addressed 
by both systems, we first needed to find out whether both repair pathways were 
active in our cell extracts and to establish experimental conditions that would allow 
us to distinguish between the two processes. To this end, we generated covalently-
closed circular phagemid substrates containing a single G/T, GO/C or GO/A base 
pair. We then incubated these heteroduplexes with extracts of human cells that 
were supplemented with radiolabelled nucleotides. Following recovery of the 
phagemids, restriction digest with NotI and BsaI, and separation of the fragments 
on agarose gels, we anticipated that long-patch repair events (MMR) would give 
rise to heteroduplexes labeled in both fragments, whereas short-patch events (BER) 
would yield fragments containing only very limited amounts of radionucleotides 
and only in fragment f (Fig. 1A). 
In the first experiment, we first introduced a nick into the Nt.BstNBI site (Fig. 1A) 
and incubated the substrates with extracts of MutLα-deficient HCT116 cells (Fig. 
S1A) that were supplemented with purified recombinant MutLα and [a-32P]dCTP. 
As shown in Fig. 1B, intense radiolabelling was seen only in the bona fide MMR 
substrate G/T (lane 4). That both fragments f and g were labeled with similar 
intensity indicates that the repair patch spanned at least the distance of 363 
nucleotides between the nick and the mispair. Only background amounts of [a-
32P]dCMP were detected in the f and g fragments of the control homoduplex, GO/C 
or GO/A substrates (lanes 1-3), which confirms that the GO/C and GO/A pairs are 
not efficiently addressed by MMR [23, 24]. 
MYH-initiated BER of the GO/A mispair should give rise to GO/C. Thus, when the 
extracts are supplemented with [a-32P]dCTP and when the substrate is unnicked, 
we should detect specific, albeit only limited, incorporation into the f fragment 
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(Fig. 1C). Moreover, this repair should be stimulated by MutSα, as reported 
previously [19].  
When the substrates were incubated with HCT116 extracts that were additionally 
immunodepleted of MutSα with anti-MSH6 antibodies (Fig. S1B), we detected low 
levels of [a-32P]dCMP incorporation into fragment f, which were approximately 
1.5-fold higher in the extract containing MutSα (Fig. 1D). 
MYH-dependent mismatch repair in human nuclear cell extracts  
Having obtained preliminary evidence that both BER and MMR are active on our 
substrates in the extracts, we next wanted to learn whether there was a cross-talk 
between these processes. To address this question, we deployed a phagemid 
substrate containing a G/T mismatch within the unique SalI restriction site 
(supercoiled or nicked with Nt.BstNBI 376 nucleotides 3' from the mispaired T), a 
phagemid containing a single GO/A mispair in addition to the G/T (GO/A-G/T) and 
a control phagemid GO/A-G/C. Upon incubation with the cell extracts, the 
recovered phagemids are digested with SalI and DraI to give rise to the pattern of 
bands shown in Fig. 2A. Successful repair of the G/T mismatch to G/C regenerates 
the SalI site and the plasmid is cut into 4 instead of 3 fragments. This process 
should be dependent on the presence of a nick in the T strand, as MMR requires a 
strand discontinuity for initiation of the EXOI-dependent excision step [38, 39]. 
When the above substrates were incubated with MMR-deficient HCT116 nuclear 
cell extracts supplemented with [a-32P]dATP, only background levels of repair and 
[a-32P]dAMP incorporation were detected in the bona fide MMR substrate, nicked 
G/T (Fig. 2B, lane 2). However, the same substrate was repaired with high 
efficiency when the extracts were supplemented with purified recombinant MutLα 
(lane 3), particularly when compared to the unnicked control G/T (lane 1), which 
was processed to a limited extent by non-canonical MMR [40]. Strikingly, while 
only low levels of [α-32P]dAMP incorporation were detected in this system when 
the supercoiled GO/A-G/C control substrate was used (lanes 6-7), around 60% of 
the unnicked GO/A-G/T phagemid were repaired in the extract supplemented with 
recombinant MutLα (lane 5). This result implies that A opposite GO can serve as a 
cryptic strand discrimination signal for MMR. 
We postulated that the MMR machinery might be hijacking intermediates of GO/A 
processing for EXOI loading. We therefore set out to confirm that the above-
described phenomenon was dependent on MYH, in the first instance by showing 
that MYH was active in the HCT116 extracts. When we incubated the homoduplex 
and the GO/A substrates with HCT116 extracts supplemented with [α-32P]dCTP, we 
observed substantial incorporation of [32P]dCMP into fragment f of the GO/A 
substrate (Fig. S3A), which contains the oxidized guanosine reside. We thus 
concluded that MYH was active at GO/A sites in HCT116 nuclear cell extracts. 
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We then immunodepleted MYH from the extract (Fig. S2A) prior to incubation 
with the substrates. This reduced the MMR efficiency on the GO/A-G/T substrate 
from 52% (Fig. 2C, lane 7) to ~20% (lane 8). The latter level was comparable to 
the efficiency of non-canonical MMR on the unnicked G/T substrates (~ 30%) 
(lanes 1-3). That the observed inhibition was due to MYH depletion was confirmed 
by complementation of the depleted extracts with purified, recombinant MYH, 
which restored the MMR efficiency on the GO/A-G/T substrate to 43% (lane 9). As 
anticipated, MMR efficiencies on the G/T (lanes 1-3) and G/T nicked (lanes 4-6) 
substrates were unaffected by the amount of MYH in the extracts.  
To confirm that processing of GO/A intermediates by the BER machinery indeed 
generates DNA termini that can be utilized by EXOI in the strand degradation step 
of MMR, we pre-incubated the supercoiled GO/A-G/T substrate with purified, 
recombinant MYH and apurinic endonuclease 1 (APE1), which cleaves the sugar-
phosphate backbone at the MYH-generated abasic site. We then incubated the 
MYH/APE1-nicked substrate (Fig. S2B, upper panel) with HCT116 extracts 
supplemented with MutLα. As shown in Fig. S2B (lower panel), the MYH/APE1-
generated nick in the GO/A-G/T substrate was efficiently recognized by MMR 
factors. That the latter substrate was even more efficiently repaired than the 
Nt.BstNBI-nicked G/T phagemid is most likely indicative of the substantially-
shorter distance between the nick and the mispair in the GO/A-G/T substrate than in 
the Nt.BstNBI-nicked G/T phagemid. 
2-Hydroxyadenine does not activate MMR in human nuclear cell extracts 
MYH has been reported to excise the oxidation product of dATP, 2-hydroxy-2'-
deoxyadenine (AO), from base pairs with guanine or cytosine [30, 31]. We 
therefore wanted to test whether, analogously to GO, AO might also serve as a 
strand discrimination signal for MMR. We incubated the supercoiled homoduplex, 
GO/A, AO/G or AO/C substrates with purified, recombinant MYH and APE1, and 
analyzed the extent of nicking (seen as conversion of supercoiled- to open-circular 
DNA) on agarose gels. As shown in Fig. 3A, the GO/A phagemid was nicked very 
efficiently by MYH/APE1 (cf Fig. S3A). In contrast, only limited nicking was 
detected on the AO/G and AO/C substrates, with only 42% of the AO/G and 38% of 
the AO/C plasmids having been nicked after 8 hours. This is only slightly higher 
than that seen with the homoduplex (26%). Similarly, upon incubation of the AO/C 
or AO/G substrate with [α-32P]dGTP- or [α-32P]dCTP-supplemented HCT116 
extracts, the amount of radionucleotide incorporated into the AO-containing 
fragment f of both substrates was only slightly greater than that detected in the 
homoduplex substrate (Fig. S3).  
We also carried out an in vitro MMR assay with substrates containing an AO/G or 
an AO/C pair in the vicinity of a T/G mismatch. These substrates differed from 
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those described above, inasmuch as the AO residues were located within a PvuI site 
(see Materials and Methods). Successful repair of the AO/G to C/G or of the AO/C 
to G/C by BER would restore the restriction site, such that PvuI digestion of the 
recovered DNA would allow quantification of BER activity at the AO sites (Figure 
3B). As anticipated from data shown in Fig. 3A, incubation of the AO/G-T/G and 
AO/C-T/G substrates with MMR-proficient HCT116 extracts supplemented with 
recombinant MutLa yielded only 15% and 12% PvuI-sensitive products 
respectively (Figure 3C, lanes 4-5), while the G/T phagemid was completely 
digested under identical conditions (lane 3). These results were reflected in MMR 
efficiency determined from the same assays by digestion of the recovered 
phagemids with SalI/DraI. Repair of the T/G mismatch in the AO/G-T/G and AO/C-
T/G substrates was very inefficient (20% and 18%, respectively), while the G/T 
nicked (lane 3) and the GO/A-G/T (lane 1) substrates were efficiently repaired to 
93% and 59%, respectively. Taken together, these data show that AO/G or AO/C 
pairs are inefficiently processed by MYH in cell extracts and therefore fail to act as 
entry sites for mismatch-activated excision. 
GO/A, but not AO/G and AO/C, act as MMR initiation sites in Xenopus laevis 
egg extracts 
Because GO/A mispairs arise during replication, MYH should be able to act on 
newly-replicated DNA, and available experimental evidence shows that this 
glycosylase is indeed more abundant during S-phase [18]. In an attempt to learn 
whether MYH is also more efficient during S-phase, we decided to make use of 
Xenopus laevis (X. laevis) egg extracts, which are enriched in S-phase proteins 
[41]. 
In the first experiment, we wanted to learn whether the extracts are proficient in 
MYH-initiated BER. We decided to make use of the assay described above (Fig. 
1C), in which the homoduplex or GO/A closed-circular substrates were incubated 
with X. laevis egg extracts supplemented with [α-32P]dCTP. Digestion of the 
recovered phagemid DNA with NotI/BsaI revealed a three-fold greater 
incorporation of [32P]dCMP into the GO-containing fragment of the GO/A substrate 
than into the corresponding fragment of the homoduplex phagemid (Fig. 4A). This 
demonstrated that MYH was active in the X. laeavis extracts.  
We also had to show that the extracts supported nick-directed MMR, because an 
earlier report indicated that mismatch processing in X. laevis oocyte extracts was 
efficient, but not nick-directed [42]. We therefore incubated the covalently-closed 
and the nicked isoforms of the G/T phagemid with the extracts supplemented with 
[α-32P]dATP, under conditions where DNA replication was inhibited. As shown in 
Fig. 4B, we were able to detect nick-directed MMR, with the G/T substrate 
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repaired to G/C (lane 2), whereas the covalently-closed phagemid was only 
inefficiently processed (lane 1). 
Under these conditions, the covalently-closed GO/A-G/T substrate (lane 3) was 
almost as efficiently repaired as the nicked G/T phagemid (lane 2). In contrast, the 
AO/G-T/G and AO/C-T/G substrates (lanes 4-5) were left largely unrepaired, which 
shows that, similarly to human extracts, 2-hydroxyadenine did not serve as a strand 
discrimination signal for MMR.  
OGG1-dependent mismatch repair is inefficient in human nuclear cell 
extracts 
Assuming that MTH1 functions with a 100% efficiency, all GO residues in oxidized 
DNA should be in the template strand following replication, irrespective of 
whether they are paired with A or C. As discussed above, MYH-initiated BER of 
GO/A would be directed to the A-strand that is also the nascent DNA strand. The 
observed interference of BER and MMR would therefore serve to improve the 
efficiency of MMR by providing this pathway with additional entry sites for EXOI. 
In contrast, BER-mediated repair of GO/C pairs arising during replication would 
have the opposite effect on MMR. GO/C repair is initiated by OGG1, a 
glycosylase/lyase that removes the GO and concurrently cleaves the sugar-
phosphate backbone of the DNA [43, 44]. Postreplicative BER-dependent 
processing of GO/C pairs would therefore introduce breaks into the template DNA 
strand and thus provide MMR with the wrong strand bias.  
We set out to test the above supposition by studying the effect on MMR efficiency 
and directionality of a GO/C pair situated in the vicinity of a G/T mismatch. We 
generated a GO/C-G/T substrate, in which the GO was positioned 54 nucleotides 5' 
from the mispaired G. OGG1-initiated BER of the GO would give rise to a break 
that should activate MMR to correct the G/T mismatch to A/T and thus regenerate 
an AclI site in the substrate. This repair bias should be identical to that introduced 
by an Nt.Bst.NBI-generated nick in the G/T substrate (Fig. 5A). 
When we incubated the G/T, nicked G/T, GO/C-G/T or GO/C-A/T phagemid 
substrates with HCT116 nuclear cell extracts supplemented with [α-32P]dATP, no 
significant repair or [32P]dAMP incorporation was observed (Fig. 5B, lanes 1, 3, 5, 
7), but when the extract was supplemented with purified, recombinant MutLα, the 
Nt.BstNBI-nicked G/T substrate was repaired (lane 4). In contrast to what was 
observed with the GO/A-G/T substrate (Fig. 2B + 3C), only background levels of 
repair and [32P]dAMP incorporation were detected with the GO/C-G/T substrate 
(Fig. 5B, lane 6) and with the control, G/T phagemid (lane 2). Similar results were 
obtained also with MutSα-deficient LoVo extracts supplemented with purified 
recombinant MutSα (Fig. 5D, lane 2). Given that both extracts contained the key 
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MMR and BER factors as ascertained by western blotting (Fig. S1, S5A), these 
results indicated that GO does not activate MMR in the GO/C-G/T substrate. 
The above result could be explained in several ways. The first possibility is that the 
MMR machinery was unable to use the BER intermediates generated during GO 
processing as strand discrimination signals. We therefore treated the covalently-
closed GO/C-G/T substrate with purified recombinant OGG1 and showed that it 
was efficiently nicked (Fig. S5B). When this DNA was incubated with extracts of 
LoVo cells supplemented with purified recombinant MutSα, it was repaired with 
similar efficiency to the control, nicked G/T phagemid (Fig. 5C, cf lanes 2&4). 
This shows that MMR can use OGG1-generated strand breaks as initiation sites. 
The second possibility was that OGG1 in the tested cell extracts was inactive, or 
that it was present in insufficient amounts. We therefore incubated the GO/C and 
homoduplex substrates with LoVo extracts supplemented with [α-32P]dGTP. As 
shown in Fig. S5C only background levels of the radiolabeled nucleotide were 
incorporated into the phagemid heteroduplex, which suggested that GO/C repair 
was indeed inefficient, despite the fact that the extracts contained readily-
detectable amounts of OGG1 (Fig. S1A, S5A). Similar results were obtained with 
[32P]-labeled GO/C-containing oligomers, which were inefficiently nicked in LoVo 
extracts, while UNG/APE1-catalyzed processing of U/G-containing oligomers was 
very efficient (Fig. S5D). The reason underlying the low OGG1 activity in the 
extracts is currently unknown, but we were able to eliminate inappropriate salt 
concentration, lack of an activator protein, or short half-life of OGG1 as possible 
causes (Fig. S6). To test whether the extracts contained an inhibitor of OGG1, we 
supplemented them with purified recombinant OGG1 (Fig. 5D). Under these 
conditions, the GO/C-G/T substrate (lane 3) was repaired with efficiency similar to 
the nicked G/T phagemid (lane 1). Importantly, this phenomenon was not limited 
to extracts of human cells, as identical results were obtained with the X. laevis 
MMR system (Fig. 6). 
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Discussion 
The postreplicative mismatch repair system improves the fidelity of DNA 
replication by several orders of magnitude by removing from nascent DNA 
nucleotides that fail to form Watson-Crick base pairs. In order to fulfill this 
function, it has to satisfy two key criteria: it has to (i) recognize base-base 
mismatches and small insertion/deletion loops (IDLs) generated by the replicative 
polymerases during DNA synthesis and (ii) direct the repair process to the newly-
synthesized DNA strand. How the major mismatch recognition factor MutSα 
recognizes the different helical distortions that are caused by purine/purine, 
purine/pyrimidine and pyrimidine/pyrimidine mispairs, as well as by IDLs, is still 
poorly understood, despite the fact that several structures of protein/DNA 
complexes have been described [45]. However, because MMR deficiency leads to 
transition, transversion and frameshift mutations, MutSα clearly has broad 
substrate specificity. Although this characteristic of MutSα is clearly beneficial as 
far as its role in the maintenance of replication fidelity is concerned, it might also 
be deleterious, should MutSα bind to lesions that should be processed by other 
repair systems. One such example are mispairs containing O6-methylguanine; these 
lesions activate MMR, but because their processing does not lead to the removal of 
the modified nucleotide from the template strand, they trigger futile repair that 
eventually leads to cell death [21]. Processing of GO/A mismatches arising through 
the incorporation of dAMP opposite GO in the template strand might also trigger 
futile MMR, but the evidence for such a process is currently lacking. As discussed 
above, the MMR system does appear to influence the efficiency of A/GO 
processing, either directly through removing from the nascent strand GO 
misincorporated opposite template A, or indirectly, through increasing the 
efficiency of MYH-dependent BER. Thus, available experimental data argue that 
the broad substrate specificity of MutSα does not deleteriously affect BER 
efficiency. In the present study, we asked whether the reverse might be true, 
namely, whether BER-dependent processing of GO could affect MMR efficiency, 
by for example interfering with its second key criterion: strand directionality. 
In our earlier studies, we could show that the MMR system could use breaks 
generated during the BER-mediated processing of uracil residues [40, 46] or during 
the RNaseH2-mediated excision of ribonucleotides misincorporated into DNA 
during replication [47] for the purpose of strand discrimination. We postulated that 
MMR might also use breaks generated during the BER-dependent processing of 
oxidative damage, but the outcome of such interference would be positive only in 
the case that the breaks were generated in the nascent DNA strand. We show here 
that MYH-dependent processing of a GO/A mispair in extracts of human cells or of 
Xenopus laevis eggs directs MMR to the A-strand (Figs. 2 + 4). In vivo, the ability 
of the MMR system to use breaks generated during the MYH-directed processing 
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of GO/A mispairs arising through the incorporation of dAMP opposite GO would 
direct mismatch correction to the nascent strand and thus possibly improve the 
fidelity of replication (Fig. 7). MYH-dependent BER and MMR would thus 
synergize during S-phase, as might have been anticipated based on their physical 
interaction [19]. 
Breaks introduced into the nascent DNA strand by OGG1 during the processing of 
C/GO pairs arising through the incorporation of dGOMP opposite template C would 
also help improve MMR efficiency and replication fidelity. However, due to the 
sanitization of dNTP pools by MTH1, dGOTP concentrations should be extremely 
low, such that dGOMP incorporation into nascent DNA during replication should 
be minimal. As a result, most GO residues present in DNA during replication 
should be in the template strand. Incision of this strand by OGG1 behind the 
replication fork would misdirect MMR to the wrong strand (Fig. 7), and OGG1-
catalyzed incision of DNA at GO/C sites in front of the replication fork could cause 
its collapse. It would therefore appear logical that GO/C processing should be 
completed prior to the onset of S-phase and that OGG1 should be inactivated 
during this cell cycle stage. Interestingly, we found that GO/C processing in both in 
vitro systems was extremely inefficient and that the presence of a GO/C pair in the 
heteroduplex substrate failed to activate MMR of the G/T mismatch (Figs. 5, 6, S5, 
S6), despite the fact that OGG1 was present in considerable quantities. Because 
addition of the recombinant polypeptide to the extracts resulted in both, efficient 
GO/C processing and GO-dependent G/T repair, we postulate that OGG1 present in 
the cell extracts is inactive, either as a result of post-translational modification, or 
through complexation with an inhibitor. We are currently attempting to identify the 
underlying cause of this inhibition, as well as carrying out a series of in vivo 
experiments that should show whether the observations described above 
correspond to the situation in living cells. Our current findings indicate that the 
repair of oxidative damage in vertebrate cells is highly regulated in order to prevent 
genomic instability and future experiments should show how this regulation is 
mediated at the molecular level.  
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Materials and methods 
Human, nuclear cell extracts 
Nuclei were isolated as previously described [48], resuspended in 1/3 of their 
packed volume in cold extraction buffer (25 mM HEPES-KOH pH 7.5, 292 mM 
sucrose, 1 mM PMSF, 0.5 mM DTT, 1 µg/ml leupeptine) and transferred to a small 
beaker fitted with a magnetic stirrer bar. NaCl was added dropwise to a final 
concentration of 150 mM and extraction continued for 1h at 4°C. The nuclei were 
pelleted by centrifugation at 14’500 x g for 20 min at 4°C in a tabletop centrifuge. 
The supernatant was transferred and dialyzed 2 x 1 h at 4°C against 1 liter of cold 
dialysis buffer (25 mM HEPES-KOH pH 7.5, 50 mM KCl, 0.1 mM EDTA, 231 
mM sucrose, 1 mM PMSF, 2 mM DTT, 1 µg/ml leupeptine). The dialyzed extract 
was clarified by centrifugation at 20’000 x g for 15 min at 4°C. The supernatant 
was aliquoted, snap frozen in liquid nitrogen and stored at -80 °C. The protein 
concentration was determined with a Bradford assay and the salt concentration was 
measured using a conductivity meter. 
Xenopus laevis egg extracts 
S-phase extract was prepared as previously described [49]. Briefly, eggs were 
dejelled, activated with calcium ionophore (Sigma-Aldrich), rinsed with S-buffer 
(50 mM HEPES-KOH pH 7.5, 50 mM KCl, 2.5 mM MgCl2 and 250 mM sucrose), 
transferred to 2 ml Eppendorf tubes and crushed by centrifugation for 12 min at 
13’200 rpm. The cytoplasmic layer was removed and after addition of CytB 
(Sigma-Aldrich) cleared by centrifugation for 25 min at 70’000 rpm (Sorvall TL55 
swinging bucket rotor). The extract was supplemented with 250 mg/ml 
cycloheximide, 25 mM phosphocreatine and 10 mg/ml creatine phosphokinase 
before use. 
Cell culture, Western blot 
HCT116 (MutLα-) and HCT116 + chromosome 3 (MutLα+) cells were obtained 
from Richard Boland [50] and were cultured in McCoy's 5a medium (GIBCO) 
supplemented with 10% fetal calf serum (GIBCO). The medium for the 
chromosome 3-complemented cell line was supplemented with 400 µg/ml G418. 
LoVo (MutSα-) cells were grown in DMEM (GIBCO) supplemented with 10% 
fetal calf serum (GIBCO). All media additionally contained 1% 
penicillin/streptomycin. Whole cell extracts of the cell lines were prepared using    
2 x Lämmli buffer (120 mM Tris-HCl pH 6.8, 4% SDS, 20% glycerol). Upon 
determination of the protein concentration by Lowry assay, proteins were analyzed 
with SDS-PAGE and Western blot. 
Antibodies 
For western blot analysis, the MYH antibody (mouse monoclonal, Abcam, 
ab55551) was used at a dilution of 1:333, OGG1 (rabbit monoclonal, Abcam, 
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ab124741) at 1:10'000, MSH6 (mouse monoclonal, BD Transduction Laboratories, 
610919) at 1:1000, MSH2 (mouse monoclonal, Calbiochem, NA-27) at 1:500, 
MLH1(mouse monoclonal, BD Transduction Laboratories, 554073) at 1:500, β-
Tubulin (rabbit polyclonal, Abcam, ab6046) at 1:10'000 and TFIIH (rabbit 
polyclonal, Santa Cruz, sc-293) was used at a dilution of 1:1000. The anti-MTH1 
antibody was a generous gift of Yusaku Nakabeppu and was used at a dilution of 
1:250. Horseradish peroxidase (HRP)-coupled anti-mouse and anti-rabbit 
secondary antibodies (GE Healthcare) were used at a dilution of 1:5000. 
Substrate production 
The detailed procedure was described previously [51]. Briefly, hetero- and 
homoduplexes were constructed by primer extension using the oligonucleotides 
listed below as primers and the single-stranded phagemid DNA listed in brackets as 
template. The single-stranded DNA templates differed in position of the Nt.BstNBI 
site, which was situated at nucleotide 2850 either in the viral (top) or 
complementary (bottom) strand. Incubation of the substrates with the nickase 
yielded substrates in which MMR occurred either 5′ to 3′, or 3’ to 5’, respectively. 
The mismatches were located within a SalI and/or AclI restriction site, that were 
restored upon repair. The desired supercoiled heteroduplex substrates were purified 
on cesium chloride gradients.  
Primers: The GO- or AO-containing primers were obtained from Eurogentec 
(Seraing, Belgium). All other primers were obtained from Microsynth (Balgach, 
Switzerland). Where necessary, the SalI (GTCGAC) and AclI (AACGTT) 
restriction sites are highlighted in bold and grey, respectively. PvuI restriction sites 
(CGATCG) are marked grey and mispaired residues are underlined. Primer 
sequences correspond to the outer strand sequence of the substrate. 
- G/T (pRichi-2850topAclI or pRichi-2850botAclI): 
 5'-CCAGACGTCTGTCGACGTTGGGAAGCTTGAG-3' 
- T/G (pRichi-2850topSalI): 
 5'-CCAGACGTCTGTTGACGTTGGGAAGCTTGAG-3' 
- GO/A-G/T (pRichi-2850botAclI): 
 5'-GAATTGTAAGOACGAACACTATAGGGCGAATTGGCGGCCGCGATCT 
 GATCAGATCCAGACGTCTGTCGACGTTGGGAAGCTTGAG-3'; 
- GO/C-G/T (pRichi-2850topAclI): 
 5'-GAATTGTAATACGOAACACTATAGGGCGAATTGGCGGCCGCGATCT 
 GATCAGATCCAGACGTCTGTCGACGTTGGGAAGCTTGAG-3' 
- AO/G-T/G (pRichi-2850topSalI):  
 5'-GGGAAGGGCGATAOGGTGCGGGCCTC-3' 
 The T/G primer was used for T/G mismatch generation. 
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- AO/C-T/G (pRichi-2850topSalI): 
 5'-GGGAAGGGCAOATCGGTGCGGGCCTC-3' 
 The T/G primer was used for T/G mismatch generation. 
- A/T (pRichi-2850topAclI) 
 5'-CCAGACGTCTGTCAACGTTGGGAAGCTTGAG-3' 
- G/C (pRichi-2850topSalI) 
 5'-CCAGACGTCTGTCGACGTTGGGAAGCTTGAG-3' 
In vitro MMR assay in human nuclear cell extracts 
The MMR assays were described previously [22, 46, 51]. Unless otherwise 
specified, the reactions were carried out with 100 ng substrate and 100 µg nuclear 
cell extract in a total volume of 25 µl in a buffer containing 20 mM Tris-HCl pH 
7.6, 5 mM MgCl2, 1 mM glutathione, 50 µg/ml BSA, 0.1 mM dNTPs, 1.5 mM 
ATP and 80 mM KCl in experiments involving MYH substrates, or 110 mM KCl 
in experiments involving OGG1 substrates. 1.8 pmol of purified MutLα or MutSα 
were added where indicated. The reactions were incubated at 37°C for 1 hour. The 
reaction was stopped by adding an equal volume of STOP solution (50% Poteinase 
K, 1 mM EDTA, 3% SDS) and subsequent incubation for 1 hr at 50°C. Substrates 
were purified on MinElute Spin columns (Qiagen), subjected to SalI/DraI 
restriction digest and the DNA fragments were separated on 1% agarose gels 
stained with GelRed. The percentage of mismatch repair was quantified from the 
ratio of the repaired bands (b+c) to the total amount of DNA (a+b+c) using 
ImageQuantTL. The band intensities were corrected according to their respective 
DNA fragment sizes. Some assays were supplemented with 2 µCi [α-32P]dATP. To 
monitor incorporation of the radiolabeled nucleotide, the agarose gels were vacuum 
dried, exposed to a PhosphoScreen and scanned with a Typhoon Scanner (FLA 
9500, GE Healthcare). 
In vitro MMR assay in Xenopus laevis egg extracts 
Briefly, the reaction mixture containing 150 ng substrate, 26 µl S-phase extracts 
and 2 µCi [α-32P]dATP was incubated in a total volume of 30 µl at 23°C for 45 
min. To inhibit replication, 500 nM geminin and 40 µg/ml p27 were added. The 
reaction was stopped by the addition of 70 µl STOP solution (76 mM EDTA, 1.5% 
SDS) and 40 µg RNase (Sigma-Aldrich) and incubated for 30 min at 37°C. 
Subsequently, 200 µg Proteinase K (AppliChem) were added and incubation 
continued at 37°C overnight. The substrates were purified on MinElute Spin 
columns (Qiagen) and subjected to SalI/DraI or AclI restriction digest in the 
presence of RNase. The digested DNA was cleaned up again and analyzed on a 1% 
agarose gel stained with GelRed. 
BER assay  
To determine AO/G to C/G or AO/C to G/C repair by MYH, a MMR assay was 
performed. After the reaction, 50% of the purified, eluted substrate were digested 
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with SalI/DraI (MMR assay), while the other half of the purified substrate was 
used for PvuI digestion. 
MMR- or BER- dependent incorporation assay 
This assay was used to test MMR or BER activities. It was performed similarly to 
the MMR assay, except for the following modifications: In order to track MMR-, 
MYH- or OGG1-dependent nucleotide incorporation, the reactions were 
supplemented with 2 µCi [α-32P]dATP, [α-32P]dCTP or [α-32P]dGTP, respectively. 
Finally, the substrates were digested with NotI/BsaI, and analyzed on a GelRed- 
stained 1% agarose gels. Repair tracts of up to 330 bp in Nt.BstNBI nicked 
substrates, up to 29 bp in the GO/A substrates and up to 22 bp in the GO/C 
substrates are seen in the 1810 bp fragment f. Longer repair tracts appear in the 
1387bp fragment g (see Figure 1 A+C). While MMR-dependent [32P]dAMP 
incorporation gives rise to a strong radioactive signal in both bands, MYH-
dependent [32P]dCMP or OGG1-dependent [32P]dGMP incorporation occurs only 
in DNA fragment f. Quantification of [32P]dCMP or [α32P]dGMP incorporation in 
MYH- or OGG1-induced BER was determined from the ratio between the band 
intensities of fragment g on the autoradiograph and the intensity of fragment f on 
the GelRed-stained agarose gel.  
Immunodepletion 
20 µl Protein A/G PLUS-agarose beads (sc-2003, SantaCruz) were washed twice 
with 750 µl binding buffer (30 mM HEPES-KOH [pH 7.6], 7 mM MgCl2) and 
spun down at 2’700 g for 2 min at 4°C. The beads were resuspended in binding 
buffer and 1 µg anti-MYH (ab55551, Abcam) or anti-MSH6 (610919, BD 
Transduction Laboratories) antibody was added. The mixture was then incubated 
for 3 hr at 4°C, the beads were washed 3x with 750 µl binding buffer and 
subsequently used to immunodeplete 100 µg nuclear cell extracts for 30 min at 
4°C. MMR assays were performed immediately after depletion. Mock-depleted 
nuclear cell extracts were obtained by incubation with beads only.  
Nicking of substrates 
MYH+APE1: 200 ng GO/A-G/T substrate were incubated with 10 ng purified 
recombinant MYH-GST and 10 U of APE1 (New England Biolabs) in 1x MMR 
buffer (20 mM Tris-HCl pH 7.6, 40 mM KCl, 5 mM MgCl2, 1 mM glutathione, 50 
µg/ml BSA, 0.1 mM dNTPs) for 4 hr at 37°C. The reaction was stopped by heat 
inactivation and 50 ng of the pre-nicked substrate were analyzed on a 1% GelRed-
stained agarose gel for nicking efficiency. The rest was purified on a MinElute 
Spin column (Qiagen) and subsequently used in a MMR assay. 
OGG1: 1 µg GO/C-G/T substrate was incubated with 0.8 µg purified recombinant 
OGG1 (a gift of Barbara van Loon) in 20mM Tris-HCl pH 8, 1mM DTT, 1mM 
EDTA and 0.1mg/ml BSA for 2.5 hours at 37°C and subsequently purified on a 
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MinElute Spin column (Qiagen). 100 ng of the pre-nicked substrate were used for a 
MMR assay. 
Nt.BstNBI: Supercoiled DNA substrates (100ng) were incubated with 1 U of 
Nt.BstNBI (New England Biolabs) according to the recommendations of the 
manufacturer. 
In vitro MYH nicking assay 
100 ng of supercoiled GO/A, AO/G, AO/C or homoduplex substrate were incubated 
with 10 ng purified recombinant MYH-GST, 10 U of APE1 (New England 
Biolabs) and 1.5 mM ATP in 1x MMR buffer (20 mM Tris-HCl pH 7.6, 40 mM 
KCl, 5 mM MgCl2, 1 mM glutathione, 50 µg/ml BSA, 0.1 mM dNTPs) in a total 
volume of 10 µl. For time course experiments, 5 µl aliquots were withdrawn at the 
indicated time points. The reactions were stopped by the addition of 2 µl of 6x 
loading dye (37.5 mg/ml Ficoll 400, 23% glycerol, 0.03% bromophenol blue) and 
subsequent heat inactivation. The samples were separated on 1% agarose gels and 
visualized with GelRed. The nicking efficiency was quantified from the ratio of the 
amount of nicked DNA product to the total amount of DNA (supercoiled + 
nicked).  
Restriction enzymes 
All restriction enzymes were purchased from New England Biolabs. 
MYH-GST purification, Recombinant proteins 
GST-tagged human full-length MYH (isoform 5) was expressed from the pET41a-
MUTYH expression vector (gift of Barbara van Loon) and partially purified using 
Glutathione SepharoseTM 4B beads (GE Healthcare) as described previously [52] 
(see SI text for details). Eluates were loaded on a HiTrapTM Heparin HP column 
(GE Healthcare), washed with 10 column volumes of washing buffer (30 mM Tris-
HCl pH 8, 0.1 mM EDTA, 10% glycerol, 1 mM DTT, 50 mM NaCl) at a flow rate 
of 0.5 ml/min. Elution was performed using a salt gradient (50-600 mM NaCl). 
MYH-GST was eluted with 400-500 mM NaCl. The active fractions were 
identified using a MYH nicking assay, pooled, aliquoted and stored at -80°C. 
Recombinant APE1 was purchased from New England Biolabs. Recombinant 
MutLα and MutSα were expressed and purified in our laboratory.  
Supplementary materials and methods 
MYH-GST purification 
GST-tagged MYH was expressed from the pET41a-MUTYH expression vector 
(gift of Barbara van Loon) and partially purified using Glutathione Sepharose 
beads (GE Healthcare) as described previously [52]. Briefly, Bl21 bacteria were 
transformed with 200 ng pET41a-MUTYH expression vector and 200 ng pRARE 
vector (a kind gift of Barbara van Loon). Transformed bacteria were grown in 
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kanamycin and chloramphenicol containing Luria-Bertani (LB) medium at 37 °C 
until an OD600 of 0.6 was reached. To induce MYH-GST expression, IPTG was 
added to a final concentration of 1 mM. Further expression was carried out at 20°C 
for 21 hr. Bacteria were pelleted at 4’000 rpm for 30 min at 4°C. All following 
steps were carried out at 4°C or in the cold room. Each pellet deriving from a 1 
liter culture was resolved in 20 ml of lysis buffer [PBS containing 0.1% Triton X-
100, 1 mM PMSF, 1 tablet protease inhibitor cocktail “Complete, EDTA-free” 
(Roche) per 66 ml, 1 µg/ml proteinase inhibitors (Leupeptin, Benzamide, 
Pepstatin)]. Subsequently, cells were mechanically disrupted in a French press 
(pressure: 1500 psi). Subsequently, the lysed cells were spun at 20,000 rpm for 2 hr 
in a Sorvall Lynx 6’000 centrifuge (Thermo Scientific) using a SS-34 rotor. 2 x 1 
ml of packed GST- beads were washed 3 times with 15 ml of cold PBS and spun at 
1’500 rpm for 30 sec. Half of the supernatant was added to 1 ml of washed GST 
beads in a 50 ml Falcon tube and the mixture was incubated on a horizontal roller 
mixer (RM5, CAT) overnight. Samples were then centrifuged at 2’000 rpm for 5 
min. The flow through was removed and the beads were washed with 30 ml of 
washing buffer [PBS containing 0.2% Triton X-100, 1 mM PMSF, 1 tablet 
protease inhibitor cocktail “Complete, EDTA-free” (Roche) per 66 ml, 1 µg/ml 
proteinase inhibitors (Leupeptin, Benzamide, Pepstatin)] during a 10 min rotation. 
Beads were collected by centrifugation at 2’000 rpm for 5 min. The supernatant 
was removed, the beads of both tubes were pooled, transferred to a 15 ml Falcon 
tube, washed 3x with 10 ml of washing buffer and once with PBS as described for 
the previous washing step. Elution was carried out by washing once with 3 ml of 
elution buffer (30 mM Tris-HCl pH 8, 50 mM glutathione pH 8, 10% glycerol, 150 
mM NaCl) and once with 2 ml. Each time, the protein in the supernatant was 
collected by a centrifugation step at 2’000 rpm for 2 min. 
Nicking assay with GO/C oligonucleotides 
The oligo sequences were as follows: 
GO/C sense 5'-GCCAGTGAATTGTAATACGOAACACTATAGGGCGA-3', 
GO/C antisense 5'-TCGCCCTATAGTGTTCGTATTACAATTCACTGGC-3'. 
U/G sense 5'-GCCAGTGAATTGTAATAUGAACACTATAGGGCGA-3', 
U/G antisense 5'-TCGCCCTATAGTGTTCGTATTACAATTCACTGGC-3'. 
The sense strands were labeled at their 5' termini with [γ-32P]ATP and T4 
polynucleotide kinase (New England Biolabs), and annealed to their 
complementary strands. 20 fmol annealed oligo and 100 µg LoVo nuclear cell 
extracts were incubated in a buffer containing 20 mM Tris-HCl pH 7.6, 80 mM 
KCl, 5 mM EDTA, 1 mM glutathione, 50 µg/ml BSA, 1.5% glycerol in a total 
volume of 10 µl at 37°C. At the indicated time points, reactions were stopped by 
addition of the same volume of stop solution (3% w/v SDS, 5 mg/ml Proteinase K, 
1 mM EDTA) and incubation for 1 hour at 50°C. NaOH was then added to a final 
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concentration of 90 mM and the sample was heated at 95°C for 5 min. Reactions 
were purified on MinElute Spin columns (Qiagen). Samples were mixed with 80% 
formamide loading dye and heated for 5 min at 95°C immediately prior to loading 
onto a denaturing 20% polyacrylamide gel. The dried gel was analyzed with a 
Typhoon scanner (FL9500, GE Healthcare).  
Purification of geminin and p27 
hGeminin-pET28 and hp27-pET21 constructs were a kind gift of Yoshi 
Hashimoto/Vincenzo Costanzo. Briefly, protein expression was induced with 0.5 
mM IPTG in BL21 cells (Invitrogen) grown at 37°C. The cell pellets were 
resuspended in 20 mM Tris-HCl pH 7.5, 500 mM KCl, 10% glycerol, 1 mM β-
mercaptoethanol, 0.1% NP40 and PMSF for lysis. After cell disruption and 
centrifugation of cell debris and membranes, the soluble fraction containing 10 mM 
imidazole was loaded onto a nickel chelating column, which was then washed with 
5-25 mM imidazole. The protein was eluted with a gradient of 50-300mM 
imidazole. Fractions were pooled and dialysed against EB (100mM KCl, 2.5mM 
MgCl2 und 50mM Hepes-KOH pH 7.5)/10% glycerol. 
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Figure 1. Mismatch repair stimulates MYH activities in human cells. (A) Schematic representation of a MMR-dependent nucleotide 
incorporation assay using 5'-nicked substrates. In the absence of a MMR target (-MMR), very little repair-mediated [32P]dNMP 
incorporation takes place. In the presence of a MMR target (+MMR), MMR-mediated [32P]dNMP incorporation can be detected upon 
NotI/BsaI digestion of the phagemid DNA in both the 1810 bp f and 1387 bp g fragments. Locations of the modified base 
pairs/mispairs: GO/A, 3183; GO/C, 3188; G/T, 45. (B) GO/A and GO/C base pairs are not addressed by MMR in a MMR-dependent 
nucleotide incorporation assay. 5'-nicked substrates containing either no mismatch, or a GO/C, GO/A or G/T mismatch 306-363 
nucleotides away from the nick, were incubated with HCT116 nuclear cell extracts supplemented with purified recombinant MutLα and 
[α-32P]dCTP. Upon NotI/BsaI restriction digestion, GelRed-stained DNA served as the DNA loading control, while the autoradiograph 
visualized MMR-dependent repair tracts in fragments f and g by means of [32P]dCMP incorporation. M, molecular size marker (1 kb 
ladder, New England Biolabs). (C) Schematic representation of a MYH-dependent nucleotide incorporation assay. Repair of GO/A to 
GO/C by MYH-mediated BER can be detected primarily by incorporation of [32P]dCMP into the 1810 bp fragment generated by 
NotI/BsaI digestion of the substrate. (D) MutSα stimulates MYH activity on GO/A mispairs in a BER-dependent nucleotide 
incorporation assay. Homoduplex or GO/A-containing closed circular substrates were incubated with HCT116 nuclear cell extracts 
depleted of MSH6 and supplemented with recombinant purified MutSα where indicated (+). The reactions were supplemented with [α-
32P]dCTP to help visualize MYH-induced BER efficiencies, which were quantitated from the intensity ratio between band f in the 
autoradiograph and in the GelRed-stained agarose gel. The value for lane 1 was set to 1. MYH-independent [32P]dCMP incorporation 
was determined from the relative intensities of band g in the autoradiograph and in the GelRed-stained agarose gel. The quantifications 
represent an average of 3 independent experiments +/- standard deviation (SD).  
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Figure 2. A single GO/A base pair in a DNA heteroduplex acts as an initiation site for MMR in human nuclear cell extracts. (A) 
Schematic representation of the GO/A-G/T substrate and the in vitro MMR assay. The substrate carries a GO/A mispair 57 nucleotides 
away from a G/T mismatch, which is located in a SalI recognition site. The presence of the mismatch makes the phagemid refractory to 
cleavage with the enzyme, such that incubation with SalI and DraI yields fragments of 2484 (a+b), 692 (c) and 19 bp (the smallest 
fragment is not detectable on 1% agarose gels strained with GelRed). Introduction of a single nick into the inner strand by Nt.BstNBI 
and incubation with human nuclear cell extracts results in a repair of the G/T mismatch to G/C, which regenerates the SalI site. Upon 
incubation with SalI and DraI, the repaired phagemid gives rise to fragments of 1328 (a), 1156 (b), 692 (c) and 19 base pairs. (B) GO/A 
mispairs serve as initiation sites for MMR. The efficiency of repair of a G/T mismatch in supercoiled G/T (lane 1), nicked G/T (lane 
2,3), supercoiled GO/A-G/T (lanes 4,5,) and supercoiled GO/A-G/C (lane 6,7) substrates incubated with nuclear extracts of MutLα-
deficient HCT116 cells, supplemented where indicated (+) with purified MutLα. (C) G/T repair in the GO/A-G/T substrate is dependent 
on MYH. The supercoiled G/T (lanes 1-3), nicked G/T (lanes 4-6), and the supercoiled GO/A-G/T (lanes 7-9) substrates were incubated 
with extracts of HCT116 cells, which were either mock-depleted (lanes 1, 4, 7), MYH-depleted (lanes 2, 5, 8) or MYH-depleted and 
supplemented with recombinant MYH (lanes 3, 6, 9). The efficiency of the repair reactions shown in panels B and C was estimated by 
ImageQuant from scans of GelRed-stained agarose gels. The indicated MMR efficiencies (%) represent an average of 3 independent 
experiments +/- standard deviation (SD). 
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Figure 3. AO/G and AO/C mispairs do not act as initiation sites for MMR in human nuclear cell extracts. (A) The supercoiled 
homoduplex, GO/A, AO/G or AO/C substrates were incubated with recombinant, purified MYH and APE1 for the indicated times and 
analyzed by agarose gel electrophoresis. The quantification shows the percentage of open circular (oc) substrate compared to the total 
DNA (oc + sc). Only the GO/A substrate was cleaved with appreciable efficiency. The mobility of the supercoiled (sc), open circular 
(oc) and linear (l) DNA molecules is indicated on the left. (B) Schematic representation of phagemid substrates containing AO mispaired 
with guanine or cytosine. The AO residue is located within a PvuI restriction site, which makes the phagemid refractory to cleavage with 
this enzyme. AO/G to C/G, or AO/C to G/C repair restores the PvuI site. Incubation with the enzyme gives rise to fragments of 1846 bp 
(d) and 1351 bp (e). Position of AO/G: 3060, AO/C: 3057. (C) AO/G and AO/C mispairs do not serve as MMR initiation sites. The 
indicated substrates were incubated with MMR-deficient HCT116 extracts supplemented (+) or not (-) with purified MutLα. Upper 
panel: Efficiency of G/T to G/C repair mediated by MMR was estimated by SalI/DraI restriction digests of the recovered substrates: 
supercoiled GO/A-G/T (lane 1), supercoiled G/T (lane 2), nicked G/T (lane 3), supercoiled AO/G-T/G (lane 4) supercoiled AO/C-T/G 
(lane 5). Lower panel: Digestion of the shown recovered phagemids with PvuI, which detects MYH-dependent BER of AO to C in the 
AO/G substrate, or AO to G in the AO/C substrate. The nicked G/T substrate (lane 3) served as the positive control for PvuI digestion. 
AO/G-T/G and AO/C-T/G substrates that were not incubated with the extracts (lanes 6-7) contain defective PvuI sites and thus served as 
negative controls. MMR and BER efficiencies (%) are indicated below the panels. 
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Figure 4. The GO/A mispair acts as a MMR initiation site in Xenopus laevis egg extracts. (A) MYH is active in Xenopus laevis eggs. 
Supercoiled homoduplex or GO/A substrates were incubated with the extracts supplemented with [α-32P]dCTP. While only background 
levels of [α-32P]dCMP were incorporated into the homoduplex substrate (lane 1), substantial incorporation into the 1810 bp fragment f 
of the GO/A substrate was detected (lane 2), which is indicative of base excision repair. For quantification, [α-32P]dCMP incorporation 
into the homoduplex substrate was set to 1. The panels show representative images of two independent experiments. (B) GO/A, but not 
AO/G or AO/C serves as an initiation site for MMR in Xenopus laevis egg extracts. G/T (lane 1), nicked G/T (lane 2), GO/A-G/T (lane 
3), AO/G-T/G (lane 4), AO/C-T/G (lane 5) or GO/A-G/C (lane 6) substrates were incubated with Xenopus laevis egg extracts. Upon 
SalI/DraI digestion of the recovered phagemids, MMR efficiencies were estimated from the GelRed-stained agarose gels, while MMR-
dependent DNA synthesis was visualized by [α-32P]dATP incorporation seen in the autoradiograph. The panels show representative 
images of three independent experiments. 
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Figure 5. A GO/C base pair does not act as an initiation site for MMR in nuclear extracts of human cells. (A) Schematic representation 
of the GO/C-G/T substrate used in the in vitro MMR assay. The circular heteroduplex substrate carries a GO/C base pair 54 nucleotides 
from a G/T mismatch in the recognition site of AclI endonuclease. The positions of two further AclI cleavage sites and the Nt.BstNBI 
site, where a nick can be introduced selectively into the outer strand, are indicated. In the absence of repair, digestion of the phagemid 
with AclI gives rise to fragments of 2824 (a+b) and 373 bp (c). Repair of the G/T mismatch to A/T regenerates a third AclI restriction 
site, such that the phagemid DNA is cleaved into 3 fragments of 1518 (a), 1306 (b), and 373 bp (c). (B) Substrates G/T (lanes 1, 2), 
nicked G/T (lanes 2, 3), GO/C-G/T (lanes 4, 5) and GO/C-A/T (lanes 7,8) were incubated with extracts of HCT116 cells supplemented 
(+) or not (-) with purified recombinant MutLα and were analyzed on a GelRed-stained agarose gel. The autoradiographs visualized [α-
32P]dAMP incorporation into the different substrate fragments. Only background levels of repair were detected in the GO/C-G/T 
substrate. (C) OGG1-generated DNA termini at GO/C sites act as MMR initiation sites. The GO/C-G/T phagemid substrate was pre-
incubated either with Nt.BstNBI (lane 2), or with recombinant, purified OGG1 (lane 4) to generate nicked substrates (see Fig S5B). The 
substrates were then purified and incubated with LoVo nuclear cell extracts supplemented with purified MutSα (lanes 1-4). Supercoiled 
G/T (lane 1) and GO/C-G/T (lane 3) phagemid substrates served as controls. (D) A GO/C base pair activates MMR in extracts 
supplemented with OGG1. The nicked G/T (lane 1) and the GO/C-G/T (lanes 2, 3) substrates were incubated with LoVo nuclear cell 
extracts supplemented with purified MutSα, supplemented (+) or not (-) with 40 ng of purified recombinant OGG1. The panels in B, C 
and D show representative images of three independent experiments. 
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Figure 6. A GO/C base pair does not act as an initiation site for MMR in Xenopus laevis egg extracts. (A) Schematic representation of 
an in vitro OGG1-dependent repair synthesis assay. OGG1-initiated BER of GO/C to G/C should incorporate [α-32P]dGMP into the 
1810 bp (f) fragment generated by NotI/BsaI digestion of the substrate. (B) Xenopus laevis egg extracts lack OGG1 activity, as only 
background levels of [α-32P]dGMP were incorporated into the control homoduplex and the GO/C substrates. OGG1-dependent BER 
efficiencies were quantified from the intensity ratio between band f in the autoradiograph and the GelRed-stained agarose gel using 
ImageQuant. The panel shows a representative image of two independent experiments. (C) The MMR activity in Xenopus laevis egg 
extracts was determined using supercoiled G/T (lane 1), nicked G/T (lanes 2), GO/C-G/T (lane 3) and GO/C-A/T (lanes 4, 5) substrates. 
That similar background levels of [α-32P]dAMP were incorporated into the control GO/C-A/T substrate in the absence (lane 4) and 
presence (lane 5) of the replication inhibitors p27 and geminin demonstrates that the phagemids were not replicated under these 
conditions [53]. The panel shows representative images of three independent experiments quantitated below. 
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Figure 7. BER-dependent mismatch repair at 8-oxoguanine sites. If MMR recognizes a mismatch (G/T) during replication, it will 
search for a close-by strand discontinuity in order to induce its repair process by EXOI-loading to the nick. We hypothesized that these 
strand discontinuities might result from OGG1- or MYH- induced BER-intermediates, but would have different effects on MMR 
fidelity. Left panel: deoxy-8-oxoguanosine triphosphate (dGOTP) in the nucleotide pool is hydrolyzed to its monophosphate (dGOMP) 
by MTH1, thus preventing GO incorporation into the newly synthesized DNA strand. The occurrence of C/GO and thus OGG1-directed 
MMR to the daughter strand is therefore unlikely. Also A/GO mispairs will be infrequently generated. It would be inexplicit whether 
MYH would excise the A from the parental strand or whether MMR would be involved in the removal of GO from the daughter strand. 
The effect on MMR fidelity at close-by mismatches is therefore unclear. Right panel: In contrast, G/C base pairs are frequently 
oxidized to GO/C in the DNA helix. Thus, GO would be in the parental strand during the next round of replication. If C is incorporated 
opposite GO, GO/C is repaired by OGG1-induced BER. During S-phase, OGG1-generated nicks would misdirect MMR to the parental 
strand, so that it could not repair the G/T mismatch to G/C but instead, mutate it to A/T. Indeed, this unfavorable event was suppressed 
in our in vitro studies. If GO/C containing DNA helices replicate, they can also give rise to GO/A mispairs with A in the daughter strand. 
GO/A is repaired by MYH-induced BER, thereby being stimulated by MMR proteins. MYH-induced nicks at the A-site, would correctly 
direct MMR to the daughter strand and enable it to repair G/T to G/C. Our studies in human and Xenopus laevis cell extracts showed 
that MYH-directed MMR takes place, suggesting that higher eukaryotes might have adopted GO/A mispairs as strand discrimination 
signals for MMR. 
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Figure S1. (A) Western blot analysis of HCT116 and HCT116 + chromosome 3 nuclear cell extracts to verify the presence and relative 
abundance of MMR (MSH6, MSH2, MLH1) and BER (MYH, OGG1, MTH1) proteins. The absence of MutLα in HCT116 cells is well 
documented and was, where indicated, complemented with the purified recombinant protein. (B) Western blot showing the efficiency of 
MSH6 immunodepletion of HCT116 nuclear cell extracts. 
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Figure S2. (A) Western blot showing MYH immunodepletion efficiency of HCT116 nuclear cell extracts. (B) MYH/APE1-generated 
DNA termini at GO/A sites are recognized by MMR. Upper panel: The G/T substrate, either supercoiled (lane 1) or pre-nicked with 
Nt.BstNBI (lane 2), or the GO/A-G/T phagemid (lane 3) were incubated with purified recombinant MYH-GST and APE1 or mock-
incubated under the same experimental conditions. Lower panel: The purified substrates were incubated with HCT116 nuclear extracts 
supplemented with MutLα, digested with SalI/DraI and analyzed on GelRed stained agarose gels. The G/T mispair in the pre-treated 
GO/A-G/T substrate was very efficiently repaired. 
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Figure S3. MYH is active in HCT116 extracts and addresses GO/A but not AO/G or AO/C sites. (A) The supercoiled homoduplex (lanes 
1-3), GO/A (lanes 4-6) and AO/G (lanes 7-9) substrates were incubated with the extracts for the indicated time points. The reactions were 
supplemented with [α-32P]dCTP. As visualized in the autoradiograph, [32P]dCMP incorporation into fragment f of a NotI/BsaI digested 
phagemid, indicative of short-patch repair, was detected above background only in the GO/A substrate. (B) The supercoiled homoduplex 
(lanes 1-3) and AO/C (lanes 4-6) substrates were incubated with the extracts for the indicated time points, in reactions supplemented 
with [α-32P]dGTP. Only low levels of radioactive nucleotide were incorporated into the fragment f of a NotI/BsaI digested AO/C 
phagemid, indicative of inefficient BER. 
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Figure S5. (A) Western blot analysis of HCT116 and LoVo nuclear cell extracts to verify the presence and relative abundance of MMR 
(MSH6, MSH2, MLH1) and BER (MYH, OGG1, MTH1) proteins. The absence of MutLα in HCT116 cells and of MutSα in LoVo cells 
is evident, and was, where required, compensated by the addition of purified recombinant protein. (B) The GO/C-G/T phagemid 
substrate was pre-incubated with purified recombinant OGG1 (lane 2), thereby generating a nicked substrate, which migrates in the 
same position in the 1% agarose gel as the G/T substrate nicked with Nt.BstNBI (lane 1). These pre-nicked substrates were purified and 
used in the MMR assays (see Figure 5C). (C) Absence of OGG1 activity in human nuclear cell extracts. Upper panel: Schematic 
representation of an OGG1-dependent nucleotide incorporation assay. Repair of GO/C to G/C by OGG1-mediated BER should result in 
incorporation of [32P]dGMP into fragment f generated by NotI/BsaI digestion of the substrate. Lower panel: OGG1-dependent 
nucleotide incorporation assay. Substrates Homoduplex or GO/C substrates were incubated with the extracts supplemented with [α-
32P]dGTP for the indicated times. As seen in the autoradiograph, both substrates incorporated similar amounts of [32P]dGMP, which 
were close to background. (D) Nuclear extracts of LoVo cells contain extremely low OGG1 activity on a GO/C oligonucleotide 
substrate, as compared to UNG activity on a U/G oligonucleotide substrate. The GO/C- or U/G-containing 34-mer oligonucleotides were 
[32P]-labeled at the 5' terminus of the GO or U-containing strand, respectively. 20 fmol oligonucleotide were incubated with 100 µg 
LoVo nuclear cell extracts (+) at 37°C for the indicated times. The oligonucleotide substrates were loaded in the control lanes (-). The 
OGG1- or UNG-mediated nicking efficiencies in the cell extracts were analyzed on 20% denaturing polyacrylamide gels. The predicted 
sites of cleavage are indicated by arrows. 
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Figure S6. Optimization of experimental conditions for in vitro MMR assays with GO/C substrates. (A) Effect of salt concentration on 
MMR efficiency. The G/T, nicked G/T and GO/C-G/T substrates were incubated with HCT116 nuclear cell extracts supplemented with 
MutLα in buffers containing 110 (lanes 1-3), 80 (lanes 4-6), 50 (lanes 7-9) or 30 (lane 12) mM KCl. Decreasing salt concentrations did 
not improve OGG1-dependent MMR activity. (B) Comparison of MMR activity in nuclear and cytoplasmic cell extracts. The G/T, 
nicked G/T and GO/C-G/T substrates were incubated in a buffer containing 110 mM KCl and HCT116 cell extracts either nuclear (1:0), 
nuclear and cytoplasmic (1:1), or only cytoplasmic (0:1). The panels A and B show UV shadowing of a 1% agarose gel stained with 
GelRed. (C) OGG1 stability in nuclear cell extracts (NE) of HCT116 cells. The extracts were freeze/thawed up to three times and 
examined for OGG1 degradation by Western blotting (lanes 2-4). The control samples (0x, lanes 1, 5) were not freeze/thawed, which 
corresponds to conditions used in our in vitro MMR assays. Purified recombinant OGG1-GST (Trevigen, lanes 6-8) and OGG1 present 
in whole cell extracts (WCE) of HCT116 cells (lane 9) served as controls.
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3.1.2 Additional data relating to the manuscript 
3.1.2.1 Establishment of an in vivo MMR assay 
In the course of my work on the interplay of MMR and BER during the processing 
of oxidative DNA damage, one of my aims was to test the in vivo relevance of the 
observations that we made in extracts of human cells and in Xenopus laevis eggs. 
Since no adequate method was available at that time, we set out to establish an in 
vivo MMR assay. For this purpose, I designed and set-up a Master project that I 
supervised during a period of 8 months. The different methods tested, their pros 
and cons, as well as the results we achieved with the newly-developed method, are 
summarized below. 
The approach we chose was to transfect plasmids containing a GO/A mismatch in 
the proximity of a MMR target into cells, recover them after 24 hours and analyze 
their repair. The MMR target G/T, as also used in the in vitro MMR assays (see 
chapter 3.1.1), is inappropriate for in vivo MMR assays. This is because it would be 
recognized not only by MMR proteins but also by the DNA glycosylases TDG and 
MBD4, which are only negligibly active in our in vitro conditions. To circumvent 
this problem, we designed substrates that contained a 2 nucleotide loop in their 
inner strand, and thus represented a target exclusively for MMR. Since the outer 
strand encodes a SalI restriction site, repair of the loop would make the substrate 
susceptible to SalI digestion (Figure 3-1). 
 
Figure 3-1:  Schematic representation of the looped substrate. 
A circular substrate contains a 2 nucleotide (GC) loop in the bottom strand. The positions of a 
potential GO/A base pair, located 67 nucleotides away from the loop, and of Nt.BstNBI nicking sites 
are indicated. In the presence of MMR, the loop is repaired and generates a SalI restriction site. 
In order to analyze repair of the recovered substrates, we tested and evaluated four 
different approaches (Figure 3-2). 
Aim 
Establishment of an in vivo 
MMR assay 
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Figure 3-2:  Flow chart, illustrating four different (1-4) approaches to analyze the repair of recovered substrates. 
In the first approach, we gel-purified the recovered substrate and subsequently 
digested it with SalI/DraI, either in-gel or upon β-agarase I treatment and ethanol 
precipitation. Both led to incomplete digestion of the samples, which made 
quantifications difficult. Furthermore, we recovered only small amounts of DNA, 
about 1/10 of what we transfected, which were difficult to detect on GelRed-
stained agarose gels. The following approaches therefore aimed to increase the 
signal by either amplification of the recovered DNA (approaches 2+3) or by 
radioactively-labeling it (approaches 3+4). 
The second method involved nicking and ExoIII-mediated degradation of the outer 
strand, to yield the single-stranded (ss) inner plasmid strand, i.e. the one that MMR 
should have been directed to. The obtained ss-DNA was transformed into DH10B 
bacteria, which generated the appropriate complementary strand and amplified it. 
Subsequent column purification of the plasmid gave rise to sufficient and 
detectable amounts of plasmid and furthermore allowed complete SalI/DraI 
digestion. One drawback we encountered here was that we had no possibility to 
clearly prove that ExoIII completely degraded the outer strand, including the site 
opposite the loop. Furthermore, a control, Nt.BstNBI pre-nicked substrate 
recovered from the transfected cells, still contained the nick in the inner strand. 
ExoIII treatment would have led to its linearization and hence would have 
prevented its transformation into bacteria. This would falsify the repair ratios 
amongst the different substrates. The next two approaches were based on the 
Approach 1 
Approach 2 
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amplification of the loop-spanning part of the inner strand. Amplicons of repaired 
substrates would hence appear two nucleotides shorter. This difference can be 
visualized on 10% polyacrylamide gels.  
Upon HindIII linearization of the plasmid, we amplified the loop-spanning inner 
strand fragment, using run-off transcription with T7 RNA polymerase and 
radioactively-labeled NTPs. Although this approach led to a clear increase in 
sensitivity, it yielded also undefined bands of similar size to the transcript, which 
could be attributed to transcript slippage during transcription initiation [344]. 
Our fourth approach was similar, but based on primer extension of the linearized 
inner-strand fragment. Though starting with small amounts of recovered template 
DNA, the use of either 5' [32P]-labeled primer, or the addition of radioactively 
labeled nucleotides, allowed an adequate detection of the primer extension 
products. Furthermore, this approach is not prone to strand slippage and hence 
leads to defined bands. Following optimization, we validated this method by 
applying it to substrates that were repaired within our standard in vitro MMR 
assay. Indeed, the repair percentages of the primer extension assay correlated 
tightly with those of the in vitro assay, thus excluding any bias of this method. 
Since this approach turned out to be suitable, we applied it to the following in vivo 
MMR assays. For details of the methods of the different approaches, as well as the 
validation of the primer extension-based method, the reader is referred to the 
Master thesis of Isabel Wassing. An overview about the different methods as well 
as their pros and cons is provided in Table 3-1.  
Table 3-1: Advantages and disadvantages of different in vivo MMR assay approaches 
No. Method of substrate analysis 
upon its recovery from cells 
Advantages Disadvantages 
1 Direct SalI/DraI digestion - Quick method - Incomplete restriction 
  digestion 
- Little amounts of 
   recovered DNA  
 hard to detect 
2 Amplification of repaired ss-
DNA in bacteria & 
subsequent SalI/DraI 
digestion 
- Amplification of substrate 
    easy to detect 
- Complete restriction digestion 
- ExoIII degradation 
  past the mismatch is 
  unverifiable 
- Falsified repair ratios 
  in case of recovery of 
  nicked substrates 
3 T7 transcription 
(length of transcript indicates 
repair) 
- Increased sensitivity due to 
  i) amplification due to multiple 
  transcripts 
  ii) radioactive nucleotide 
  incorporation  
- Undefined transcripts 
- unstable RNA product 
    degradation 
4 Primer extension 
(length of DNA fragment 
indicates repair) 
- Increased sensitivity due to 
  radioactive nucleotide 
  incorporation 
- stable DNA product  
  defined bands 
 
Approach 3 
Approach 4 
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3.1.2.2 MYH-dependent mismatch repair in vivo 
The validated primer extension-based in vivo MMR assay was applied to our 
substrates of interest. MMR-proficient HCT116 + chromosome 3 cells, either 
siLUC- or siMYH-treated, were transfected with different substrates (Figure 3-3 B, 
left panel). Upon recovery, the plasmids were linearized by HindIII digestion. 
Primer extension yielded fragments of defined lengths: 83 bp in the absence of 
repair or 81 bp in case of MMR-catalyzed loop removal (Figure 3-3 A). 
 
Figure 3-3: MYH-addressed GO/A sites serve as initiation sites for MMR in vivo. 
(A) Schematic representation of an in vivo MMR assay. In the presence of MMR, the loop is repaired, which can be visualized by a 
primer extension assay. After recovery and linearization of the plasmid with HindIII, a [32P]-labeled primer binds to the binding site in 
the bottom strand (bright blue) and generates an 81 bp product. In the absence of MMR, the loop remains, which results in an 83 bp 
fragment. (B) In vivo MMR assay in HCT116 + chromosome 3 cells. (Left) Repair of substrates, either containing a loop, a loop and 
two 3' nicks (loop nicked), a GO/A base pair in the proximity of a loop (GO/A-loop) or a homoduplex (no loop) was analyzed upon 
recovery from human cells. Primer extension revealed repair of both the loop nicked and the GO/A-loop substrates. Upon siRNA-
mediated knockdown of MYH, repair of the GO/A-loop substrate was abolished. (Middle) The MYH knockdown efficiency at the time of 
substrate transfection is shown on a Western blot. (Right) Transfection of siLUC- and siMYH-treated cells with pEGFP shows 
comparable transfection efficiencies. 
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As expected, nicked loop substrates (lanes 2+6) were repaired in the extracts and 
served as positive control. In addition, we could show that GO/A sites in the close 
proximity of the loop served as initiation sites for MMR also in vivo, as an 81 bp 
fragment could be detected on the gel (lane 3). We could furthermore show that 
knockdown of MYH (Figure 3-3 B, Western blot) abolished MMR on the GO/A-
loop substrate (lane 7), indicating that MMR acted MYH-dependent in vivo. As the 
transfection efficiencies of both siLUC- and siMYH-treated cells were comparable 
(Figure 3-3 B, right panel), the above observations confirm our in vitro data.  
3.1.2.3 MYH is physically stabilized by mismatch repair proteins 
In the previous chapter 3.1.1 we described that MMR enhances MYH activity on 
GO/A-containing plasmids, thus confirming the data of Gu et al. [35] using another 
experimental approach. They also observed a physical interaction between MutSα 
and MYH [35], which could not clearly be confirmed in our pulldown experiments 
(see chapter 3.2.4). However, the data presented below point into the same 
direction: siRNA-mediated knockdown of MSH6 or MSH2 led to a clear decrease 
of MYH levels, indicating that MYH is stabilized by MutSα (Figure 3-4). We 
showed this effect in three different cell lines and used three different siRNA 
sequences against MSH6 in order to exclude any off-target effects, but the result 
was the same for all of them. Unexpectedly, MLH1 knockdown brought about the 
same effect, most noticeably in U2OS cells. Conversely, the presence of MYH 
seemed not to be required for mismatch repair protein stability). 
 
Figure 3-4: MutSα physically stabilizes MYH. 
MYH levels in whole cell extracts (WCE) of (A) HCT116 + chromosome 3, (B) U2OS and (C) HeLa Kyoto (stably expressing MSH6-
GFP) cells were analyzed by Western blotting. Cells were treated with the indicated siRNAs for 3 days. Three different siRNAs were 
used against MSH6 (1-3). 
  
The effect of a transient 
MutSα knockdown on   
MYH levels 
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Interestingly, we observed the converse effect in two cell lines that have a 
permanent defect in MutSα. HEC59 cells, which have two heterozygous hMSH2 
mutations and HCT15 cells, which exhibit two mutations in the hMSH6 gene, 
express higher levels of MYH than their chromosome 2 -complemented, repair-
proficient counterparts (Figure 3-5). Also the BER enzyme polymerase-β is slightly 
increased in the MMR-deficient cell lines, as previously observed by Martin et al. 
[285]. 
 
 
Figure 3-5:  MYH is overexpressed in HEC59 and HCT15 
cells when compared to their repair proficient counterparts. 
The Western blot shows expression levels of MutSα, MYH 
and polymerase-β in whole cell extracts (WCE) of HEC59 
and HCT15 cells as well as in cells of their mismatch repair 
proficient (+ chromosome 2) counterparts [345]. 
3.1.2.4 Testing the activity of OGG1 in nuclear cell extracts  
During our studies on the interplay of MMR and BER at GO sites, we discovered 
that MMR cannot initiate at GO/C sites in extracts. However, addition of 
recombinant purified OGG1 to the extracts generated entry points that were 
efficiently used by MMR. The reason why endogenous OGG1 cannot bring about 
this effect could be traced back to its low activity or low abundance in the extracts 
(see chapter 3.1.1). Furthermore, we could exclude that this was caused by 
inappropriate salt concentrations in the reaction buffer, missing co-factors from the 
cytoplasm or its instability in the extracts (chapter 3.1.1, Figure S6). Another factor 
that might be responsible for the lack of OGG1-dependent MMR in the extracts 
could be OGG1's slow kinetics, as described for recombinant OGG1 by several 
research groups [242, 244]. If this was the case, MMR proteins in the extracts 
could be inactive by the time that OGG1 has inserted nicks. To test MMR protein 
activity over time, we incubated HCT116 nuclear cell extracts and MutLα at 37°C. 
G/T nicked substrate was added either immediately or at the indicated time points 
to different reactions. Repair efficiencies in each reaction were analyzed by 
restriction enzyme digestion. Encouragingly, MMR was similarly active up to 3 
hours (Figure 3-6 A). Thus, a decrease in its activity could be excluded as a factor 
restricting OGG1-dependent MMR. 
Since our extracts are capable of performing plasmid supercoiling by nucleosome 
loading [74], we furthermore asked whether DNA packaging could restrict plasmid 
accessibility for OGG1. To address this, we incubated the GO/C-G/T substrate with 
The effect of permanent 
MutSα deficiency on     
MYH levels 
Time course: activity of 
MMR proteins in extracts 
Time course: substrate 
accessibility in extracts 
Doctoral Thesis Results:  Interdependence of BER and MMR at 8-oxoguanine sites page 91 
 
 Simone Repmann / IMCR - Institute of Molecular Cancer Research / D-BIOL 
Ei d gen öss isch e Tech n isch e H och sch ul e  Z ür i ch 
Swi ss  Fede ra l In s ti tu te  o f Tech n olo g y Zu r ich  
HCT116 extracts and MutLα. Recombinant OGG1 was then added at the indicated 
time points. Since we showed before that MMR proteins are similarly active during 
the entire incubation period, and since purified OGG1 generates entry points for 
MMR, any time-dependent change in OGG1-dependent MMR activity would result 
from supercoiling and inaccessibility of the substrate. After 1 hour of pre-
incubation, OGG1-dependent MMR still occurred (Figure 3-6 B). Only longer pre-
incubation times abolished repair to background levels (lane 1). 
 
Figure 3-6:  Time course: MMR activity & substrate accessibility. 
(A) MMR proteins in nuclear cell extracts are active up to 3 hours. MMR assay. To test the activity of 
MMR factors in nuclear cell extracts over time, HCT116 extracts and MutLα were incubated at 37°C. 
G/T nicked substrate was added to the extracts at the indicated time points. From the time of adding 
the substrate, each reaction continued for 30 min. Upon SalI/DraI digestion, repair efficiencies were 
analyzed on a GelRed-stained 1% agarose gel and quantified (MMR [%]). (B) GO/C-G/T substrate is 
accessible for purified OGG1 up to 1 hour. MMR assay. (Left panel) To test accessibility of closed-
circular GO/C-G/T substrate for OGG1, the substrate was incubated with HCT116 nuclear cell 
extracts and MutLα. 0.03 U purified OGG1 (Trevigen) were added to the mixture at the specified time 
points. From the time of adding the substrate, each reaction continued for 1 hour. Upon SalI/DraI 
digestion, repair efficiencies were analyzed on a GelRed-stained agarose gel and quantified. (Right 
panel) The Western blot shows that the OGG1 amount added to each MMR reaction corresponded to 
the OGG1 amount present in the volume of nuclear cell extracts usually used for one MMR reaction. 
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To additionally prove that the used in vitro assay conditions are adequate for 
OGG1 activity, we tested the nicking activity of recombinant OGG1 on GO/C-G/T 
substrates. This was performed in a buffer containing no salt (nicking buffer) or in 
MMR buffer containing 110 mM KCl that was also used for the other in vitro 
MMR experiments (Figure 3-7). Nicking in both buffers worked, but was more 
efficient in the MMR buffer (compare lanes 2+6). In line with other observations 
[240], addition of APE1 even increased OGG1 activity in the MMR buffer (lane 8). 
This proves that the conditions we used are compatible with OGG1 activity). 
 
Figure 3-7:  Purified OGG1 is active under in vitro MMR assay conditions. 
Nicking assay. To prove suitability of the in vitro MMR assay conditions for OGG1, its activity on 
GO/C-G/T substrates was tested in MMR buffer (lanes 5-8) and compared to its activity in nicking 
buffer containing no salt (lanes 1-4). 39 ng OGG1 or 0.05 U APE1 (NEB) were added where 
indicated (+). Separation of the phagemid substrates on an agarose gel gave rise to nicked (ni) 
plasmid where OGG1 was active, or to supercoiled (sc) configurations where no OGG1 activity was 
detected. li, linearized. 
3.1.3 The involvement of PARP-1 and PARP inhibition in BER-dependent 
mismatch repair 
Poly(ADP-ribose) polymerase 1 (PARP-1) is an abundant nuclear protein and key 
regulator of various processes such as DNA damage response. Numerous studies 
attributed PARP-1 to an involvement in the base excision repair (BER) pathway 
(see chapter 1.9.3.4), but it was also linked to oxidative DNA damage response. 
This suggests a role of PARP-1 in BER of oxidative DNA lesions. Based on our 
previous results that showed that mismatch repair (MMR) initiates at MYH/APE1-
generated nicks (see chapter 3.1.1), we became interested to test the effect of PARP 
inhibition on MYH-dependent MMR in vitro. At the same time, these experiments 
should reveal whether PARP-1 is involved specifically in MYH- or OGG1-induced 
BER.  
OGG1 activity in          
MMR buffer 
Background 
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To elucidate this, we performed biochemical studies, which have the advantage 
that GO/A and GO/C sites can be generated at specific sites in the plasmids, while 
oxidative stress in cells can lead to various undefined DNA modifications [168]. 
We took advantage of the previously described in vitro MMR assay and incubated 
nuclear cell extracts with the substrates that contained GO/A or GO/C sites in the 
close proximity of a G/T mismatch. Since MMR activity on G/T mismatches 
restored a SalI (in GO/A-G/T substrates) or AclI (in GO/C-G/T substrates) 
restriction site (see chapter 3.1.1, Figures 2A + 5A), this served as read-out for the 
accessibility of MYH- and OGG1-initiated nicks for MutSα-activated EXOI. 
Addition of Olaparib to the reactions should clarify whether PARP-1 was able to 
transiently bind MYH- and OGG1-initiated nicks and how this would affect BER-
dependent MMR.  
As discussed in detail in chapter 1.9.4.1, 'trapping' of PARP-1 on DNA breaks 
upon PARP-1 inhibition is currently the most accepted model. Since MMR is able 
to displace BER proteins immediately after the glycosylase-mediated nick 
generation, trapping of PARP-1 on MYH- or OGG1-initiated nicks could have 
three different outcomes on BER-dependent MMR (Figure 3-8). 
 
Figure 3-8:  Model showing how PARP inhibition could affect MYH-initiated MMR. 
The model suggests PARP-1 binding to MYH/APE1-generated nicks. Under normal conditions, 
PARP-1 would be auto-modied by poly(ADP-ribosyl)ation. This would lead to recruitment of other 
BER factors and dissociation of PARP-1. If the remaining nick was located in the proximity of a 
MMR target (G/T), it would serve as an initiation site for MMR proteins, namely EXOI. This would 
allow MMR to repair the close-by mismatch. In the presence of PARP inhibitors (PARPi), PARP-1 
would not be modified, which could lead to several scenarios: PARP-1 could remain bound to the 
nick thereby a) preserving the nick, which would provide better accessibility for EXOI. b) physically 
block the nick for other enzymes, including EXOI. A last scenario would suggest that c) PARP-1 is 
not involved in this process and PARPi would not affect MMR activity at all. 
Experimental set-up 
Possible outcomes 
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One possible scenario would be that PARP-1 preserved the nick, thereby making it 
accessible for MMR for a longer time period. This should result in increased MMR 
activity on the G/T mismatch. Another scenario could be that PARP-1 would 
physically block the nick, thus making it inaccessible for other enzymes, such as 
EXOI. A third scenario would be that PARP-1 played no role at MYH- and OGG1-
initiated nicks, and PARP inhibition would not affect MMR activity. During the 
limited time that was available for this project, I gained some interesting results 
that will be presented below. In chapter 4.2, I will discuss it and provide a detailed 
outlook on future experiments that could be carried out based on our observations 
to date. 
First, we tested the ability of nuclear cell extracts to perform poly(ADP-ribose) 
(PAR) formation (Figure 3-9 A). Nuclear cell extracts of HCT116 + chromosome 3 
cells were incubated for 1 min either in the absence (lane 1) or presence (lanes 2-3) 
of activated DNA, which contains a large number of breaks. One sample was 
additionally supplemented with 50 µM NAD+ (lane 3). Western blot analysis of 
PAR levels in the protein samples revealed that our extracts were able to form PAR 
polymers (lane 2). However, PAR levels were substantially increased upon NAD+ 
addition (lane 3). This can be explained by the fact that cell extracts were dialyzed 
during the preparation procedure, hence most NAD+ was removed. Although 
intracellular NAD+ concentrations are ∼500 µM [346, 347], no clear difference in 
PAR levels was detectable upon addition of 50 or 500 µM NAD+ on the Western 
blot (data not shown). To test whether addition of 50 µM NAD+ affects repair 
efficiencies on GO/A-G/T substrates, we performed a MMR assay in HCT116 cell 
extracts supplemented with MutLα and increasing amounts of NAD+ (Figure 3-9 
B). Quantifications demonstrate that MYH-dependent MMR efficiencies did not 
change with NAD+ concentration. This allowed us to perform MMR assays as 
described in the previous chapter 3.1.1, but in the presence of NAD+. Furthermore, 
we defined the Olaparib concentration needed to inhibit PAR formation upon 
addition of NAD+ to the extracts (Figure 3-9 C). HCT116 + chromosome 3 cell 
extracts were incubated in the presence of 500 µM NAD+, activated DNA and 
various concentrations of Olaparib. It turned out that already the lowest dose of 
Olaparib, 500 µM (lane 4), was enough to abolish PAR formation to the same level 
as in extracts that were not subjected to activated DNA. Thus, all further 
experiments were performed with 500 µM Olaparib.  
  
PAR formation and PARP 
inhibition in extracts 
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Figure 3-9: PAR formation can be activated and inhibited in nuclear cell extracts.  
(A) The ability of HCT116 + chromosome 3 nuclear cell extracts to form PAR was tested by incubation of 50 µg extracts and 100 ng 
activated/sheared DNA. One reaction was supplemented with 50µM NAD+ (lane 3) while one reaction was not (lane 2). Extracts in the 
control reaction (lane 1) were not activated with sheared DNA. Incubations were carried out for 1 min and subsequently prepared for 
Western blot analysis using anti-PAR and anti-PCNA (= loading control) antibodies. (B) The presence of additional NAD+ in nuclear 
cell extracts does not affect MMR or MYH activities. MMR assay using a GO/A-G/T substrate, HCT116 extracts and MutLα was 
performed under standard conditions (lane 1) or supplemented with the indicated amounts of NAD+. MMR efficiencies (%) of each 
reaction were quantified. (C) Olaparib inhibits PAR formation in nuclear cell extracts. 50 µg HCT116 + chromosome 3 nuclear cell 
extracts were either incubated with 0.5 mM NAD+ (lane 1), 100 ng sheared DNA (lane 2) or both (lanes 3-6). Samples 4-6 were 
additionally treated with 0.5, 5 or 50 mM Olaparib. Reactions were performed for 5 min. Western blot analysis was carried out for PAR 
detection. PCNA: loading control. 
Our first aim was to elucidate the effect of PARP inhibition by Olaparib on MYH-
dependent MMR (Figure 3-10 A). We incubated GO/A-G/T plasmids with HCT116 
nuclear cell extracts and, where indicated, with MutLα. Reactions were either 
supplemented with NAD+ or Olaparib. Treatment with Olaparib in the absence of 
NAD+ increased chances for efficient PARP inhibition. As expected, no MMR on 
the GO/A-G/T substrate was observed in the absence of MutLα (lane 1), while, in 
the presence of MutLα, it was repaired to 60% (lane 2). Interestingly, PARP 
inhibition decreased GO/A-G/T repair 0.7 fold to 43%. A heteroduplex substrate 
without any nick was repaired to 37%, both in the absence (lane 4) or presence 
(lane5) of Olaparib. Thus, repair efficiencies of the GO/A-G/T substrate were 1.6 
fold higher than of the G/T substrate in the absence of Olaparib, but only 1.16 fold 
higher in the presence of Olaparib. Thus MYH-dependent MMR efficiency was 
almost abolished by PARP inhibition. 
A similar observation was made for OGG1-dependent MMR (Figure 3-10 B). We 
had shown before (chapter 3.1.1) that OGG1 activity in extracts is insufficient to 
provide entry points for MMR at GO/C sites. Nevertheless, addition of 
recombinant, purified OGG1 increased its activity, thereby allowing access for 
MMR at OGG1-generated nicks. To be able to test the effects of PARP-1 inhibition 
on OGG1-initiated MMR, we had to add additional OGG1 to the reactions (Figure 
3-10, lanes 1, 3-6). As previously shown, in the absence of extra OGG1 (lane 2), 
repair efficiencies on GO/C-G/T substrates were low compared to G/T control 
PARP inhibition in MYH-
dependent MMR 
PARP inhibition in OGG1-
dependent MMR 
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substrates (lanes 5-6). The presence of purified OGG1 allowed MMR to access the 
nick and to repair G/T to A/T with an efficiency of 86% (lane 3). Interestingly, in 
the presence of Olaparib (lane 4), MMR efficiency on GO/C-G/T substrates 
dropped down to 71%, thereby decreasing 0.8 fold. The effect on the control G/T 
plasmid was less, decreasing 0.9 fold from 41% to 37% in the presence of 
Olaparib. Interestingly, the effect of PARP inhibition on MYH-initiated MMR was 
stronger than on OGG1-inititated MMR: in the presence of Olaparib, MMR 
efficiency on the GO/A-G/T substrate was only 1.16 fold increased compared to the 
G/T substrate while on the GO/C-G/T plasmid it was still 1.9 fold more than on the 
G/T plasmid. 
 
Figure 3-10: Olaparib decreases repair efficiencies on GO/A-G/T and GO/C-G/T substrates. 
(A) The MMR assay was performed with HCT116 nuclear cell extracts that were incubated with 
GO/A-G/T (lanes 1-3) or G/T (lanes 4-5) substrate, either in the presence of 50 µM NAD+ (lanes 1, 2, 
4) or of 800 µM Olaparib (lanes 3+5). MutLα was added where indicated. The quantification 
represents an average of 3 independent experiments +/- standard deviation. (B) The assay was 
performed similarly to what is described in (A) but using the GO/C-G/T substrate (lanes 1-4). Since 
OGG1 activities were not detectable in extracts (compare lane 2 with negative controls 5+6), purified 
OGG1 was additionally added to all other reactions (lanes 1, 3-6). The quantification represents an 
average of 3 independent experiments +/- standard deviation. 
Doctoral Thesis Results:  Towards the elucidation of the interactome of MSH6 page 97 
 
 Simone Repmann / IMCR - Institute of Molecular Cancer Research / D-BIOL 
Ei d gen öss isch e Tech n isch e H och sch ul e  Z ür i ch 
Swi ss  Fede ra l In s ti tu te  o f Tech n olo g y Zu r ich  
3.2 Towards the elucidation of the interactome of MSH6 during 
oxidative stress 
As described in detail in chapter 1.8.1, the role of the mismatch repair (MMR) 
recognition factor MutSα during the repair of oxidative DNA lesions is poorly 
understood to date. A promising approach to gain more insights into potential 
novel roles of MutSα is the performance of interactome studies of its component 
MSH6. Studying it in the absence or presence of oxidative stress should reveal the 
relevant interaction partners of MSH6 that are specifically required during 
oxidative DNA damage response. Besides its essential binding partner MSH2, 
other MSH6 interaction partners have been described, such as PCNA, MYH, 
CAF1, H3K36me3, 9-9-1 complex, BRCA1, BARD1, BLM, ATM, ATR and 
CHEK1 [35, 47, 73, 74, 348-353]. The interaction with ATM/ATR/CHEK1 
suggests a role for MSH6 in signaling [353], but might not necessarily be linked to 
oxidative DNA damage response. Hence, among the proteins listed above only the 
interaction with MYH points towards a direct involvement of MSH6 in oxidative 
DNA damage processing. This limited information reflects the need for further 
insights into this enigmatic role of MutSα. My contribution to the elucidation of the 
MSH6 interactome during oxidative DNA damage response was the generation and 
evaluation of tools needed for successful MSH6 pulldowns. My achievements are 
summarized below.  
3.2.1 Generation of a destination vector that allows inducible gene 
replacement 
In order to circumvent antibody-mediated blockage of potential interaction sites on 
the MSH6 protein during immunoprecipitation, we decided to work with a C-
terminally tagged version of MSH6. The location of the tag was determined by the 
nature of the MSH6 structure. Since it contains a multifunctional N-terminal 
domain including an essential PCNA interaction site between amino acids 4 and 11 
(see Figure 1-5), tagging the N-terminus might impair some of those functions. 
When we started this project, no mammalian cell line expressing exogenous tagged 
MSH6 existed. The probable reason for that was that indeed, technical difficulties 
in expressing exogenous MSH6 have been reported previously [79] and have also 
been observed in our laboratory. The reason for that is currently unclear (see 
chapter 4.3). To try to overcome this obstacle, we chose to work with a system and 
tag that was previously validated to be suitable for Mass Spectrometry [354]. This 
system is based on the Gateway® technology (Invitrogen) and allows doxycycline- 
(Dox-) inducible expression of a protein of interest, tagged with streptavidin 
binding peptide and a hemagglutinin epitope (Strep/HA), under the regulation of a 
CMV promoter. Vector integration occurs via FRT recombination in Flp-In T-REx 
cell lines. Since our long-term goal was not only the expression of tagged wild type 
Background 
Generation of the 'pTO+AIO 
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MSH6 but also of its mutants, we modified the vector in the way that it additionally 
allowed simultaneous knockdown of the endogenous protein of interest, thus 
resulting in inducible gene replacement. The different cloning steps are listed under 
material and methods (chapter 6.2, Table 6-3). A schematic illustration of the 
functional elements of the final destination vector named 'pTO+AIO CSH GW 
FRT' is presented in Figure 3-11. 
 
Figure 3-11: Scheme showing crucial elements in the pTO+AIO CSH GW FRT vector. 
H1 = Doxycycline- (Dox-) inducible promoter (containing a Tet repressor binding site) for the 
regulation of shRNA expression. CMV = Dox-inducible promoter (containing a Tet repressor binding 
site) for the regulation of Strep/HA-tagged protein expression. BglII-stuffer-HindIII site: shRNA can 
be cloned between the BglII and HindIII site, thereby destroying the BglII site. The stuffer allows 
improved accessibility of the restriction enzymes to the BglII and HindIII sites and its excision serves 
as control for successful double restriction digestion. StrepIII/HA = Strep/HA = SH = C-terminal 
tag of the protein of interest. The tag consists of a streptavidin-tag III and a hemagglutinin epitope. 
Hygro = hygromycin B resistance gene. Selection marker in mammalian cells. Amp = ampicillin 
resistance gene. Selection marker in bacteria. FRT = recombination site. It serves as binding and 
cleavage site for the Flp recombinase, leading to site-specific integration of the vector into a single 
FRT site in the Flp-In cell line. ccdB = gene, encoding a toxic product for bacteria. Selection marker 
for successful integration of the cDNA of interest into the vector. attR1/attR2 sites: recombination 
site, allowing the recombination of an ENTRY and a destination vector. 
Table 3-2: Features and corresponding advantages of the 'pTO+AIO CSH GW FRT' vector when 
  recombined with a protein of interest containing entry vector. 
Feature Advantage 
Simultaneous Dox-inducible 
a) expression of C-terminal Strep/HA-tagged 
protein and 
b) knockdown of endogenous protein 
1. Gene replacement: 
-  decreased risk of losing interaction partners     
that bind to the endogenous protein 
-   suitable for mutant studies 
-   counteracting protein overexpression 
2. isogenic cell system 
3. prevention of mutations caused by stable 
knockdown or stable expression of (mutant) 
exogenous proteins  
Strep/HA tag 1. Efficient two-step pulldown of the protein of 
    interest 
FRT recombination site allows vector insertion 
into Flp-In cell lines at only one specific gene 
locus 
1. Fast generation of stable cell lines 
2. No variations amongst different clones 
Stuffer Allows efficient BglII/HindIII digestion, hence 
facilitating shRNA insertion 
The color code clarifies interrelated features and advantages. 
While a shRNA targeting a non-coding mRNA region is inserted between the BglII 
and HindIII site of the destination vector, the gene of interest is inserted from an 
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entry vector via attR-mediated LR recombination. The shRNA and tagged protein 
will be expressed under an inducible H1 and CMV promoter, respectively. The 
advantages of the 'pTO+AIO CSH GW FRT' destination vector are summarized in 
Table 3-2. This vector can be used for expression and knockdown of any protein of 
interest. Furthermore, it can be used for just one of both purposes. 
3.2.2 Generation of a vector that allows simultaneous induction of MSH6-
Strep/HA expression and shRNA-mediated knockdown of endogenous 
MSH6  
In this project, MSH6 represented our protein of interest. The different cloning 
steps are schematically shown in Figure 3-12 and the corresponding vector maps of 
vectors A-D (Figure 3-12) are shown in appendices A1-A4. In the first instance, 
shRNA targeting the 3' UTR region of MSH6 mRNA was inserted into the 
'pTO+AIO CSH GW FRT' vector generated earlier. In parallel, MSH6 A116G 
cDNA was amplified from a pcDNA3-hMSH6 vector and inserted into the 
pENTR3C vector. Subsequently, the MSH6 mutation was corrected using PCR 
site-directed mutagenesis, and both entry and destination vectors were recombined 
in a LR-reaction. The detailed cloning methods are described under material and 
methods (see chapter 6.2, pages 131-132). 
 
Figure 3-12: Generation of 'pTO+AIO hMSH6-SH FRT + shMSH6' vector. 
The generation of the 'pTO+AIO hMSH6-SH FRT + shMSH6' vector (= D) required previous 
construction of the vectors A), B) and C). The 'pTO+AIO CSH GW FRT' vector (= A) served as 
starting vector into which the shRNA, targeting MSH6 mRNA, was inserted, resulting in vector (B). In 
parallel, the hMSH6 cDNA sequence was integrated into the entry vector pENTR3C (= C). Both 
vector B) and C) were recombined using an LR-reaction, giving rise to the final 'pTO+AIO hMSH6-
SH FRT + shMSH6' vector (= D). The corresponding vector maps are presented in appendices A1-A4 
and show all crucial vector elements. 
  
Generation of 'pTO+AIO 
hMSH6-SH GW FRT + 
shMSH6' vector 
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3.2.3 Generation of stable Flp-In T-REx cell lines 
The resultant 'pTO+AIO hMSH6-SH GW FRT + shMSH6' and 'pTO+AIO CSH 
GW FRT + shMSH6' vectors were used for the generation of stable Hek293 (data 
not shown) and U2OS Flp-In T-REx cell lines (Figure 3-13). Although generation 
of cell clones was, in theory, not necessary, FRT-independent vector integration 
into the cells genome had previously been observed in our laboratory. Thus, upon 3 
days of doxycycline treatment, different clones were tested for MSH6 knockdown 
and exogenous protein expression levels (Figure 3-13). 'pTO+AIO CSH GW FRT 
+ shMSH6' based cell lines express only 3' UTR shMSH6 (Figure 3-13 A). Four of 
those, especially clone 8, showed efficient MSH6 knockdown and thus represented 
a useful isogenic and inducible system that can be used to study MutSα-dependent 
phenotypes in future. 
 
Figure 3-13: Screening stable U2OS Flp-In T-REx clones for suitability. 
A) U2OS Flp-In T-REx clones, stably expressing the 'pTO+AIO CSH GW FRT + shMSH6' vector, 
were screened for efficient MSH6 knockdown. Cells were treated with 10 µg/ml Dox, which was 
replenished every 2 days. After 3 days, the cells were harvested in Lämmli buffer and MutSα protein 
levels were analyzed by Western blotting. B) U2OS Flp-In T-REx clones stably expressing the 
'pTO+AIO hMSH6-SH GW FRT + shMSH6' vector were screened for efficient expression of 
exogenous hMSH6-Strep/HA and simultaneous knockdown of endogenous MSH6, following the 
procedure described in A). 
Inducible isogenic cell line 
expressing shMSH6 
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'pTO+AIO hMSH6-SH GW FRT + shMSH6' based cell lines expressed both 
3'UTR shMSH6 and exogenous MSH6-Strep/HA (Figure 3-13 B). Only clone 11 
expressed the tagged version of MSH6, but only at low levels, resulting in a 1:1 
ratio of endogenous to exogenous MSH6 levels. This low MSH6-Strep/HA 
expression indicates that our system is suboptimal since normally CMV-controlled 
gene expression leads to substantial overexpression of the protein or, in case of 
MSH6 which gets stabilized by MSH2, at least comparable expression levels to 
endogenous MSH6. All in all, clone 11 failed to show complete gene replacement, 
which makes the cell line inappropriate for prospective mutant studies. A 
prolonged period of doxycycline treatment did not induce substantial changes in 
protein levels (Figure 3-14). 
 
Figure 3-14: Testing MSH6-Strep/HA expression and MSH6 knockdown levels of the most suitable 
U2OS Flp-In T-REx clones over time. 
U2OS Flp-In T-REx cells either expressing the 'pTO+AIO CSH GW FRT + shMSH6' (clone 8, panel 
A) or 'pTO+AIO hMSH6-SH GW FRT + shMSH6' (clone 11, panel B) vector were treated with 10 
µg/ml Dox for 3 to 10 days. Endogenous MSH6 and exogenous MSH6-Strep/HA levels of whole cell 
extracts were analyzed by Western blotting. 
3.2.4 HeLa Kyoto MSH6-LAP cell line: Characterization & MSH6 
pulldown 
In 2008, the laboratory of Anthony Hyman published a novel high-throughput 
technique for the generation of stable BAC transgenic mammalian cell lines in 
which transgenes are tagged with a 'localization and affinity purification' (LAP) tag 
[355]. 
Amongst others, they generated a HeLa Kyoto cell line stably expressing C-
terminally LAP-tagged MSH6. To our knowledge, this BACmid based approach is 
the first that succeeded in stably expressing exogenous tagged MSH6. The LAP tag 
allows GFP based localization of the tagged protein within the cell, as well as a 
two-step purification of the protein via GFP and, upon pre-scission protease 
cleavage, S-protein. The scheme of the C-terminal tagging cassette including the 
structure of the LAP tag is presented in Figure 3-15.  
Inducible isogenic cell line 
expressing shMSH6 and 
MSH6-Strep/HA 
BAC TransgeneOmics 
HeLa Kyoto MSH6-LAP   
cell line 
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Figure 3-15: Tagging cassette for C-terminal LAP-tagging. 
Schematic representation of a genomic region that contains the gene of interest (orange) and the 
cassette for tagging it at the C-terminus. The tag is inserted as a cassette with a neomycin resistance 
gene downstream of an internal ribosome entry site (IRES:neo). gb3, bacterial promoter. The LAP 
tag consists of the following elements: extended green fluorescent protein (EGFP), Pre-Scission 
protease cleavage site (P), S-peptide (S) and tobacco etch virus protease cleavage site (T). Adapted 
from [355]. 
We characterized the HeLa Kyoto MSH6-LAP cell line in terms of growth, GFP 
expression and functionality of the exogenous protein. FACS and 
immunofluorescence analysis revealed GFP expression localized to the nucleus 
(Figure 3-16 A-B). Cells exhibited a normal growth behavior with a doubling time 
of 24 hours (Figure 3-16 D). More importantly, we could show that the tagged 
MSH6 version was functional: Upon MNNG treatment, both endogenous and 
exogenous MSH6 were recruited to the chromatin accompanied by mono-
ubiquitylated PCNA, a MMR-dependent event occurring in response to MNNG 
treatment [94] (Figure 3-16 C). 
Cell line characterization 
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Figure 3-16: Characterization of a HeLa Kyoto MSH6-LAP cell line. 
This HeLa Kyoto cell line contains a stably integrated BACmid vector encoding C-terminally LAP-
tagged MSH6. The cell line was a kind gift of Anthony A. Hyman, MPI, Dresden, Germany. A) Flow 
cytometry analysis of GFP expression in HeLa Kyoto MSH6-LAP cells (blue) and HeLa Kyoto wild 
type cells (red). B) Immunofluorescence analysis of GFP expression in HeLa Kyoto MSH6-LAP cells. 
Cells were fixed in 3.7% formaldehyde, permeabilized with 0.2% Triton X-100 and stained with 
DAPI. C) The functionality of LAP-tagged MSH6 was tested in cells by pretreating them with 10 µM 
O6-benzylguanine for 1 hour and subsequently with 5 µM MNNG for 6 hours. At this time point, 
chromatin-enriched cell extracts, as well as whole cell extracts, were prepared and MSH6-GFP 
recruitment to the chromatin upon MNNG treatment was analyzed by Western blotting. D) A growth 
curve was generated by seeding 50'000 HeLa Kyoto MSH6-LAP cells into four 6-well dishes, 
respectively. After 1, 2, 3 and 4 days, cell numbers were counted. 
Furthermore, we wanted to ensure that the MMR-dependent behavior of HeLa 
Kyoto MSH6-LAP cells towards oxidative stress corresponded to the behavior of 
previously tested cell lines [260]. Indeed, knockdown of both endogenous and 
exogenous MSH6 (Figure 3-18, right panel) brought about sensitivity to KBrO3 
(Figure 3-18, left panel). Additional cell cycle studies revealed an accumulation of 
cells in G2/M phase 4 to 8 hours post KBrO3 treatment. In agreement with the cell 
survival data, 24 hours post KBrO3 treatment, control cells (siLUC) had recovered, 
while the number of siMSH6-treated cells that were arrested in G2/M had even 
increased (Figure 3-17). Even though this cell line does not allow MSH6 gene 
page 104 Role of Mismatch Repair, Base Excision Repair and PARP-1 in the Processing of Oxidative DNA Damage 
 
 Simone Repmann / IMCR - Institute of Molecular Cancer Research / D-BIOL 
Ei d gen öss isch e Tech n isch e H och sch ul e  Z ür i ch 
Swi ss  Fede ra l In s ti tu te  o f Tech n olo g y Zu r ich  
replacement, based on its characterization, it represents a suitable tool for MSH6 
pulldowns. 
 
Figure 3-17: MutSα-deficient cells show prolonged G2/M arrest upon oxidative stress. 
Cell cycle analysis. HeLa Kyoto MSH6-LAP cells, either treated with siLUC or siMSH6, were 
exposed to 50 mM KBrO3 or to PBS/Hepes (mock) for 30min. 4, 8 and 24 hours after treatment, the 
cells were harvested and fixed in 70% ethanol. The DNA was stained with propidium iodide (PI) and 
the cell cycle stages were analyzed by flow cytometry. 
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Figure 3-18: MutSα deficiency sensitizes cells towards oxidative stress. 
HeLa Kyoto MSH6-LAP cells, either treated with siLUC or siMSH6, were exposed to different 
concentrations of KBrO3. 72 hrs after treatment, the cells' survival was measured in terms of their 
metabolic activity, using a CellTiter-Blue cell viability assay. The graph represents the results of five 
independent experiments, each carried out in triplicate. Each data point represents an average +/- 
standard deviation. The Western blot shows MSH6 knockdown efficiency of one representative 
experiment at the time of the drug treatment. 
Since proteins that are involved in oxidative DNA damage repair should be 
recruited to the DNA in this process, we performed pulldown experiments in 
chromatin-enriched cell extracts. This should allow enrichment of potential 
proteins of interest. The p150 subunit of chromatin assembly factor 1 (CAF-1) 
served as 'quality control' of these extracts, since it should only be present in the 
chromatin fraction. First pulldown experiments, carried out as one-step purification 
using GFP-Trap_A beads in untreated chromatin-enriched cell extracts, were 
extremely efficient in terms of MSH6-LAP and MSH2 enrichment (Figure 3-19). A 
problem we encountered was inconsistence with regard to detection of expected 
interaction partners such as MYH, PCNA or CAF-1. As ascertained by Western 
blotting, most pulldown experiments revealed low presence of known interaction 
partners (data not shown), while in others they could be detected but at the cost of a 
high non-specific background (Figure 3-19, see Western blot). Possible strategies 
for pulldown optimization, as well as prospective experiments that can be carried 
out based on the hitherto-generated and evaluated tools will be discussed in chapter 
4.3. 
MSH6 pulldown 
page 106 Role of Mismatch Repair, Base Excision Repair and PARP-1 in the Processing of Oxidative DNA Damage 
 
 Simone Repmann / IMCR - Institute of Molecular Cancer Research / D-BIOL 
Ei d gen öss isch e Tech n isch e H och sch ul e  Z ür i ch 
Swi ss  Fede ra l In s ti tu te  o f Tech n olo g y Zu r ich  
 
Figure 3-19: GFP-pulldown in chromatin-enriched cell extracts of HeLa Kyoto MSH6-LAP cells. 
A GFP-pulldown, usingGFP-Trap_A beads, was performed in chromatin-enriched cell extracts of 
HeLa Kyoto cells expressing either C-terminally LAP-tagged MSH6 or only GFP (= control 
reaction). Upper panel: Analysis of the pulldown reaction was performed by Western blotting, which 
was used to detect known and expected MSH6-binding partners. 2% input of chromatin-enriched cell 
extracts (chromatin) served as control for the efficiency of protein enrichment after the pulldown. 2% 
input of the cytoplasmic (cyt) and nuclear soluble (nuc) fraction served as quality control for 
chromatin-enriched cell extracts (quality marker: CAF1). Lower panel: Silver staining of the same 
pulldown reaction was performed for visualization of all present proteins. Pictures from the input and 
the pulldown, which are presented in separate pictures here, derive from the same gels with the same 
exposure times. 
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3.3 MYH-induced oxidative DNA damage repair partially contributes 
to PARP inhibitor sensitivity in BRCA1-deficient cells  
We hypothesized that MYH and/or OGG1 induced base excision repair (BER) 
intermediates of oxidative DNA lesions would contribute to PARP inhibitor 
sensitivity in the absence of homologous recombination (HR). To test this we 
performed survival studies with BRCA1-deficient cells that were treated with the 
PARP inhibitor Olaparib. If the hypothesis was true, knockdown of MYH and/or 
OGG1 should overcome sensitivity to Olaparib, leading to increased survival rates. 
Since siRNA-mediated knockdown of OGG1 protein levels was inefficient even 6 
days after treatment, and even though mRNA levels were downregulated by 80% 
(data not shown), we turned our experimental focus on MYH. 
Before we started the survival assays, we validated the potency of Olaparib, which 
is a selective inhibitor of mammalian PARP-1, PARP-2 and PARP-3, thus one of 
the most specific inhibitors on the market. Nevertheless, since PARP-1 and -2 were 
reported to have overlapping functions, inhibition of both might be even beneficial. 
Since H2O2 is known to lead to nuclear poly(ADP-ribose) (PAR) formation, 
SUM149PT and HeLa cells were treated with 1 mM H2O2 for 10 minutes. To 
validate the effect of Olaparib, other cells were pretreated with 0.1 µM Olaparib (= 
evaluated IC50 value of Olaparib in SUM149 PT cells) for one hour, following a 
short 1 mM H2O2/0.1 µM Olaparib combination treatment. Mock-treated cells 
served as control. Immunofluorescence staining of PAR revealed efficient 
inhibition of PARP-mediated poly(ADP-ribose) formation in the cells that were 
pretreated with Olaparib (Figure 3-20). We therefore continued with the survival 
studies. 
 
Figure 3-20: Olaparib inhibits PAR formation in cells upon H2O2 treatment.  
SUM149PT (A) and HeLa (B) cells were either mock-treated (PBS) or treated with 0.125 µM or 50 
µM Olaparib for 1 hour. After 1 hour, the medium was replaced by 1 mM H2O2 and the 
corresponding amount of PBS or Olaparib for 10 min. Cells were fixed immediately with 
methanol/acetic acid and stained with anti-PAR 10H antibody (GFP) and DAPI. 
Background 
Testing Olaparib 
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In this study we made use of two BRCA1-deficient breast cancer cell lines. The 
SUM149PT cell line contains a 2288delT mutation in exon 11 of the BRCA1 gene 
and shows low BRCA1 transcript levels [356]. Similar BRCA1 transcript levels 
were observed in SUM1315MO2 cells, which have a 185delAG mutation in exon 2 
of the BRCA1 gene [356]. Ovcar-8 cells, deriving from ovarian adenocarcinoma 
tissue, and U2OS osteosarcoma cells exhibit a wild type BRCA1/-2 status and 
were, where required, treated with siRNA against BRCA1. 
To evaluate our hypothesis, SUM149PT and SUM1315MO2 cells were transfected 
with siRNA against luciferase (= control) or MYH. Three days after siRNA 
transfection, when MYH knockdown was complete (data not shown), cells were 
subjected to a continuous Olaparib treatment with various doses. 10 days 
posttreatment, cells were fixed and stained with 0.5% crystal violet / 20% ethanol 
and colonies were counted (Figure 3-21 A-B). A similar assay was performed in 
Ovcar-8 cells (Figure 3-21 C), but since they exhibit a BRCA1/-2 wild type 
phenotype, they were treated with siRNA against luciferase (= control), MYH, 
BRCA1, or BRCA1 and MYH together. In these experiments we did not observe 
any differences in colony survival when comparing siLUC- with siMYH- 
(SUM149PT, SUM1315MO2) or siBRCA1- with siBRCA1/siMYH-treated cells 
(Ovcar-8). Nevertheless, BRCA1 knockdown in Ovcar-8 cells brought about the 
expected Olaparib sensitivity, proving that PARP inhibition worked. Equal survival 
of the control and MYH knockdown cells could be explained by the fact that 
siRNA-mediated knockdown of MYH is only transient and protein expression will 
recur about 2 days posttreatment. The clonogenic survival assay, in contrast, was 
performed until 10 days posttreatment. If Olaparib were stable in the medium over 
several days and was not washed out, this would result in a continuous exposure of 
the cells to the drug. Any effect of MYH knockdown on cell survival would hence 
be masked as soon as MYH is expressed again. However, if oxidative DNA lesions 
were the source of PARP inhibitor toxicity in HR-deficient cells, the effect of 
Olaparib should be enhanced upon additional DNA oxidation. Two possibilities 
would be to either additionally expose cells to reactive oxygen species (ROS), such 
as H2O2, or to co-downregulate the hydrolase MTH1, which hydrolyzes oxidized 
purine nucleoside triphosphates to monophosphates, thereby preventing their 
incorporation from the deoxynucleotide pool into newly-synthesized DNA. 
However, a higher number of oxidized bases in the DNA would be expected from 
exposure to ROS, since this would not only increase incorporation of oxidized 
deoxynucleotides from the pool but also oxidize non-replicating DNA. 
Cell lines 
Long-term survival studies: 
continuous PARPi treatment 
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Figure 3-21: In long-term survival studies, a transient MYH knockdown has no effect on cell 
survival in BRCA1-deficient cells upon continuous Olaparib treatment. 
Clonogenic survival assay of BRCA1-deficient (A) SUM149PT, (B) SUM1315MO2 and BRCA1-
proficient (C) Ovcar-8 cells upon continuous treatment with various concentrations of Olaparib. 
Three days before treatment, cells were either treated with siLUC or siMYH. Since the BRCA1 status 
is crucial for the cells' response to Olaparib, Ovcar-8 cells (C) were additionally treated with 
siBRCA1. 
We performed clonogenic survival assays with SUM149PT cells that were treated 
with either 50 or 100 µM H2O2 for 1 hour, or continuously with 0.065 µM 
Olaparib. A combination treatment involved preincubation of the cells with 
Olaparib for one hour and subsequent addition of H2O2 for another hour. In this 
case, the drugs were washed off and replaced with Olaparib-containing medium for 
continuous treatment (Figure 3-22). The Western blot shows MYH knockdown 
efficiency at the day of treatment. Despite only a transient siRNA-mediated 
knockdown of MYH, the additional exposure to H2O2 brought about differences in 
cell survival of siLUC- or siMYH-treated cells. Monotreatment with H2O2 resulted 
Long-term survival studies: 
continuous PARPi treatment 
& H2O2 
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in a dose-dependent response of control cells (siLUC), while MYH knockdown 
cells were 1.5 (50 µM H2O2) and 1.7 fold (100 µM H2O2) more resistant as 
compared to control cells. Reduced DNA damage recognition in the absence of 
MYH, can explain the observed resistance to H2O2 in those cells. As already 
observed in the previous experiment (Figure 3-21), Olaparib monotreatment did 
not lead to any differences in colony survival. However, similar to H2O2 treatment 
alone, a combination treatment of H2O2 and Olaparib resulted in 1.9 (50 µM H2O2) 
and 1.4 fold (100 µM H2O2) increased survival of MYH knockdown cells when 
compared to the control cells. Overall, toxicity in H2O2 + Olaparib-treated cells was 
increased compared to single treatments. These results show that Olaparib activity 
is enhanced in the presence of oxidative stress, supporting the idea that PARP 
inhibitor sensitivity in HR-deficient cells depends on oxidized DNA products. 
Furthermore, since MYH knockdown led to tolerance of the combination 
treatment, this experiment suggests that the oxidized DNA was, at least partially, 
addressed by MYH. 
 
Figure 3-22: In long-term survival studies, a transient MYH knockdown in BRCA1-deficient cells 
leads to increased cell survival upon H2O2 / Olaparib combination treatment. 
Clonogenic survival assay of BRCA1-deficient SUM149PT cells either treated with siRNA against 
luciferase (siLUC) or MYH (siMYH). Cells were treated with either H2O2 or Olaparib alone, or with 
Olaparib and H2O2 together. In the last case, cells were treated with 0.065 µM Olaparib for 1 hour, 
and then H2O2 was added for another hour. After that, the medium was removed, cells were washed 
with PBS and new medium supplemented with 0.065 µM Olaparib (= continuous treatment) was 
added. The graph represents the results of two independent experiments, each carried out in 
triplicate. Each data point represents an average +/- standard deviation. Whole cell extracts (WCE) 
were prepared at the day of treatment and used for Western blot analysis of the MYH knockdown 
efficiency. 
In the next step, we aimed to work under natural conditions, i.e. in the absence of 
H2O2. In order to avoid possible masking of MYH knockdown-dependent changes 
in cell survival, we performed a clonogenic survival assay in SUM149PT cells, but 
this time using an acute 1 day Olaparib treatment (Figure 3-23). Consequently, 
Long-term survival studies: 
acute Olaparib treatment 
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cells were only exposed to Olaparib at the day of complete MYH knockdown 
(Figure 3-23, Western blot). Any masking effects were herewith excluded. Indeed, 
under those assay conditions, MYH knockdown cells were more tolerant to 
Olaparib than the control cells. 
 
Figure 3-23: In long-term survival studies, a transient MYH knockdown in BRCA1-deficient cells 
leads to increased cell survival upon acute Olaparib treatment. 
Clonogenic survival assay of BRCA1-deficient SUM149PT cells, either treated with siRNA against 
luciferase (siLUC) or MYH (siMYH), upon acute Olaparib treatment. Cells were treated with the 
indicated concentrations of Olaparib. 24 hours later, Olaparib was washed off and fresh medium was 
added to the cells. Standard deviations were calculated from triplicates within one experiment. Whole 
cell extracts were prepared on the day of Olaparib treatment and were used for Western blot analysis 
of the MYH knockdown efficiency. 
Another approach to circumvent that MYH knockdown-dependent changes in cell 
survival might be masked, was to use short-term survival assays. We took 
advantage of a CellTiter-Blue cell viability assay (Promega) and measured cells' 
survival in terms of their metabolic activity, already 3 days after Olaparib 
treatment. For this purpose, at the day of measurement, Resazurin was applied to 
the cells, which then reduced it to Resorufin, a fluorescent substance with an 
emission wavelength of 590 nm. Since this assay lasted much shorter, MYH 
knockdown should be complete over the majority of the time. Again, SUM149PT 
cells were treated with siRNA against luciferase (= control) or MYH. The Western 
blot presents MYH protein levels at the time of Olaparib treatment. We observed 
that at doses of 0.1 - 10 µM Olaparib, MYH knockdown resulted in about 1.4 fold 
increased survival compared to control cells (Figure 3-24). Thus, those data were in 
agreement with the previous results shown in Figure 3-23. 
Short-term survival studies 
in SUM149PT cells 
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Figure 3-24: In short-term cell survival studies, a transient MYH knockdown leads to increased cell 
survival upon continuous Olaparib treatment in BRCA1-deficient SUM149PT cells. 
CellTiter-Blue cell viability assay of BRCA1-deficient SUM149PT cells, either treated with siRNA 
against luciferase (siLUC) or MYH (siMYH), upon continuous Olaparib treatment. 72 hours after 
treatment, the cells' survival was measured in terms of their metabolic activity using a CellTiter-Blue 
cell viability assay. Standard deviations were calculated from triplicates within one experiment. 
Whole cell extracts for Western blot analysis of MYH knockdown efficiency were prepared on the day 
of Olaparib treatment. 
We finally decided to confirm those results in another cell line, using the same 
short-term survival assay. U2OS cells are BRCA1 wild type, hence cells were 
treated with siRNA against luciferase (= control), BRCA1, or BRCA1 and MYH 
(Figure 3-25, A). As expected, BRCA1 knockdown resulted in PARP inhibitor 
sensitivity, proving efficient Olaparib treatment. In line with the previous 
experiment (Figure 3-24), additional MYH knockdown lead to 1.3 fold more 
survival when compared to BRCA1-deficient cells. An advantage of the U2OS cell 
system is that it allows the comparison of different survival curves with that of 
'wild type'/BRCA1-proficient cells. Therefore, this was the first experiment that 
revealed that MYH deficiency does not fully rescue the BRCA1-deficient 
phenotype in the presence of Olaparib, but at least by 50%. In chapter 3.1.1, we 
provided in vitro evidence that MutSα enhances MYH activity. In this regard, we 
made an interesting side observation. Similar to MYH, a MSH6 knockdown in 
BRCA1 deficient cells resulted in slight tolerance to Olaparib. A triple knockdown 
of BRCA1, MYH and MSH6 even increased the tolerance to the same level than in 
BRCA1/MYH double knockdown cells (Figure 3-25, B). This suggests that MYH 
and MSH6 act in the same pathway during oxidative DNA damage repair, as 
observed in vitro. The data described here, will be discussed in chapter 4.4. 
Short-term survival studies 
in U2OS cells 
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Figure 3-25: In short-term survival studies, a transient MYH knockdown partially rescues BRCA1 deficiency-mediated cell 
sensitivity towards Olaparib. 
CellTiter-Blue cell viability assay of U2OS cells upon continuous Olaparib treatment. Cells were either treated with siRNA against 
luciferase (siLUC), BRCA1 (siBRCA1) or BRCA1 and MYH (siBRCA1 + siMYH) (panels A+B). Panel B additionally represents results 
for siBRCA1 + siMSH6 as well as siBRCA1 + siMYH + siMSH6 combination knockdowns. 72 hours after treatment, the cells' survival 
was measured in terms of their metabolic activity using a CellTiter-Blue cell viability assay. The graph represents the results of four 
independent experiments each carried out in triplicate. Each data point represents an average +/- standard deviation. (C) Whole cell 
extracts for Western blot analysis of the knockdown efficiencies were prepared on the day of Olaparib treatment. 
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4 Discussion & Outlook 
4.1 The interdependence of base excision repair and mismatch repair 
during the processing of 8-oxoguanine 
The principle mechanism of eukaryotic mismatch repair (MMR) during replication 
is well documented [40, 41] and its key players have been identified [357]. 
Nevertheless, some key mechanistic details of this pathway are still not clearly 
understood. One of these concerns the question how is MMR directed to the 
daughter strand in order to increase replication fidelity. On the lagging strand, this 
can be explained by preexisting, transient nicks between Okazaki fragments that 
occur every ∼200 base pairs [358]. In contrast, the only preexisting strand 
discontinuity on the leading strand is its 3'-terminus. It was unclear for many years 
how 3' nicks could serve as entry-sites for 3'-5' strand degradation, given that the 
only nuclease implicated in MMR to date, EXOI, has an obligate 5'-3' polarity. 
This mystery was resolved by the finding of an intrinsic endonuclease activity of 
the MutLα subunit PMS2 [67], which was shown to be able to incise the daughter 
strand in the vicinity of the mismatch, thereby creating 5' nicks that can be used for 
EXOI-catalyzed degradation. A remaining question was how MutLα might be able 
to incise the strand that contained the preexisting 3' strand discontinuity. This was 
first proposed to be regulated by signaling between the MutSα/MutLα complex and 
the nick [67]. Later, however, Pluciennik et al. showed that this strand 
directionality is determined by an interaction of MutLα with PCNA [68]. MutSα 
would replace the polymerase at the 3'-terminus of the leading strand, recruit 
MutLα and form a PCNA/MutSα/MutLα complex that slides back to the mismatch 
in 3'-5' direction (see Figure 1-4). The assumption that MutLα can only cleave 5'-
3'-oriented phosphodiester linkages could explain its strand bias for the primer 
strand [69]. However, strand discontinuities should not be more than 1000 base 
pairs away from the mismatch to allow efficient MMR [63]. Since the leading 
strand seems to lack sufficient amounts of nicks or gaps, this raised the question 
whether it might contain other strand discontinuities that might be used by the 
MMR system for the purpose of strand discrimination.  
We shed light onto this issue by showing that MMR can "hijack" MYH/APE1-
generated breaks at GO/A sites, allowing it to initiate its repair process (see chapter 
3.1.1). Since GO/A sites are frequently generated by polymerases [179, 182] but not 
recognized by their proofreading activity [184], each should be addressed by MYH 
and converted into a transient nick by the downstream-acting AP endonuclease. We 
also observed that MMR stimulates the activity of MYH, as described previously 
[35], but found an additional explanation how this might be achieved. Since 
siRNA-mediated knockdown of MMR proteins led to decreased MYH levels, this 
indicated that the former proteins stabilized MYH (see chapter 3.1.2.3). This 
MMR activity on the leading 
strand 
The mutual dependence of 
MutSα & MYH 
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furthermore showed that MMR proteins indirectly enhance the activity of the 
MMR pathway by stabilizing their own nick-generator. In contrast, HEC59 and 
HCT15 cells, which have mutations in the MSH2 or MSH6 gene, respectively, 
showed higher levels of MYH than their undepleted controls. This scenario differs 
from that above, in that the MMR-deficient cell lines permanently lack MutSα 
expression. Therefore, they might have developed mechanisms to overexpress or 
stabilize MYH, possibly through enhanced transcription. The need for MYH in the 
absence of MMR can be explained by the synthetic lethality of MMR and the BER 
polymerase-β [285]. Both pathways are involved in the processing of oxidative 
damage [246], but if one is defective, the other can compensate for its absence. 
However, since MMR defects are the result of mutagenesis rather than evolution, 
MYH instability associated with transient knockdowns of MutSα/MutLα is most 
likely caused by the loss of interacting partners. 
We furthermore observed that OGG1 was almost inactive in the cell extracts, 
which prevented "hijacking" of OGG1-generated nicks by MMR. Assuming that 
this low OGG1 activity reflects the in vivo situation, it can be explained by the fact 
that GO/C sites are not directly mutagenic and therefore do not need to be repaired 
efficiently. This would also explain why OGG1-deficient mice do not develop 
tumors [245] and why OGG1 defects in humans have not been reported to cause 
cancer. In contrast, the efficient removal of mutagenic GO/A sites by MYH is much 
more important, as reflected by the development of colorectal cancer when MYH is 
mutated. 
However, we had to demonstrate that the lack of OGG1 activity in the extracts was 
not caused by our extract preparation or assay conditions (see chapters 3.1.1 + 
3.1.2.4). We therefore first confirmed the presence of the protein in the extracts by 
Western blotting, and tested its stability by several freeze-thaw cycles. The protein 
appeared to be relatively abundant and stable. We next combined nuclear and 
cytoplasmic extracts in order to eliminate the possibility that OGG1 is inactive due 
to a lack of an activator protein. This assay also yielded no explanation for OGG1 
inactivity. Another possibility is that the sluggish mode of action of OGG1 in vitro 
[240, 242] would preclude it from competing with MMR proteins or nucleosome 
loading. This scenario was also discarded, because substrate accessibility was 
observed to be diminished only after 1.5 hours of plasmid incubation, and MMR 
proteins were still active after 3 hours. One crucial factor that could affect OGG1 
activity might be inappropriate salt concentration. Since the assay is performed 
under physiological salt concentration (110 mM KCl) that favors MMR, MYH and 
recombinant OGG1, this explanation can also be ruled out. The protein extraction 
from the nuclei was also performed at low salt concentration (150 mM NaCl), 
which is rather unlikely to cause inactivition of the protein. Another possibility 
could be that we did not extract an active form of OGG1, in that it might lack 
The meaning of low OGG1 
activity 
Reasons of low OGG1 
activity in extracts 
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essential posttranslational modifications (PTMs). The only reported PTM of OGG1 
is phosphorylation [243], but an in vivo experiment showed that serine 
phosphorylation of OGG1 seems to rather determine its cellular localization to the 
chromatin than affect its activity [244]. However, given that the recombinant 
OGG1 used in our experiments was active despite having been purified from 
bacteria, which lack serine, threonine and tyrosine kinases [359], the lack of 
phosphorylation is unlikely to be the reason for OGG1 inactivity in the extracts. 
Taken together, our data suggest that what we observed in vitro reflects the 
situation in vivo. The most likely scenario would therefore be that OGG1 is 
inhibited in the extracts by other proteins such as chaperones. This would also 
explain why we observe OGG1-dependent MMR upon addition of recombinant 
OGG1 to the extracts. The latter would cause an imbalance in the ratio of OGG1 
and its inhibitor; no inhibitor would be available for the extra OGG1, which would 
then be functional.  
To test this assumption, our next goal is to study BER-dependent MMR in vivo. 
For this purpose, we developed an in vivo MMR assay and we could confirm that 
MMR also "hijacks" MYH-initiated nicks on substrates transfected into human 
cells (see chapters 3.1.2.1 + 3.1.2.2). To entirely clarify the issue discussed above, 
one main focus of future studies will be to study OGG1-dependent MMR in vivo. 
This could be achieved with the described assay or, since its sensitivity is limited 
due to co-recovery of plasmids that were not available for repair, using a 
fluorescence-based approach. This would have the advantage that only substrates 
that reached the nucleus would be analyzed, thus reducing background levels of 
unrepaired plasmids. 
We should point out that GO/A intermediates are unlikely to be the only strand 
discontinuities besides Okazaki fragments and 3' termini of the leading strand. 
Their limited contribution is apparent from the fact that MAP-tumors rarely exhibit 
microsatellite instability (MSI), a hallmark of MMR-deficiency. In tumours 
displaying MSI, MMR deficiency was caused either by biallelic promoter silencing 
of the MLH1 gene [221] or by G to T transversion mutations in MMR genes, 
resulting from MYH dysfunction [222, 224]. However, our laboratory has shown 
that also RNaseH2-induced nicks can be "hijacked" by MMR. We therefore 
propose that many different kinds of repair intermediates could be "hijacked" by 
MMR, and hence collectively contribute to MMR directionality and efficiency, and 
thus also to replication fidelity. A future challenge is to identify the nature of all 
these intermediates. The ability of MMR to use breaks generated by other 
pathways of DNA metabolism as strand discrimination signals represents a perfect 
back-up system for MutLα, ensuring that the loss of one nick-generator would not 
impair MMR function and hence its role in cancer prevention. 
In vivo MMR studies 
Impact of the study 
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4.2 The involvement of PARP-1 and PARP inhibition in BER-
dependent mismatch repair 
We extended the study described above and asked whether PARP-1, which was 
previously linked to oxidative DNA damage response and base excision repair 
(BER), might play a role during MYH- and OGG1-directed mismatch repair 
(MMR). As described in chapter 3.1.3 (Figure 3-8), trapping of PARP-1 on DNA 
glycosylase-generated nicks by PARP inhibition, could affect MMR in different 
ways: it could preserve the nick thereby increasing its accessibility for MutSα-
activated EXOI, or it could block the single-strand break. In this case, EXOI would 
not have access to the nick and MMR activity would decrease. Our data point 
towards the last scenario, thereby giving insights into possible effects of PARP 
inhibition on MMR activity. Furthermore, these experiments implicate that PARP-
1 binds to MYH/APE1- and OGG1-generated nicks in vitro. We made several 
observations during this study, which are discussed in the following sections. 
Interestingly, MYH-dependent MMR was more affected by Olaparib than OGG1-
dependent MMR (Figure 3-10). This might be due to a more prominent role of 
PARP-1 at MYH/APE1-generated nicks, but it might also be a result of the 
position of the nick relative to the mismatch. While MYH generates 3' nicks at 
GO/A-G/T substrates, OGG1 generates 5' nicks at GO/C-G/T plasmids. Since EXOI 
acts in a 5'-3' direction, MMR on 3' nicked substrates depends on the intrinsic 
endonucleolytic activity of MutLα (see chapter 1.3.2.2) [67]. MutLα will generate 
various nicks in the proximity of the initial nick and the mismatch, thus generating 
5' nicks that can be used by exonuclease EXOI. This increased number of nicks, 
representing potential binding sites for PARP-1, might also explain the stronger 
effect of PARP inhibition on GO/A-G/T substrates. Whether this assumption is 
correct could be clarified with experiments using G/T-GO/A and G/T-GO/C 
substrates, leading to MYH/APE1-induced 5' and OGG1-induced 3' nicks, 
respectively.  
In order to exclude any unspecific, PARP-1-independent, inhibitory effects of 
Olaparib on the MMR machinery or other factors involved in this process, PARP-
1-depleted cell extracts could serve as control. Furthermore, removal of histones 
from the extracts could exclude any NAD+ or PARP inhibitor-dependent effects on 
chromatin packaging, thus influencing repair-processes. Such effects cannot be 
fully excluded in our experiments. However, we showed that the NAD+ 
concentrations that were used in our assays did not affect GO/A-G/T repair (Figure 
3-9 B). Furthermore, G/T unnicked control plasmids also exhibited background 
levels of MutLα-dependent MMR (Figure 3-10). Since those repair levels did not 
change upon Olaparib addition, we can assume that the MMR machinery itself and 
chromatin packaging was, at least not significantly, affected by Olaparib. 
Achievements 
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In order to distinguish the effects of Olaparib on BER from its effects on MMR, 
future experiments should involve 5' and 3' Nt.BstNBI prenicked G/T substrates. 
This would allow studying the effect of Olaparib exclusively on MMR and should 
indicate whether PARP-1 exhibits different binding affinities to nicks introduced 
by MYH/APE1, OGG1 or a nickase. In fact, reconstituted systems, involving all 
enzymes that are required for efficient 3'- or 5'-directed MMR, were defined [62, 
63, 66, 357] and did not include PARP-1. It therefore does not play an essential 
role during this process, but this does not exclude transient protection of the nicks 
by PARP-1. If the latter was indeed the case, PARP-1 inhibition on Nt.BstNBI 
nicked heteroduplex substrates should also affect MMR. Indeed, a study of Liu et 
al. showed that increasing amounts of PARP-1 in the absence of NAD+, thus 
imitating a PARP inhibition situation, to a 4- (MutSα, MutLα, EXOI, RPA) or 6- 
(+PCNA, RFC) protein system, decreased 5' and 3' excision by EXOI on nicked 
heteroduplex substrates [308]. PARP inhibition might therefore not only affect 
BER-dependent MMR as shown in our study, but also BER-independent MMR 
processes as shown by Liu et al [308]. 
Taken together, the effect of PARP inhibition on DNA repair that we describe here 
could represent possible side effects of PARP inhibition in non-cancerous cells. 
However, even if PARP inhibition would affect MYH-dependent MMR processes, 
in terms of clinical application the number of GO/A mispairs in cells might not be 
enough to give rise to a MMR-deficient phenotype upon PARP inhibition. But if 
this observation could be extrapolated to other MMR events, such as MMR 
initiating at Okazaki fragments or RNaseH2-generated nicks [72], PARP inhibition 
could seriously affect the overall MMR efficiency. A consequence could be an 
altered response to other treatments, since a lack of MMR leads to resistance of 
various kinds of drugs (see chapter 1.8.2). Although we also showed an effect of 
PARP inhibition on OGG1-dependent MMR, this finding is expected to be less 
relevant, since OGG1-dependent MMR does not occur in cell extracts (see chapter 
3.1.1). Thus far, we have not questioned how it is possible at all that the well 
coordinated BER pathway can be interrupted by MMR and enable it to displace 
BER proteins from the DNA prior to completion of repair. It is likely that this 
process is coordinated by other factors and it will be a future challenge to test if 
PARP-1 might be one of those by controlling access of the different repair 
enzymes to the nick. 
4.3 Towards the elucidation of the interactome of MSH6 during 
oxidative stress 
As described in detail in chapter 1.8.1, there is emerging evidence that mismatch 
repair (MMR) is involved during oxidative DNA damage repair, but its precise role 
in this process is poorly understood. Our long-term aim is thus to get more insights 
into potential novel roles of the mismatch recognition factor MutSα during 
PARP inhibition in 3' and 5' 
directed MMR 
Impact of the study 
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oxidative DNA damage response. This should be achieved by studying the 
interactome of the MutSα heterodimer component MSH6 using mass spectrometry. 
As mentioned in chapter 3.2, my goal was to establish and evaluate the required 
tools for efficient MutSα pulldowns. For this purpose I modified a destination 
vector that was provided by Matthias Gstaiger, according to our needs. The 
resultant 'pTO+AIO CSH GW FRT' vector (see Figure 3-11, Table 3-2) can be 
used for either i) isogenic inducible gene replacement or for ii) inducible 
knockdown, of any protein of interest. In the former case, it allows C-terminal 
Strep/HA tagging of the protein, making it suitable for pulldown experiments. 
Though MSH6 expression in this vector was not sufficient, I succeeded in the 
generation of an isogenic inducible MSH6 knockdown cell line, which can be used 
for future MutSα studies (Figure 3-14 A). Due to the vector's universal 
applicability, it could in future also be tested for MSH2 gene replacement, and in 
case of success be used for MutSα/β interactome studies. In a second step, I 
characterized a HeLa Kyoto MSH6-LAP cell line in terms of exogenous MSH6 
expression, functionality, its behavior towards oxidative stress and its suitability for 
GFP pulldowns (Figure 3-18, Figure 3-17, Figure 3-19). In fact, to our knowledge, 
this is the first cell line that successfully expresses exogenous tagged MSH6. As 
expected, MSH6 knockdown in this cell line lead to increased sensitivity and G2/M 
arrest upon KBrO3 treatment. Furthermore, I could show that GFP pulldowns of 
LAP-tagged MSH6 were extremely efficient, a prerequisite for future interactome 
studies (Figure 3-19). In the following two sections, the reasons for successful 
MSH6 expression from BACmids, as well as various other approaches for 
interactome studies that can be done based on my work, will be discussed. 
We showed that MSH6 expression from bacterial artificial chromosomes 
(BACmids) was much more efficient than from cDNA vectors. In general, there are 
various reasons that can underlie low protein expression levels in mammalian cell 
lines. One possibility is an impairment of protein folding or function due to the tag, 
which could block active sites or interactions with other proteins. In the case of 
MSH6, it would thus be illogical to tag the N-terminal domain, since this possesses 
multifunctionality and a PIP domain at its extreme N-terminus (see chapter 
1.3.2.2). The C-terminus in contrast is part of the ATPase containing domain. 
Whether its linkage to a tag affects MSH6 activity is difficult to anticipate, but it 
seems unlikely, since C-terminal LAP-tagged MSH6 in HeLa Kyoto cells was 
functional. Besides the location of the tag, its size could also influence the protein's 
function. For instance, bulky tags bring about greater chances of impairing 
proteins' functionality. However, it seems that the rather big (≈ 29 kDa) S-
protein/GFP containing tag does not negatively influence MSH6 activity. Though it 
is not proven, it is likely that also the comparably small (≈ 5 kDa) Strep/HA tag 
would not affect MSH6 activity. It should also be considered that overexpression 
MSH6 expression 
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of proteins that are involved in signaling processes as might be the case for MSH6 
[80, 82], can be 'toxic' for the cell. This might protect itself by enhanced 
degradation of the protein or its mRNA. However, although controlled by a strong 
CMV promoter, overexpression of MSH6-Strep/HA in U2OS Flp-In T-REx cells 
should not present a problem, as MSH6 protein levels should be self-limiting when 
not accompanied by a concomitant rise in MSH2 [56, 360]. Based on our 
observation, low MSH6 protein expression from the 'pTO+AIO hMSH6-SH GW 
FRT + shMSH6' vector may more likely be caused by problems in the MSH6 
expression itself than by post-expressional influences. Like in our approach, 
expression of tagged proteins in mammalian cells is typically performed with 
cDNA-based transgenes that lack the normal endogenous regulatory information 
and are driven by unrelated promoters. This approach led however to unsuccessful 
attempts of our and probably other laboratories in expressing tagged versions of 
MSH6. The first success was achieved recently by the laboratory of Anthony 
Hyman that expressed tagged MSH6 from a BACmid [355], which has the 
advantage that it allows insertions with more than 300 kilobases. BACmids 
therefore contain complete genes with all their endogenous regulatory sequences, 
such as introns or untranslated regions (UTRs), and furthermore allow protein 
expression under the control of its natural promoter, thereby ensuring normal 
expression levels. Our observations indicate that some of those natural regulatory 
sequences might be essential for successful MSH6 expression. This assumption 
would moreover be supported by the fact that MutSα activity could be restored in 
the MSH6-mutated HCT15 cell line by introducing chromosome 2 [345]. In this 
case, comparable to expression from a BACmid, MSH6 expression occurs from its 
entire gene including its own promoter and regulatory sequences. 
Based on the high pulldown efficiency of exogenous MSH6 and its binding partner 
MSH2 from HeLa Kyoto cell extracts, the specificity of co-precipitated interaction 
partners of MSH6-LAP could be enhanced in various ways, each bringing along 
advantages and disadvantages. Co-precipitation of expected interaction partners in 
GFP control cells points towards insufficient purification of the beads (Figure 
3-19), which might be achieved by more stringent washing or a second purification 
step via S-protein. Both approaches however could be at the cost of losing 
interaction partners of the actual protein of interest. Those were, apart from MSH2, 
already only rarely detectable and, if so, only in little amounts. This could be 
explained by non-functionality of the exogenous protein, but is unlikely, since we 
showed that it is recruited to chromatin upon MNNG treatment (Figure 3-16 C). It 
might well be that only in the presence of DNA damage, such as oxidative stress, 
interaction partners increase their binding affinity to MSH6, which would then 
facilitate their detection. MSH6 might also bind weakly or only transiently to many 
of its interaction partners. In this case, protein crosslinking in cells could increase 
their detection. In fact, another possibility would be to use BirA or ascorbate 
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peroxidase (APEX) tags. An engineered form of the 35 kDa biotin protein ligase 
BirA has promiscuous properties and thus biotinylates all proximate proteins, 
which can subsequently be purified in a streptavidin-dependent manner [361, 362]. 
Also an engineered variant of APEX biotinylates proximate proteins (< 20 nm) in 
an APEX- and H2O2-dependent manner [363]. Since this approach is inducible by 
H2O2, it even allows for snapshots of 'interacting' complexes. Regarding the 
available tools that were developed and evaluated during this project, future 
pulldown and interactome studies might make use of the following approaches. 
The hitherto lack of inducible gene replacement in the otherwise suitable HeLa 
Kyoto MSH6-LAP cell line could be resolved by engineering of the BACmid. 
Furthermore, future studies could be done based on the generated 'pTO+AIO 
hMSH6-SH GW FRT + shMSH6' vector. One approach would be the replacement 
of the Strep/HA tag on this vector by GFP. Although, as discussed above, a 
negative effect of the Strep/HA tag on MSH6 functionality is rather unlikely, 
replacement with a GFP tag could be tested, since this worked in the BACmid 
approach. Additionally, if expression of tagged MSH2 from cDNA turns out to be 
efficient, a cell line allowing for inducible gene replacement with MSH2-Strep/HA 
could be generated based on the 'pTO+AIO CSH GW FRT' vector and be used for 
MutSα/β interactome studies.
4.4 The underlying sources of DNA damage and repair that mediate 
PARP inhibitor sensitivity in HR-deficient cells 
Although the potency of PARP inhibitors in homologous recombination (HR)-
deficient tumors can plausibly be explained by the 'concept of synthetic lethality' 
[328, 329] (chapter 1.9.4.1), the underlying sources of DNA damage that lead to 
single-strand breaks (SSBs), and thus to PARP inhibitor sensitivity, have not been 
examined yet. Since PARP inhibitors work as monotherapies in the described 
genetic background, it is likely that SSBs arise from endogenous sources of DNA 
damage. It is assumed that, since oxidation is a main source of endogenous DNA 
damage [169], it could be a main contributor to PARP inhibitor sensitivity. 
However, this had not been proven to date. Using survival studies, we showed that 
MYH knockdown in BRCA1-deficient cells gave rise to increased survival upon 
Olaparib treatment, suggesting that MYH-generated nicks can contribute to 
Olaparib sensitivity. These data represent first in vivo evidence that oxidation 
indeed contributes to PARP inhibitor sensitivity in HR-deficient cells. 
Furthermore, they prove that PARP-1 is involved in MYH-mediated BER in vivo.  
These observations might have clinical relevance. In the described genetic 
background, the effect of PARP inhibitors could be potentiated with additional 
oxidizing agents, such as Methotrexate. This drug is already used for treatment of 
various kinds of cancers and was furthermore shown to lead to accumulation of 8-
Achievements 
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oxoguanine [284]. In terms of personalized medicine, it might be beneficial to 
apply PARP inhibitors to tumors that exhibit high MYH and/or low MTH1 protein 
levels. Another possibility would be a simultaneous inhibition of MTH1. In fact, an 
important step in the direction of such a clinical application was achieved recently, 
since selective and potent MTH1 inhibitors have been developed and validated in 
human cells and mice [256, 257]. Overall, our observations are in line with other 
studies that also described MYH to induce lethal SSBs. Oka et al. showed that 
accumulation of MYH-generated SSBs in either mitochondria or in the nucleus 
upon oxidative stress, activated two distinct cell death pathways [364]. Knockdown 
of MYH suppressed both kinds of cell death. This suggested that MYH induces cell 
death under oxidative stress in order to prevent mutagenesis [365], as happens for 
example in APC or KRAS genes of MAP patients. Those and our studies imply that 
MYH can introduce SSBs that lead to cell death. The mechanisms of cell death will 
be different, however. During our study, we made several observations that are 
discussed in the following sections. 
Since little information about Olaparib stability under culture conditions is 
publically available, except sensitivity to temperature and light (material safety 
data sheet, Olaparib), we initially assumed Olaparib to be unstable in cell culture 
medium at 37°C over a long period of time. Thus, first experiments (Figure 3-21) 
were carried out with a continuous Olaparib treatment in long-term clonogenic 
survival assays. Here, we did not observe any differences in colony survival 
between control and MYH knockdown cells. We thereupon performed similar 
assays, but using acute Olaparib treatment (Figure 3-23) or short-term survival 
assays (Figure 3-24 + Figure 3-25). Under those conditions, MYH knockdown 
cells exhibited resistance to the drug. Contrary to what we assumed, these different 
outcomes can be explained with long-term stability of Olaparib under culture 
conditions. Since in all experiments MYH knockdown was transient, re-expression 
of the protein would mask any effect of PARP inhibition on cell survival. 
Furthermore, we showed that MYH knockdown in SUM149PT cells led to H2O2 
tolerance (Figure 3-22). We observed this effect also in other, HR-proficient cell 
lines such as Hek293 or HeLa Kyoto MSH6-LAP (data not shown). Due to the 
enhanced oxidative DNA damage tolerance in MYH knockdown cells, this 
observation can be well explained. Those data are in line with studies of Yusaku 
Nakabeppu and colleagues. Here, they showed that accumulation of 8-oxoguanine 
led to cell death, which was triggered by MYH-induced single-strand breaks. 
Knockdown of MYH reduced the number of SSBs and thus led to 8-oxoguanine 
tolerance and better cell survival [364, 365]. By contrast, other studies 
demonstrated that MYH knockdown in HeLa cells [366] or in cells carrying 
mutated MYH [216, 367] brought about more sensitivity to oxidative stress. 
Further studies are required to evaluate those discrepancies. 
Olaparib stability 
Role of MYH in response to 
oxidative stress 
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Experiments with siBRCA1-treated Ovcar-8 cells showed that additional 
knockdown of MYH brought about Olaparib resistance (Figure 3-25). However, 
survival was only restored by 50% when compared to BRCA1-proficient Ovcar-8 
cells. This means that MYH is a contributor to Olaparib sensitivity in this genetic 
background, but apparently other factors also play a role here. Assuming that 
PARP inhibitor sensitivity could be entirely attributed to intermediates of the BER 
pathway, glycosylases that address endogenous DNA damages, such as OGG1, 
UNG, SMUG1, TDG, MBD4, MPG, NTH1 or NEILs, could also play a role here. 
How efficiently they could contribute to such effect would depend on the incidence 
of the respective lesions and the effect of PARP-1 upon their activities. In fact, 
oxidative DNA lesions are more abundant in cells than other endogenous DNA 
damages [169]. This would suggest that glycosylases such as MBD4, MPG, UNG 
or TDG might play more minor roles in PARP inhibitor toxicity than oxidative 
DNA damage specific glycosylases such as OGG1, NTH1, NEIL1, NEIL2 or 
NEIL3. Amongst those, OGG1 might be a main contributor to PARP inhibitor 
sensitivity in HR-deficient cells, given that its substrate 8-oxoguanine is a 
predominant modification amongst oxidative DNA lesions. Furthermore, it should 
be considered that also spontaneous depurination represents a main threat to 
genomic integrity [169], leading to the loss of about 5000 purine bases and thus 
apurinic sites per cell per day. This means that if APE1 incised AP-sites were also 
recognized by PARP-1, its inhibition could have significant effects on cells' fates 
even in the absence of any glycosylase.  
Due to time constraints, this project had to be stopped at this point, but our findings 
represent a promising starting point to extend the project in various directions. 
Future experiments should validate our findings in SUM149PT cells using 
CellTiter-Blue and clonogenic survival assays. To further evaluate the contribution 
of oxidative stress to PARP inhibitor sensitivity, survival studies with Olaparib-
treated BRCA1/-2 deficient cells should be performed under hypoxic or hyperoxic 
conditions. In line with our findings, hypoxia would be expected to increase cell 
survival. As discussed in the previous section, it would be interesting to use similar 
experiments to elucidate the contributions of other glycosylases to Olaparib 
sensitivity. Overall, such extension of the project should provide fundamental 
evidence for the origin of PARP inhibitor toxicity in HR-deficient cells.
Other contributors to PARPi 
sensitivity in HR-deficient 
cells 
Outlook 
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5 Conclusions 
The correct propagation of genetic information is indispensable for the 
maintenance and proper function of cells and organisms. However, faithful 
replication depends on various factors and multiple DNA repair mechanisms that 
contribute to its high fidelity. The work of this PhD thesis concentrated on two of 
those repair mechanisms, mismatch repair (MMR) and base excision repair (BER), 
as well as on the protein PARP-1 in the context of oxidative DNA damage. 
Postreplicative MMR increases replication fidelity by several orders of magnitude, 
but to do so it needs to be directed to the newly-synthesized daughter strand. How 
this is regulated in vivo is still poorly understood, but it is assumed that strand 
discrimination signals primarily derive from gaps between Okazaki fragments on 
the lagging strand and from 3' termini of the leading strand. The imbalance in the 
abundance of strand discontinuities between the two strands is obvious and begs 
the question how accessibility of the leading strand for MMR is ensured. In this 
work we show that MMR can “hijack” breaks generated as intermediates of MYH-
initiated BER of GO/A mispairs and use them as strand discrimination signals. This 
we showed in human nuclear extracts as well as in extracts of Xenopus laevis eggs, 
and we are currently extending these studies also to human cells in vivo. 
Taken together with recent findings from our laboratory, which demonstrated that 
ribonucleotides misincorporated into the nascent DNA strand during replication 
can also be “hijacked” by the MMR system as strand discrimination signals, it 
might be expected that MMR deploys breaks generated during all base excision 
repair events in this manner. However, only the “hijacking” of breaks in nascent 
DNA strands would contribute to increased replication fidelity, whereas breaks in 
the parental strand would provide the system with the wrong strand directionality, 
as well as possibly bringing about a collapse of the replication forks. Interestingly, 
GO/C pairs in which the oxidized guanine would be in the parental strand do not 
appear to be processed by BER during the time course of the MMR reactions in the 
cell extracts. This suggests that MMR and BER are highly regulated as to which 
lesions may serve as strand discrimination signals at replication forks and which 
cannot. How such ingenious fine-tuning of strand accessibility is regulated and 
whether it takes place also in vivo needs further detailed investigation. Does it 
involve active inhibition of certain BER glycosylases? Or is the regulation simply 
the result of the different abundances of certain DNA lesions, the individual repair 
enzymes or the different kinetics of the respective repair processes? It would also 
be useful to gain more insights into how ongoing BER is displaced by MMR 
proteins, as exemplified at sites of GO/A processing. Does it involve inhibition of 
the downstream BER enzymes such as polymerase β/λ, or is the exchange 
regulated by other nick binding enzymes, such as PARP-1? This remains to be 
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tested. Also interactome studies of MMR proteins could help to identify such 
'regulator'. However, our preliminary data point towards an involvement of PARP-
1 in BER-dependent MMR and this topic is the subject of future studies. 
PARP inhibitors are currently in Phase III clinical trials for the treatment of 
BRCA-deficient breast and ovarian cancer. Surprisingly, the biological role of the 
main target of these inhibitors, PARP-1, is not fully understood. In the current age 
of “personalized medicine”, full understanding of the mode of action of all cancer 
chemotherapeutics is required if we are to predict the response of individual 
patients to combination cancer therapy and also avoid deleterious side effects. 
During the course of this work, we took a small step towards identifying the source 
of spontaneous DNA damage that leads to the death of BRCA-deficient cells. By 
demonstrating that the effect of PARP inhibition was reduced by the 
downregulation of MYH activity in human cell lines, we implicated oxidative 
DNA damage as one of the underlying sources of strand breaks that feed into the 
homologous recombination pathway inactivated by BRCA malfunction. Other 
sources of endogenous DNA damage involved in the sensitivity of BRCA-deficient 
cells to PARP inhibitors remain to be identified, and the involvement of repair 
mechanisms responsible for their processing must be closely studied. The putative 
involvement of PARP-1 in MMR represents one such example. Should PARP-1 
inhibition indeed affect MMR efficiency, as indicated in our preliminary in vitro 
experiments, this could have deleterious consequences, given that MMR 
dysfunction leads to DNA damage tolerance, which represents a serious problem in 
cancer therapy. The experiments described in this thesis address only a small 
fraction of the questions that remain to be answered in the future. If we are to 
develop more efficient ways of treating cancer, we must gain detailed 
understanding of the mechanisms of action of cancer therapeutics and of the 
biological pathways involved in their metabolism. In this way, we should be able to 
use the differences between tumor types and individuals in the design of 
therapeutic strategies that would optimize the patient response to this important 
class of substances. 
Doctoral Thesis Materials & Methods  page 127 
 
 Simone Repmann / IMCR - Institute of Molecular Cancer Research / D-BIOL 
Ei d gen öss isch e Tech n isch e H och sch ul e  Z ür i ch 
Swi ss  Fede ra l In s ti tu te  o f Tech n olo g y Zu r ich  
6 Materials & Methods 
6.1 Studies relating to the manuscript 
In vivo MMR assay 
HCT116 + chromosome 3 cells were transfected with siRNA against luciferase or 
MYH using RNaiMax (Invitrogen) as per manufacturer's protocol. 48 hours later, 
the cells were seeded in 6-well plates at a density of 500'000 cells per well and in 
triplicates. The following description refers to the treatment of a single well. 24 
hours after seeding, the cells were transfected with 500 ng GO/A-loop, loop, or 
homoduplex substrate or with 1 µg nicked loop substrate using Lipofectamine 2000 
(Invitrogen) as per manufacturer's protocol. Transfection of 500 ng EGFP 
expression plasmid in a separate well served as control for transfection efficiency. 
The substrates were recovered 24 h later, EGFP expression was recorded by 
immunofluorescence (Olympus IX81) and whole cell extracts were prepared from 
separate wells for western blot analysis of knockdown efficiencies. The recovery 
process was performed as follows: cells were washed twice with PBS, trypsinized 
and transferred to 1.5 ml tubes. They were then pelleted at 1’000 rpm for 2 min, 
washed once with PBS and resuspended in P1 buffer (Qiagen). SDS and Proteinase 
K (AppliChem) were added to final concentrations of 0.6% (w/v) and 2.4 mg/ml, 
respectively. After incubation at 55°C for 1 hour, NaOH was added to a final 
concentration of 45.5 mM and incubation continued for 5 min at room temperature. 
Buffer A3 (Macherey Nagel) was added to a final concentration of 0.23% (v/v) and 
incubated for 5 min on ice. The mix was loaded on NucleoSpin®Plasmid columns 
(Macherey Nagel) the substrates were recovered according to the manufacturer's 
protocol and eluted in water. Contaminating linear genomic DNA was removed by 
Plasmid-SafeTM ATP-dependent DNase (Epicentre) treatment as per manufacturer's 
protocol. Substrates from three 6-well plates were pooled, concentrated by ethanol 
precipitation and digested with HindIII-HF (NEB) in 1x NEBuffer 2 (NEB). The 
substrate amounts were estimated on a GelRed- stained 1% agarose gel and equal 
amounts of substrate were used for primer extension. A 30 µl mix containing 1x 
NEBuffer 25 ng recovered substrate, 0.67 mM dNTPs and 4 nM [γ-32P]ATP 5'-
labeled primer (5'-GAATTGTAATACGACTCACTATAGGGCGAATTGGCGG-
3') was heated at 95°C for 10 min. Primer annealing to the denatured substrate was 
performed at 50°C for 15 min. 1 U DNA polymerase I, Large Klenow fragment 
(NEB) was added and elongation performed at 37°C for 30min. After heat 
inactivation at 75°C for 20 min, the samples were concentrated by ethanol 
precipitation and resolved in 10 µl loading dye (80% formamide, 1 mM EDTA, 50 
mM Tris-HCl pH 8.3). To visualize repair efficiencies, 2µl of each primer 
extension product were separated on a 10% denaturing polyacrylamide gel and 
analyzed with a Typhoon scanner (FLA 9500, GE Healthcare). 
In vivo MMR assay 
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Substrates for the in vivo MMR assay were produced as described in chapter 3.1.1. 
The oligonucleotides listed below served as primers and the single-stranded 
phagemid DNA listed in brackets, served as template. The SalI (GTCGAC) 
restriction site is highlighted in bold and mispaired residues are underlined. Primer 
sequences correspond to the outer strand sequence of the substrate. 
- loop (pRichi-2850botSalI(+2)): 
 5'-CCAGACGTCTGTCGACGTTGGGAAGCTTGA-3' 
- GO/A-loop (pRichi-2850botSalI(+2)): 
5'-GACGGCCAGGOGAATTGTAATACGACTCACTATAGGGCGAATTGGC
GGCCGCGATCTGATCAGATCCAGACGTCTGTCGACGTTGGGAAGCTT
GAG-3' 
- no loop (pRichi-2850botSalI): 
 5'-CCAGACGTCTGTCGACGTTGGGAAGCTTGA-3' 
Cell culture, Transfection, Western blot 
HCT116 (MutLα-) and HCT116 + chromosome 3 (MutLα+) cells were obtained 
from Richard Boland and were cultured in McCoy's 5a medium (GIBCO) 
supplemented with 10% FBS (GIBCO). HCT15 and HCT15 + chromosome 2 cells 
[345] were cultured in RPMI medium (GIBCO) and 20% FBS (GIBCO). Hec59 
and Hec59 + chromosome 2 cells [1] were grown in 50% Ham's F12 and 50% 
DMEM medium (GIBCO) supplemented with 10% FBS. The medium for the 
chromosome 2 or 3 complemented cell lines was supplemented with 400 µg/ml 
G418. U2OS cells were grown in DMEM (GIBCO) supplemented with 10% FBS. 
All media additionally contained 1% penicillin/streptomycin. 
Cells were transfected with siRNA 
siMSH6 (1): 5'-CGCCAUUGUUCGAGAUUUA-3' (Microsynth); 
siMSH6 (2): 5'-AUCGCCAUUGUUCGAGAUUUA-3' (Qiagen); 
siMSH6 (3): 5'-UUCUGACAAAGGUGGUAAAUU-3' (Microsynth); 
siMSH2: 5'-UCCAGGCAUGCUUGUGUUGAA-3' (Qiagen); 
siMLH1 (ON-TARGETplus human MLH1 siRNA-SMARTpool, Dharmacon); 
siMYH: 5'-UCACAUCAAGCUGACAUAUCAAGUA-3' (Microsynth); 
siLUC: 5'-CGUACGCGGAAUACUUCGA-3' (Microsynth) using Lipofectamine 
RNAiMAX (Invitrogen) as per manufacturer's protocol. 3 days after transfection, 
whole cell extracts were prepared using 2 x Lämmli buffer (120 mM Tris-HCl pH 
6.8, 4% SDS, 20% glycerol). Upon determination of the protein concentration by 
Lowry assay, proteins were analyzed with SDS-PAGE and Western blot. 
In vitro OGG1 nicking assay 
100 ng of supercoiled GO/C-G/T substrate was, where indicated, incubated with 39 
ng recombinant, purified OGG1 (gift from Dr. Barbara van Loon) and 0.05 U of 
APE1 (New England Biolabs), in either 1x nicking buffer (20mM Tris-HCl pH8 
Primers for substrate 
production 
Cell lines 
siRNA treatment & 
Western blot 
In vitro OGG1 nicking assay 
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1 mM DTT, 1 mM EDTA pH 8, 0.1mg/ml BSA) or 1x MMR buffer (20 mM Tris-
HCl pH 7.6, 110 mM KCl, 5 mM MgCl2, 1 mM Glutathione, 50 µg/ml BSA, 0.1 
mM dNTPs, 1.5 mM ATP) for 30 min at 37°C. The reactions were stopped by 
adding 2 µl of 6x loading dye (37.5 mg/ml Ficoll 400, 23% glycerol, 0.03% 
bromophenol blue) and subsequent heat inactivation. Samples were separated on a 
1% agarose gel and visualized with GelRed. 
6.2 Studies on the interactome of MSH6 
Cell survival assays 
HeLa Kyoto MSH6-LAP cells were seeded at a density of 200'000 cells per dish 
(Ø = 6 cm). The next day, they were treated with siRNA against luciferase or 
MSH6. 48 hours posttransfection, cells were re-seeded in triplicates in 96-well 
plates at a density of 1500 cells/well (siLUC) and 4500 cells/well (siMSH6), 
respectively. 24 hours after seeding, cells were treated with the indicated 
concentrations of KBrO3 (see: KBrO3 treatment of cells). 72 hours after drug 
treatment, cell viability was measured with the CellTiter-Blue® Cell Viability 
Assay (Promega) according to the manufacturer's protocol. Fluorescence 
(560Ex/590Em nm), an indicator of metabolic activity, was measured 4 hours after 
addition of Resazurin.  
A 500 mM KBrO3 stock was prepared in water and was stored in aliquots at -20°C. 
For treatment purposes, the KBrO3 stock was diluted to the desired concentrations 
in PBS containing 20 mM Hepes (pH 7.5). The cells were washed once with PBS 
and subsequently treated with the appropriate KBrO3 dilution for 30 min in the 
dark. To stop the treatment, the KBrO3 solution was removed and replaced by 
medium. 
Cloning 
DH10B 
genotype: F- endA1 recA1 galE15 galK16 nupG rpsL ΔlacX74 Φ80lacZΔM15 
araD139 Δ(ara,leu)7697 mcrA Δ(mrr-hsdRMS-mcrBC) λ- [368, 369]. Unless 
otherwise specified, transformations were performed with this E.coli strain. 
One Shot® ccdB Survival TM 2 T1R 
genotype: F-mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacX74 recA1 
araΔ139 Δ(ara-leu)7697 galU galK rpsL (StrR) endA1 nupG fhuA::IS2 
(InvitrogenTM Life Technologies). Feature: resistant to the ccdB gene product. 
  
siRNA treatment and 
CellTiter-Blue® cell viability 
assay 
KBrO3 treatment of cells 
E. coli strains 
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Table 6-1: List of vectors 
Name Purpose Reference / Supplier 
pTO CSH GW FRT Empty Gateway Destination vector: Tet-inducible 
CMV promoter for C-term Strep/Strep/HA-tagged 
protein expression.  
Matthias Gstaiger, 
IMSB, ETHZ 
pTO+AIO NSH GW 
FRT 
Empty Gateway Destination vector: Tet-inducible 
H1 and CMV promoter for shRNA and N-term 
Strep/HA-tagged protein expression, respectively. 
Svenja Kaden, IMCR 
pFastBac1 hMLH1 Provides 486 bp stuffer sequence upon HindIII 
digest 
Margaret Fäsi, IMCR 
pcDNA3-hMSH6 Template for PCR amplification of MSH6 (pSR6-
FW+pSR6-RV) 
Nina Mojas, IMCR 
pENTR3C Empty Gateway Entry vector. Harbors attL1 and 
attL2 sites to allow LR recombination with 
destination vector 
InvitrogenTM 
pENTR3C + hMSH6 Gateway Entry vector containing the MSH6 wild 
type ORF 
This study 
pTO+AIO CSH GW 
FRT 
Empty Gateway Destination vector: Tet-inducible 
H1 and CMV promoter for shRNA and C-term 
Strep/HA-tagged protein expression, respectively. 
This study 
pTO+AIO CSH GW 
FRT + shMSH6 
Gateway Destination vector: Tet-inducible H1 
promoter for shMSH6 expression. 
This study 
pTO+AIO hMSH6-SH 
GW FRT + shMSH6 
Gateway Destination vector: Tet-inducible H1 and 
CMV promoter for shMSH6 and C-term MSH6- 
Strep/HA expression, respectively. 
This study 
 
3'UTR targeted shMSH6 sequence: 
(P)5'-GATCCCTTCTGACAAAGGTGGTAAATTTTCAAGAGAAATTTACCACCTTTGTCAGAATTTTTA-3' 
       3'-GGAAGACTGTTTCCACCATTTAAAAGTTCTCTTTAAATGGTGGAAACAGTCTTAAAAATTCGA-5'(P) 
shRNA sequence 
hairpin 
BglII restriction site 
HindIII restriction site 
Table 6-2: Primer sequences for MSH6 amplification and sequence correction 
Name Sequence 5'-3' Purpose 
pSR6-FW TCGAAATTAATACGACTCACTATAG Forward amplification of MSH6 
A116G from pcDNA3-hMSH6 
pSR6-RV ATATCTCGAGCATAATTCCTTAATCAAAG
TCAGCA 
Reverse amplification of MSH6 
A116G from pcDNA3-hMSH6 
FW-MSH6 
A116G 
GGGCCTCACGCGAAGGCGGCCGTGCCGC
CGCTGCCCCCGGGGCCTCTCCTTCCCC 1) 
Correction of MSH6 A116G to 
MSH6 wild type (forward) 
RV-MSH6 
A116G 
GGCCACCAGGGGTAACCCTCCATCTTGGC
CC 2) 
Correction of MSH6 A116G to 
MSH6 wild type (reverse) 
1) EagI restriction site, corrected base 
2) BstEII restriction site 
Vectors 
shRNA targeting MSH6 
Primers 
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Table 6-3: Cloning steps and corresponding methods for generating the 'pTO+AIO CSH GW FRT' 
vector 
Cloning step Method Resulting vector 
1. Removal of an interfering 
BglII site 
Digestion of pTO+AIO NSH GW FRT (E) and 
pTO CSH GW FRT (F) vectors with 
NotI/XmaI. Insertion of the 1189 bp fragment 
of vector (E) into the 5857 bp fragment of 
vector (F). 
(G) 
2. Insertion of an element, 
containing a H1 promoter and 
a downstream integration site 
(BglII/HindIII) for shRNA  
Digestion of pTO+AIO NSH GW FRT (E) and 
pTO CSH GW FRT (G) vectors with 
PciI/KpnI.  Insertion of the 3258 bp fragment 
of vector (E) into the 4215 bp fragment of 
vector (G). 
(H) 
3. Insertion of a stuffer 
sequence between the BglII 
and HindIII sites 
Digestion of vector (H) and the pFastBacI 
hMlhI vector with HindIII. Insertion of a 486 
bp fragment (= stuffer) of pFastBacI hMlhI 
between the BglII/HindIII sites via HindIII. 
pTO+AIO CSH 
GW FRT vector 
(= A) 
 
1 µg pTO+AIO CSH GW FRT vector was digested with 20 U BglII for 5 hours at 
37°C and subsequently with 40 U HindIII for another hour. The stuffer that was 
cloned between both restriction sites brings about the advantage that successful 
digestion by both enzymes gives rise to a 486 bp fragment that can be detected on a 
1% GelRed-stained agarose gel. shMSH6 and the BglII/HindIII digested pTO+AIO 
CSH GW FRT vector were mixed in a 4:1 ratio and were ligated by T4 DNA ligase 
(New England Biolabs) overnight at 16°C. Since successful insertion of shMSH6 
into the destination vector destroys the BglII restriction site, the ligation product 
was purified using an ethanol precipitation, dissolved in water and subsequently 
subjected to a second BglII digestion for 3hrs at 37°C. Subsequent transformation 
into a ccdB-resistant E. coli strain gave rise to bacterial colonies that were analyzed 
by restriction enzyme digestion and sequencing. 
PCR-amplification of the MSH6 A116G sequence from the pcDNA3-hMSH6 
vector was performed according to the following protocol: 
Temperature [°C] Time Cycles 
98 30 sec 1x 
98 10 sec 
20x 60 20 sec 
72 5 min 
72 10 min 1x 
4 ∞ 1x 
For the generation of sufficient amounts of PCR product, the described PCR 
reaction was performed 8x in parallel and in separate tubes. One PCR reaction was 
performed in 1x Phusion buffer (New England Biolabs), 0.2 mM dNTPs, 0.5 µM 
pSR6-FW and pSR6-RV primers, 10 ng pcDNA3-hMSH6 vector and 0.4 U of 
Generation of 'pTO+AIO 
CSH GW FRT' vector 
Insertion of shMSH6 into 
pTO+AIO CSH GW FRT 
vector 
PCR amplification of   
MSH6 A116G 
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Phusion polymerase (New England Biolabs) according to the thermocycling 
conditions stated above. The PCR products were purified by ethanol precipitation, 
pooled and the DNA concentration was measured with a DNA standard on a 1% 
GelRed-stained agarose gel. 
2 µg of both purified PCR product and pENTR3C vector were digested in 1x 
NEB1 buffer, 1x BSA (NEB), 40 U KpnI-HF (NEB) and 30 U XhoI (Roche) in a 
total volume of 50 µl for 15 h at 16°C. Following gel purification, the insert and 
the pENTR3C vector were ligated by T4 DNA ligase in a 2:1 ratio overnight at 
16°C. 
For correction of the MSH6 A116G sequence to MSH6 wild type, PCR-site 
directed mutagenesis was performed according to the following protocol: 
Temperature [°C] Time Cycles 
98 30 sec 1x 
98 10 sec 
20x 60 30 sec 
72 15 sec 
72 10 min 1x 
4 ∞ 1x 
For the generation of sufficient amounts of the PCR product, the described PCR 
reaction was performed 6x in parallel and in separate tubes. One PCR reaction was 
performed in 1x Phusion buffer, 0.2 mM dNTPs, 0.5 µM FW-MSH6 A116G and 
RV-MSH6 A116G primers, 10 ng pENTR3C + hMSH6(G116A) vector and 0.4 U 
Phusion polymerase-HF (New England Biolabs) according to the thermocycling 
conditions stated above. After gel purification, both 2 µg of PCR product and 
pENTR3C + hMSH6(G116A) vector were digested with 25 U EagI overnight at 
37°C and subsequently 25 U BstEII were added and the temperature was increased 
to 60°C for another hour. The desired DNA fragments were again purified by gel 
extraction. The digested 211 bp PCR fragment containing the corrected MSH6 
sequence was inserted into the digested pENTR3C + hMSH6(G116A) vector in a 
1:1 ratio by T4 DNA ligase overnight at 16 °C, thereby replacing the MSH6 
mutated part in the pENTR3C vector. 
Insertion of the MSH6 wild type ORF into the destination vector was achieved by 
LR recombination of the attL and attR sites of the pENTR3C + hMSH6 vector and 
the pTO+AIO CSH GW FRT + shMSH6 destination vector. The LR-reaction was 
performed according to the "GatewayTM Cloning Technology" manual (GibcoBRL® 
Life Technologies) using the Gateway® LR Clonase® enzyme mix, Invitrogen. 
  
Insertion of MSH6 A116G 
into the pENTR3C vector 
PCR-site directed 
mutagenesis of MSH6 
A116G to wild type 
pTO+AIO hMSH6-SH GW 
FRT + shMSH6 vector 
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Generation of stable cell lines 
U2OS Flp-In T-REx (generated by Daniel Durocher) and Hek293 Flp-In T-REx 
(Invitrogen) cells were cultured in DMEM (GIBCO), supplemented with 10 % Tet 
System approved FBS (GIBCO), 100 ug/ml Zeocin (Invitrogen) and 15 ug/mL 
Blasticidin (Invitrogen). 
Four different stable cell lines were generated. U2OS and Hek293 Flp-In T-REx 
cells were transfected with the pTO+AIO hMSH6-SH GW FRT + shMSH6 or the 
pTO+AIO CSH GW FRT + shMSH6 vector using X-tremeGENE 9 DNA 
Transfection Reagent (Roche), 0.2 µg destination vector and 1.8 µg pOG44 vector. 
Mock-treated cells served as control during the selection process. Furthermore, the 
generation of the cell lines was performed according to the "Flp-In system - for 
generating stable mammalian expression cell lines by Flp recombinase-mediated 
integration" manual, Invitrogen. The selection procedure was initiated two days 
after transfection using a concentration of 50 µg/ml Hygromycin B, which was 
increased to 250 µg/ml on day 3. After approximately 2 weeks, single clones as 
well as one bulk culture from several clones were picked, expanded and screened 
for suitability: 2x105 cells were seeded in a dish (Ø = 6 cm) and were immediately 
treated with 10 µg/ml doxycycline (Dox). At day 2, Dox was replenished and at 
day 3, whole cell extracts were prepared with 2x Laemmli buffer (120 mM Tris-
HCl [pH 6.8], 4% SDS, 20% glycerol). Endogenous MSH6 as well as MSH6-GFP 
protein levels were analyzed by Western blotting. 
MSH6-LAP pulldown 
HeLa Kyoto MSH6-LAP and HeLa Kyoto GFP cell lines were obtained from Prof. 
Anthony A. Hyman (MPI-CBG, Dresden, DE). Both cell lines were grown in 
DMEM (GIBCO) supplemented with 10% FBS, 1% penicillin and streptomycin 
and in case of HeLa Kyoto MSH6-LAP cells additionally with 500 µg/ml G418. 
Extracts were prepared from two different cell lines: HeLa Kyoto MSH6-LAP (= 
cell line of interest) and HeLa Kyoto GFP (= control cell line). For each cell line, 
extracts were prepared from six 80% confluent cell culture dishes (Ø = 15 cm). All 
following steps were performed in the cold room. Each dish was washed with 20 
ml PBS and then with 20 ml buffer A (10 mM Hepes pH 7.9, 100 mM KCl, 1.5 
mM MgCl2, 0.34 M sucrose, 10% glycerol, 1 mM DTT, 1mM PMSF, 1 EDTA-free 
protease inhibitor cocktail tablet (Roche) per 100 ml). The buffer was removed 
completely and 800 µl of the same buffer were added back. Cells were scraped 
from the dish and transferred to a 1.5 ml Eppendorf tube. The cell membrane was 
disrupted, by 8 passages through a syringe needle (size: Ø = 0.5 mm). Disrupted 
cells were incubated on ice for 5 min and spun at 1700 rcf for 5 min to pellet the 
nuclei (P1). Nuclei were lysed by adding 800 µl of buffer B (3 mM EDTA, 0.2 mM 
EGTA, 1mM DTT, 1 mM PMSF, 1 EDTA-free protease inhibitor cocktail tablet 
(Roche) per 100 ml) and rotating the mixture for 10 min. The insoluble chromatin 
Cell lines 
Generation & Screening of 
stable Flp-In T-REx cell 
lines 
Cell lines 
Preparation of chromatin-
enriched cell extracts for 
immunoprecipitation 
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(P2) was collected by centrifugation at 2000 rcf for 5 min. Fraction P2 was 
resuspended in 400 µl NP40 buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 0.5 % 
NP40, 1 mM EDTA), sonicated briefly (puls: 30%, 15 pulses) and spun at 20 000 
rcf for 5 min. The protein concentration of the supernatant containing the 
chromatin-enriched protein fraction was estimated with a Bradford protein assay.  
All following procedures were performed in the cold room. Preclearing of the cell 
extracts: 40 µl blocked agarose beads (bab-20, Chromotek) were equilibrated by 3 
washes with 500 µl ice cold dilution buffer (50 mM Tris-HCl pH8, 150 mM NaCl, 
1 mM EDTA, 1 mM PMSF, 1 EDTA-free protease inhibitor cocktail tablet (Roche) 
per 30 ml). Centrifugation steps were performed at 2700 rcf for 2 min. Beads were 
then mixed with 2.5 mg chromatin-enriched cell extracts, NP40 buffer and dilution 
buffer so that a final concentration of 0.2 % NP40 and a total volume of 500 µl was 
reached. After 1 hr of rotation, beads were centrifuged and the pre-cleared cell 
extracts (= supernatant) were transferred to 30 µl new, equilibrated GFP-Trap®_A 
beads (Chromotek). Pulldown: Binding of the proteins to the GFP beads was 
performed for 2 hr during rotation at 4 °C. Beads were then washed thrice with 500 
µl NP40 buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 0.5 % NP40, 1 mM 
EDTA). Each washing step included 5 min of rotation and subsequent 
centrifugation at 2000 rcf for 2min. Subsequently, the beads were resuspended in 
30 µl 2x SDS buffer and boiled for 10 min at 95°C. Samples were spun at 2700 rcf 
for 2 min. The supernatant containing the dissociated immunocomplexes was 
analyzed by Western blotting. 
6.3 Studies on PARP-1 and PARP inhibition 
In vivo studies 
SUM149PT, SUM1315MO2 and Ovcar-8 cell lines were obtained from KuDOS 
Pharmaceuticals, UK. SUM149PT cells were cultured in Ham's F12 medium 
(GIBCO) supplemented with 5% FBS (GIBCO), 5 µg/ml insulin (Sigma-Aldrich), 
1 µg/ml hydrocortisone (Sigma-Aldrich) and 10 mM Hepes (GIBCO). 
SUM1315MO2 cells were grown in the same medium without hydrocortisone but 
10 ng/ml EGF (Sigma-Aldrich) instead. Ovcar-8 cells were cultured in RPMI 
medium (GIBCO) supplemented with 10% FBS (GIBCO). All media additionally 
contained 1% penicillin and streptomycin.  
Cells were seeded at a density of 2x106 cells per dish (Ø = 10 cm) containing a 
cover slip. 24 hours later, SUM149PT and HeLa cells were either mock-treated 
(PBS) or treated with 0.125 µM and 50 µM Olaparib, respectively. After 1 hour, 
the medium was replaced by PBS containing 1 mM H2O2 for 10 min. After 10 min, 
H2O2/PBS was removed, cells were washed once with PBS and immediately fixed 
with methanol/acetic acid (3:1) on ice for 1 hour. Cells were blocked with PBSMT 
Pulldown of MSH6-LAP 
Cell lines 
Immunofluorescence for 
PAR detection 
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(5% (w/v) milk powder, 0.05% (v/v) Tween20 in PBS) for 30 min, incubated with 
anti-PAR 10H antibody (1:500 dilution in PBSMT) overnight at 4°C, subsequently 
washed with PBS and incubated with the secondary antibody FITC-goat-anti-
mouse (Sigma) (1:700 dilution in PBSMT) for 1 hour at room temperature. Cover 
slips were washed with PBS, fixed with DAPI-containing mounting medium 
(Vector Laboratories) and analyzed by microscopy (Olympus IX81). 
Cells were seeded at a density of 500'000 cells per dish (Ø = 6 cm). 24 hours later, 
cells were transfected with 40 pmol siRNA against luciferase (siLUC), MYH or 
BRCA1 or a combination of them, using RNaiMax (Invitrogen) as per the 
manufacturer's protocol. 15 hours posttransfection, the medium was replaced and, 
in order to increase the knockdown period of time, 8 hours later a second 
transfection was performed similarly to the first. For survival assays, 48 hours after 
the first transfection, cells were seeded in triplicates in 6-well plates at a density of 
500 (Ovcar-8), 1000 (SUM149PT) or 2000 cells (SUM1315MO2) per well. 24 
hours after seeding, the cells were treated with the indicated concentrations of 
Olaparib, H2O2 or both. Olaparib treatment was performed either continuous or 
acute (see Olaparib treatment of cells). 8 days (Ovcar-8) or 10 days (SUM149PT, 
SUM1315MO2) after treatment, the cells were fixed and stained with 0.5% crystal 
violet in 20% ethanol and colonies containing more than 30 cells were counted. 
Whole cell extracts for Western blot analysis of the transfection efficiencies were 
prepared on the day of the drug treatment, using 2x Laemmli buffer (120 mM Tris-
HCl [pH 6.8], 4% SDS, 20% glycerol). 
U2OS or SUM149PT cells were seeded at a density of 100'000 or 180'000 cells per 
6-well, respectively. 24 hours later, cells were transfected with 40 pmol siRNA 
against luciferase, MYH, BRCA1 or MSH6 or their combination, using RNaiMax 
(Invitrogen) as per the manufacturer's protocol. 15 hours posttransfection, the 
medium was replaced and, in order to increase the knockdown period of time, 8 
hours later a second transfection was performed as described before. For survival 
assays, 48 hours after the first transfection, cells were re-seeded in triplicates in 96-
well plates at a density of 1000 cells/well. 24 hours after seeding, cells were treated 
with the indicated concentrations of Olaparib (see: Olaparib treatment of cells). 72 
hours after continuous drug treatment, cell viability was measured with the 
CellTiter-Blue® Cell Viability Assay (Promega) according to the manufacturer's 
protocol. Fluorescence (560Ex/590Em nm), an indicator of metabolic activity, was 
measured 4 hours after the addition of Resazurin. 
siLUC: 5'-CGUACGCGGAAUACUUCGA-3' 
siMYH: 5'-UCACAUCAAGCUGACAUAUCAAGUA-3' 
siBRCA1: 5'-ACCAUACAGCUUCAUAAAUAA-3' 
siMSH6: 5'-CGCCAUUGUUCGAGAUUUA-3' 
siRNA treatment and 
clonogenic survival assay 
siRNA treatment and 
CellTiter-Blue® cell 
viability assay 
siRNA sequences 
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For acute treatment, Olaparib (Seleckchem) was directly added to the culture 
medium. 24 hours posttreatment, cells were washed once with PBS and fresh 
medium was added. For continuous treatment, cells were not washed and Olaparib 
remained in the medium. Mock cells were treated with an appropriate amount of 
DMSO. 
Olaparib (Seleckchem) was directly added to the culture medium. After 1 hour, 
H2O2 was diluted in PBS and was immediately added to the Olaparib-containing 
medium. 1 hour post H2O2 treatment, cells were washed once with PBS, and 
Olaparib containing medium was added back for continuous treatment. Mock cells 
were treated with appropriate amounts of DMSO and PBS. 
In vitro studies 
The MMR assay was performed as described in chapter 3.1.1, but with slight 
alterations: 100 ng activated DNA (Amsbio) and 50 µg HCT116 + chromosome 3 
nuclear cell extract were incubated in a total volume of 12.5 µl in a buffer 
containing 20 mM Tris-HCl pH7.6, 5 mM MgCl2, 1 mM Glutathione, 50 µg/ml 
BSA, 0.1 mM dNTPs, 1.5 mM ATP, 80 mM KCl and the indicated concentrations 
of NAD+ or Olaparib. The reaction was incubated at 37°C for max 5 min, stopped 
by the addition of 5 µl 5x loading dye (0.25 M Tris pH 6.8, 50% glycerol, 8% SDS, 
0.5 M DTT, 0.1% Bromphenol Blue), heated at 95°C for 5 min and analyzed by 
Western blotting. The anti-Poly(ADP-ribose) antibody (rabbit, polyclonal, BD 
Pharmingen, cat: 551813) was used at a dilution of 1:1000.  
To investigate the role of PARP-mediated PAR formation during MMR processes, 
in vitro MMR assays (see chapter 3.1.1) were performed in the presence of either 
500 µM Olaparib (Selleckchem) or 50 µM NAD+ (New England Biolabs). 
 
Olaparib treatment of cells 
Olaparib/H2O2 combination 
treatment of cells 
Preparation of whole cell 
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Appendix 1: Vector map of pTO+AIO CSH GW FRT 
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Appendix 2: Vector map of pTO+AIO CSH GW FRT + shMSH6 
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Appendix 3: Vector map of pENTR3C + hMSH6 
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Appendix 4: Vector map of pTO+AIO hMSH6-SH GW FRT + shMSH6 
 
